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ABSTRACT 
 The efficacy of some vaccines is enhanced by the presence of adjuvants added to 
their formulations or, in the case of live attenuated or killed whole cell vaccines, because 
of their endogenous adjuvant activity. The immune system responds robustly to these 
endogenous adjuvants, which includes Pathogen Associated Molecular Patterns, which 
stimulate innate immune responses through Pattern Recognition Receptors, such as 
TOLL-like receptors (TLRs). The development of most vaccine adjuvants has occurred 
despite little understanding of their overall mechanisms of immune enhancement. We 
hypothesized that TLR-dependent adjuvant activities are mediated through TLR 
stimulation of antigen presenting cells (APCs), and each APC type may play a unique 
role in the immune-stimulating ability of these adjuvants, including effects on 
downstream T cell stimulation. We used a mouse model where TLR/MyD88 signaling is 
prevented in specific APC types, in vivo, using loxP/cre recombinase transgenic mice (B 
cells, dendritic cells and macrophages) to investigate its role in vaccine adjuvant activity. 
We found that intact MyD88 signaling is essential, separately, in all three APC types for 
optimal TLR-ligand based adjuvant (PorB, CpG, MPLA), but not for TLR-independent 
(Alum, MF59) adjuvant activity. However, the immune responses were reduced to the 
		 ix 
greatest extent in mice with macrophage specific MyD88 deletion (Mac-MyD88-/-). We 
demonstrated that TLR-dependent adjuvants are potent inducers of germinal center (GCs) 
formation needed for an effective and robust immune response. Interestingly, GCs are 
nearly absent in Mac-MyD88-/- mice upon immunization with TLR-dependent adjuvants, 
but not with TLR-independent adjuvants. Further investigations revealed a significant 
impairment in T cell cytokines important for GC formation in Mac-MyD88-/- mice when 
immunized with TLR-dependent adjuvants. Through these studies we discovered that 
vaccine formulated with PorB/OVA induced a robust and diverse T cell response 
including highly functional OVA-CD4 and CD8 T cells. These CD8 T cells are protective 
and significantly reduced the bacterial burden and increased survival in a Listeria mouse 
infection model. Our findings reveal that PorB has broad adjuvant activity, signaling 
through all three APC types, inducing strong and diverse humoral and cellular responses. 
These insights will allow for a more intelligent use of adjuvants in future vaccine 
development.	
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CHAPTER ONE: INTRODUCTION 
Vaccines 
History and Successes 
Vaccines are the most successful life-saving medical invention in history. In 
1798, Edward Jenner made the world’s first vaccine and published his findings in London 
by Sampson Low (Jenner, 1800). Jenner inspired by a common practice in other parts of 
the World, such as Turkey and China, where people would inoculate themselves with 
scabs from smallpox infected individuals in an attempt to protect themselves from disease 
(Behbehani, 1984). Jenner protected people from smallpox by injecting them with 
cowpox, a related virus. Over time he enhanced the efficacy and formulation of the 
smallpox vaccine, thereby helping to eradicate humankind’s deadliest infection 
(Behbehani, 1983). There was a big gap in time (~100 years) where no new vaccines 
were developed. Louis Pasteur made the world’s next vaccines, an anthrax vaccine to 
protect animals. He prevented infection with rabies in humans by drying spinal cords 
from rabies-infected rabbits and using it in vaccine formulation (Pasteur, 1880). Pasteur 
made numerous vaccines for livestock and demonstrated that vaccines could be made 
from dangerous viruses.  
From Max Theiler, scientists learned that human pathogenic viruses could be 
weakened and made into vaccines by growing them in animal cells. He developed the 
very successful yellow fever vaccine by growing the virus in mice and chickens eggs 
(Norrby, 2007). He is the only scientist who won a Nobel Prize for an effective vaccine. 
This technique of weakening human viruses through cell passage using animal tissues 
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remains the single most important method for making live attenuated viral vaccines. It is 
still used today, for example, in the manufacturing of the measles, mumps, rubella and 
varicella vaccine (ProQuad) by Merck as well as by other vaccine manufacturers. 
Development of these early vaccines was necessitated by the severity and disease burden 
of these pathogens. All of these vaccines were developed empirically, without a full 
understanding of the underlying mechanism of protection induced by the vaccine and 
without an extensive understanding of the pathogen’s biology.  
More vaccines were developed at the beginning of the twentieth century as a 
result of an increased understanding of immunology and microbiology, including worked 
done by Behring on antibodies (Behring, 1890), the development of antitoxin theory by 
Ehrlich, Koch’s seminal work on bacterial cultures (Koch, 1881) and investigations by 
other scientists who contributed to the knowledge for vaccine development (Makela, 
2000; Paul, 2013). Scientists discovered that bacteria made toxins, which could be treated 
with chemicals to decrease their toxicity and subsequently used these non-toxic toxoid 
formulations as vaccines. This led to development of vaccines against diphtheria, tetanus 
and whooping cough (Leroux-Roels, 2010). From the beginning to the middle of the 
twentieth century many techniques were developed that allowed for development of new 
vaccines such as growth of virus in chicken eggs (Woodruff & Goodpasture, 1931), cell 
culture (Enders, Weller, & Robbins, 1949) and development of killed whole cell 
vaccines. In the middle of the twentieth century Jonas Salk and Albert Sabin made the 
polio vaccines and eradicated polio in most countries, reducing the disease by 99% 
(WHO, 2015). In the second half of the century Maurice Hilleman, the scientist who 
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probably saved more lives that any other scientist combined, developed vaccines against 
measles, mumps, rubella, chickenpox, hepatitis A and B, and Haemophilus influenza type 
b (Offit, 2007). As of January 2013, there were 74 vaccines licensed for immunization in 
the United States. A majority of these vaccines, about 58%, are inactivated or live 
attenuated vaccines made in embryonated eggs, 35% represent vaccines with microbial 
non-toxic toxoids or polysaccharide antigens and 7% are recombinant proteins or virus 
like particles (McCluskie et al., 2013; Woodruff & Goodpasture, 1931).  
These vaccines have been a great success story in medicine and are responsible 
for a significant reduction in mortality and disease severity worldwide. These successful 
vaccines prevent more than 3 million deaths yearly and over 700,000 children are 
protected from disability (O'Hagan & Fox, 2015). They have also been the safest medical 
intervention for humans. 
 
The Need for New and Improved Vaccines 
 Despite the great success story of vaccines, there is still an unmet clinical need for 
new novel vaccines against pathogens that remain resistant to traditional vaccine design. 
Many of these pathogens are immune evading and require diverse vaccine induced 
immune responses, including T cell responses, for host-protection (Leroux-Roels, 2010). 
For example, new vaccines are needed because conventional vaccine designs are 
ineffective against Human Immunodeficiency Virus (HIV), Mycobacterium tuberculosis 
(TB), Hepatitis C virus (HCV), Respiratory Syncytial Virus (RSV), Plasmodium 
parasites (malaria) or pathologies such as cancer and certain autoimmune disease 
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(Leroux-Roels, 2010). Highly efficacious vaccines are needed against emerging and re-
emerging diseases such as Sever Acute Respiratory Syndrome (SARS), Ebola, Dengue 
and Hanta viruses as well as the pandemic influenza virus (Mortellaro & Ricciardi-
Castagnoli, 2011). We need to have to ability to rapidly manufacture vaccines that are 
effective against Francisella tulerensis, Bacillus anthracis, and potential laboratory-
engineered pathogens (Mortellaro & Ricciardi-Castagnoli, 2011). An urgent need for a 
vaccine might arise at any point against these pathogens because of their potential use as 
a bioweapon. Great advances have been made in understanding the biology of these 
pathogens, using structural biology and reverse vaccinology scientist have been able to 
identify and manufacture some relevant antigen to be used in vaccine formulations. 
However, these purified antigens are poorly immunogenic and cannot be used alone in 
vaccine formulations. There is a need to supplement these vaccines with components, 
termed adjuvants that can enhance the immunogenicity of poorly immunogenic antigens. 
 
Adjuvants 
Definition and History 
Adjuvants are vaccine components that enhances the immunogenicity of the 
poorly immunogenic antigens that may be able to induce protective immunity (Leroux-
Roels, 2010). This term “Adjuvant” stems from the Latin word “adjuvare” which means, 
“to help”. An adjuvant is usually admixed with an antigen during vaccine formulations 
and has been used in vaccines throughout their use and development. All vaccines 
contain some form of adjuvants whether it is exogenously added or inherently present in 
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the vaccine (Lahiri, Das, & Chakravortty, 2008). Various adjuvants exist and one of the 
very interesting types that have been used for decades is “exogenous adjuvant”, which is 
admixed with the antigen in vaccine formulations to boost its immunogenicity. One 
example of this type of adjuvant is aluminum salts (Alum) which have been used in 
vaccines for almost 90 years and alum has been successful in enhancing the humoral 
responses induced by some vaccines (Allison & Byars, 1991; Brewer, 2006; Leroux-
Roels, 2010). Alum was first used in a diphtheria vaccine for animals (Glenny AT, 1926) 
and is widely used in a variety of vaccines either as the main adjuvant or in combination 
with other adjuvants. However, there still are multiple studies that are being performed to 
further understand its mechanism of action. Alum is not only the most commonly used 
adjuvant, but it is also the first adjuvant approved by the FDA. The inclusion of alum in 
vaccine preparations has been shown to induce strong antibody production (Kool, 
Fierens, & Lambrecht, 2012) and activate the NLRP3 inflammasomes by crystal 
formation and disruption of lysosomes (Eisenbarth, Colegio, O'Connor, Sutterwala, & 
Flavell, 2008). However, the role of inflammasomes activation in alum’s adjuvant 
activity is not completely understood. It induces IL-1β and activates antigen-presenting 
cells (Kool, Petrilli, et al., 2008). Alum also stimulates monocytes to develop into DCs, 
which contributes to alum’s adjuvant activity. Alum’s adjuvant activity is directed mainly 
towards a Th2 type immune response and it is independent of MyD88 and TRIF adaptor 
proteins, although TLR signaling might be important for innate monocyte recruitment 
(Gavin et al., 2006). Another efficacious adjuvant is MF-59, which is a Novartis patented 
adjuvant made from shark liver oil (squalene) emulsified with two surfactants 
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polysorbate 80 and sorbitan trioelate, resulting in a droplet size of 160 nm (Seubert et al., 
2011). It has been a licensed adjuvant for the seasonal influenza vaccines since 1994 in 
Europe. In vitro data suggest that MF-59 does not activate dendritic cells, but rather 
induces the secretion of chemokines by macrophages and monocytes (Seubert, Monaci, 
Pizza, O'Hagan, & Wack, 2008). MF-59 adjuvant activity in vitro suggests that it is 
MyD88 dependent but TLR independent (Seubert et al., 2011). Even though MF-59 has 
been widely used in the seasonal Flu vaccine, there are still on going studies 
characterizing its adjuvant activity in more detail. 
Traditionally, vaccine formulations were prepared empirically by using live 
attenuated strain of the pathogens, whole cell inactivated organisms, or non-toxic toxoid. 
These types of vaccines contained components from pathogens that are being recognized 
by the host innate immune system. It has been observed that the impurities in vaccine 
formulations correlate with enhanced immunogenicity of the vaccine (Lahiri et al., 2008). 
These components (endogenous adjuvants) are Pathogen Associated Molecular Patterns 
(PAMPs) that are being recognized by the innate immune system, which has evolved to 
recognize these PAMPs via their Pattern Recognition Receptors (PRRs) (Maisonneuve, 
Bertholet, Philpott, & De Gregorio, 2014). Most of the vaccines currently licensed were 
developed without a precise understanding of their mechanism of action. 
Pattern Recognition Receptors (PRRs) 
 The innate immune system has evolved to protect its host from infections. It 
accomplishes this vital task of detecting PAMPs by using PRRs, which includes the Toll-
like receptors (TLRs), Nod-like receptors (NLRs), and RIG-I-like receptors (RLRs) 
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(Mbow, De Gregorio, Valiante, & Rappuoli, 2010). These PRRs are located either inside 
the cell or extracellular, on the cell membrane, allowing for survey of microbial 
components inside and outside of the cells (Mbow et al., 2010). This concept of microbial 
detection was first suggested by Charles Janeway who proposed that the innate immune 
system is able to detect infectious non-self components from self molecules, which 
triggers the innate immune system and enhances induction of a potentially protective 
adaptive immune response (Janeway, 1989). In this thesis, I shall mainly focus on TLRs 
and their ligands, which contribute to vaccine-induced immune responses. TLRs were 
first identified in Drosophila (termed TOLL receptors in the fly, TOLL-like receptors 
[TLR] in other species) where they function to respond to fungal and bacterial pathogens 
and infections (Imler & Zheng, 2004). These TLRs signal through various intracellular 
adaptor proteins, initially MyD88 and/or TRIF/TRAM (Imler & Zheng, 2004). There are 
different types of TLRs (TLR1 to 10 in humans and TLR1 to 9 and TLR11 to 13 in mice) 
that have been identified, each able to recognize different types of PAMPs (Figure 1.1). 
TLR2, 4 and 5, are extracellular TLRs, and TLR7, 8 and 9, are endosomal TLRs, signals 
through MyD88 and the IRAK signaling cascade activating multiple transcription factors 
in the process (Figure 1.1) (Akira, Uematsu, & Takeuchi, 2006). Signaling through these 
TLRs can lead to the induction of immune effector molecules, such as pro-inflammatory 
cytokines IL-6 and TNF-α, type I interferons and various chemokines (Akira et al., 2006). 
These effector molecules shape the immune system responses, linking the innate to the 
adaptive arm of the immune system, with important roles in controlling infections. TLR9 
and 7 also leads to the activation of IRF7 cascade, which is a MyD88-dependent process 
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with a role in inducing Type I IFN gene expression (O'Neill, Golenbock, & Bowie, 
2013). Lack of MyD88 adaptor protein affects signaling of TLR2, 5, 7, 8 and 9.  
However, TLR4, unique to these other receptors, can also signal through the TRIF 
pathway and localized in endosomal compartment (Akira et al., 2006). Once TLR4 binds 
its ligand, with the aid of MD2 when LPS is the ligand, MyD88 is engaged and 
downstream signaling occurs, followed by endocytosis of this receptor, where it then 
engages the TRIF adaptor protein and initiates signaling from the endosomal 
compartments (Brubaker, Bonham, Zanoni, & Kagan, 2015). TLR3, an endosomal TLR 
and unlike any of the other TLRs, signals exclusively through TRIF adaptor protein, 
which mainly results in induction of type I IFN and other effector molecules. 
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Figure 1.1. TLR signaling pathways. 
Toll-like receptors (TLRs) are an important type of Pattern Recognition Receptors 
(PRRs). TLR signaling is initiated upon receptor dimerization and binding of the ligand. 
This ligation results in engagement of the TLR domain with TIR-domain containing 
adaptor protein (MyD88 and/or TRIF), which stimulates downstream signaling pathways 
that includes interaction of IRAK complexes. This leads to activation of transcription 
O’Neill et al. Nature Reviews 2013	
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factors and production of effector molecules such as pro-inflammatory cytokines, 
chemokines and Type I interferons (O'Neill et al., 2013).   
One of the significant foci of this thesis will be TLR2. TLR2 is a relatively unique 
TLR because of its ability to recognize the highest number of PAMPs as compared to 
other TLRs (O'Neill et al., 2013). TLR2 ligands are broad and structurally diverse. They 
originate from a wide variety of microbes including bacteria, fungi and viruses (O'Neill et 
al., 2013). Some of these TLR2 ligands that have been identified are lipoproteins, 
peptidoglycans, polysaccharides, glycosylphosphatidyl-inositol-anchored structures from 
Gram positive bacteria, lipomannans (from Mycobacterium tuberculosis), as well as 
certain viral components (Steinhagen, Kinjo, Bode, & Klinman, 2011). In the present 
study Neisseria meningitidis PorB (PorB), a TLR2 ligand, was extensively studied. It is 
still not completely understood how TLR2 is able to recognize such diverse types of 
PAMPs. This might be partially because TLR2 dimerizes with TLR1 or 6 in mice and 
TLR1, 6 and 10 in humans (Steinhagen et al., 2011). This heterogeneous receptor usage 
allows the recognition of a wide array of PAMPs. TLR2 is also expressed on a wide 
variety of cell types such as dendritic cells, macrophages, microglial cells, and 
lymphocytes. Signaling through TLR2 by different TLR ligands induces up-regulation of 
MHC class II, CD80, CD83, IL-12, IFN-γ (in DCs), stimulates macrophages for the 
production of pro-inflammatory cytokines, promotes maturation of B cells and increases 
antigen specific CTL responses (Deres, Schild, Wiesmuller, Jung, & Rammensee, 1989; 
Hertz et al., 2001; Liu, Wetzler, & Massari, 2008; Mackinnon et al., 1999b; Muhlradt & 
Schade, 1991). 
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These PPRs discussed above play an important role in vaccine-induced immune 
responses. Early vaccines that were formulated as live attenuated or killed whole cell 
vaccines are efficacious because they engaged PRRs. Their formulations contained 
bacterial DNA, viral DNA, bacterial cell wall/membrane components (LPS), and/or other 
components that can be recognize by TLRs or other PRRs like NODs or RIGs (Mbow et 
al., 2010). TLR engagement shapes the vaccine-induced immune responses required for 
protection against the pathogens. A good understanding of PRRs will allow scientist to 
use PAMPs, such as TLR-ligand based adjuvants, in the development of efficacious 
vaccines. 
TLR-ligand Based Adjuvants 
TLR2-Ligand Based Adjuvant, Meningococcal PorB 
PorB is one of the major outer membrane proteins of Neisseria meningitidis. It 
forms a trimeric β barrel structure in the bacterial membrane allowing ions in and out of 
the bacteria (Kutzner, Grubmuller, de Groot, & Zachariae, 2011). Our laboratory has 
been investigating the immunobiology of meningococcal PorB for the last two decades. 
Gonococcal PorB has been investigated as a potential anti-Neisserial vaccine candidate 
(Blake, Wetzler, Gotschlich, Rice, & Atassi, 1989; Wetzler, Blake, Barry, & Gotschlich, 
1992; Wetzler et al., 1991; Wetzler et al., 1988), but through this work our laboratory 
discovered that PorB protein had unique immune stimulatory abilities above and beyond 
its own potential use as a vaccine antigen. After purification, PorB is formed into protein 
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micelles termed “proteosomes” as illustrated in the electron micrograph (Figure 1.2) 
(Massari, King, MacLeod, & Wetzler, 2005).  
 
Figure 1.2. Electron micrograph of PorB Proteosomes.  
PorB clusters termed “proteosomes”. The scale bar is in the lower left corner and 
measures 100nm. This electron micrograph was generated by Dr Lee Wetzler. 
 
We have demonstrated that PorB can be used as an immune adjuvant for vaccines 
and that this property was directly related to its ability to stimulate antigen-presenting 
cells (APC) and increase expression of the co-stimulatory molecule CD86 and class II 
MHC (Mackinnon et al., 1999a; MacLeod, Bhasin, & Wetzler, 2008; Massari et al., 
2002; Massari, Ram, Macleod, & Wetzler, 2003; Platt, MacLeod, Massari, Liu, & 
Wetzler, 2013; Singleton, Massari, & Wetzler, 2005; Wetzler, Ho, & Reiser, 1996). PorB 
stimulates antigen-presenting cells through direct interaction with TLR2 and requires the 
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TLR adaptor protein MyD88 (Massari et al., 2002; Massari et al., 2003; Massari et al., 
2006; Singleton et al., 2005). TLR2 needs to heterodimerize with TLR1 (and not TLR6) 
in order for PorB to stimulate these APCs (Massari et al., 2006). PorB has adjuvant 
activity with a wide range of antigens including bacterial capsular polysaccharides, 
bacterial oligosaccharides and proteins (Chiavolini, Weir, Murphy, & Wetzler, 2008; 
Latz, Franko, Golenbock, & Schreiber, 2004). Our laboratory showed that PorB in 
combination with Francisella tularensis LPS increases protection in a mouse model of 
tularemia (Chiavolini et al., 2008). PorB is also a major component of meningococcal 
Outer Membrane Proteins Complexes (OMPC). OMPC have been used as a carrier 
protein for the Haemophilus influenza type B (Hib) human vaccine (Chiavolini et al., 
2008; Latz et al., 2004). This glycoconjugate vaccines using OMPC have had a dramatic 
role in significantly decreasing Hib disease (Latz et al., 2004). Since PorB as a 
component of OMPC has been part of a human vaccine, it has a proven safety profile and 
great potential to become a licensed adjuvant for use in vaccines. PorB is among the very 
few TLR2 ligands being investigated as a vaccine adjuvant. The other TLR2 ligand that 
has been extensively studied is Pam3CSK4. This TLR2 ligand was linked to outer surface 
protein A (OspA) of Borrelia burgdorferi (the agent that causes lyme disease) and used 
safely in a human vaccine against Lyme disease (Sigal, 1985; Sigal & Tatum, 1988; Sigal 
et al., 1998). This vaccine has been highly effective in inducing high antibody titers 
against the epitope of OspA (Nigrovic & Thompson, 2007). It is a licensed vaccine by the 
FDA. However this vaccine is no longer being produced by the manufacturer because of 
its low demands and because of concerns by a select few in the public who claim that this 
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vaccine causes autoimmune disease (Steinhagen et al., 2011). Importantly, the FDA and 
the CDC completely disagree with this view and no link was found to autoimmune 
disease by multiple studies done on subjects that received this vaccine (Steinhagen et al., 
2011). It is important that we continue to investigate PorB as an adjuvant, since a better 
understanding of this TLR2 adjuvant will allow scientist to use it more intelligently alone 
or in combination with other TLR ligands to induce a specific type of immune response 
or to target a specific type of immune cell. 
 
TLR4-Ligand Based Adjuvant, Monophosphoryl Lipid A (MPLA) 
Monophosphoryl lipid A (MPL-A) is a synthetic lipid A from E.coli, which is the 
bioactive part of lipopolysaccharide (LPS) that has been detoxified while maintaining its 
immune-stimulating activity (Johnson, Tomai, Solem, Beck, & Ribi, 1987). MPL-A 
adjuvant activity depends on its interaction with TLR4 and MD2. TLR4 signals through 
Myeloid Differentiation primary response 88 (MyD88) and/or TIR-domain-containing 
adaptor-inducing interferon-β (TRIF) adaptor proteins, however the MyD88 pathway 
produces a stronger pro-inflammatory response (Casella & Mitchell, 2008). MPL-A 
triggers a more robust Th1 type response compared to alum adjuvant (Mata-Haro et al., 
2007). MPL-A (purified from Salmonella minnesota LPS) is also the first TLR-ligand 
based adjuvant licensed for use in the United States. It is currently being used in the HPV 
vaccine along with alum and together they are known as AS04. Using these two 
adjuvants together enhances the humoral and memory B cell responses compared to alum 
alone (Rappuoli, 2007). This results in a significant improvement in the quality of the 
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response, inducing high titers of neutralizing antibodies in humans (Giannini et al., 2006; 
Tong et al., 2005). AS04 also induces antigen specific CD4 T cells and enhances Th1 
type responses in vivo (Didierlaurent et al., 2009) 
 
TLR9-Ligand Based Adjuvant, CpG 
TLR9 is expressed intracellularly in a variety of cells types such as B cells, 
macrophages, and different subsets of DCs. Signaling through this TLR leads to 
activation of the immune system which includes induction and proliferation of NK cells, 
T cells, B cells, monocytes, and macrophages (Steinhagen et al., 2011). TLR9 ligand 
CpG DNA (CpG) is a synthetic oligodeoxynucleotides containing CpG motifs that are 
unmethylated bacterial DNA. It has been designed to mimic the effect of bacterial DNA. 
CpG exerts its adjuvant activity through endosomal TLR9 and MyD88 adaptor protein. 
Its effect has been shown on different cell types in vitro inducing a wide variety of 
effector molecules and strong Th1 type responses (McCluskie et al., 2013). In this study, 
we used the type B ODN 1826 CpG as an immune adjuvant, as it has been shown to be 
highly immunostimulatory in mice. CpG has been investigated for human clinical trials 
for vaccines designed to prevent malaria (Malkin et al., 2005; Mullen et al., 2008), 
hepatitis B (Cooper, Angel, Seguin, Davis, & Cameron, 2008; Cooper et al., 2005), 
influenza and anthrax (Krieg, 2006). Since CpG is a well-studied adjuvant and an 
endosomal TLR ligand that is MyD88 dependent, we included CpG in this study for a 
head to head comparison to our cell surface TLR2/MyD88 dependent adjuvant, PorB. 
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Specific Aims and Hypothesis 
Most vaccines have been successful because of adjuvants added to their 
formulations or in the case of live attenuated vaccines because the adjuvants are inherent. 
The immune system has responded well to these vaccines and mounts robust protection 
against pathogens. Part of the reason for this success is because our immune system has 
evolved to respond to foreign molecules, which stimulate innate immune responses 
through pattern recognition receptors. These efficacious vaccines exploit this property of 
the immune system to mount protection. However, despite vaccination’s great success, 
the development of most vaccines and adjuvants happened without an understanding of 
vaccine immunity and their immunological mechanisms. There have been many failures 
to develop vaccines against pandemics such as HIV infection, Mycobacterium 
tuberculosis, Hepatitis C and Respiratory Syncytial Virus (Pulendran & Ahmed, 2011).  
One of the major limitations in vaccine development is the lack of understanding 
of the cellular and molecular mechanisms of adjuvants. This is true for both currently 
licensed adjuvants and new novel adjuvants that are under investigation. Adjuvants may 
act through various mechanisms, which include formation of antigen depot, induction of 
cytokines and chemokines, recruitment of immune cells, enhancement of antigen uptake 
and presentation. The type of innate immune responses triggered by the adjuvants can 
change the quality and quantity of adaptive immune responses. One major goal of this 
proposal is to better understand the mechanisms of adjuvants, as this will provide critical 
information on how their activity affects the intensity of the innate immune response and 
development of adaptive immunity.  
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In vaccine design, it is important to know the type of immune responses elicited 
by the adjuvant or combination of adjuvants and the type of immune cells involved in the 
adjuvant activity. Previous studies showed that the successful yellow fever vaccine 
activates multiple subsets of DCs by signaling through a specific set of TLRs (Pulendran 
& Ahmed, 2006). Absence of one of these TLRs affected the type of responses induced 
by the vaccine on DCs (Pulendran & Ahmed, 2006). Other studies have suggested that B 
cells are not different from dendritic cells (DCs) or macrophages in regards to the 
generation of T-dependent antigen specific antibody responses, which require activation 
of TLRs in B cells (Pasare & Medzhitov, 2005; Ruprecht & Lanzavecchia, 2006). The 
roles of the different antigen presenting cell types in most adjuvants activity are not very 
well understood and it is crucial to understand the underlying mechanisms for a more 
intelligent use of adjuvants in vaccines (Alving, Peachman, Rao, & Reed, 2012). We 
hypothesized that PorB and other TLR-dependent adjuvant (MPLA and CpG) activities 
are mediated through TLR stimulation of antigen presenting cells (APCs), and each APC 
type plays a unique role in the immune-stimulating ability of these adjuvants, including 
effects on downstream T cell stimulation.  We addressed this hypothesis with the 
following three aims: 
 
Aim 1: Examine the role that antigen presenting cell types, including dendritic cells, 
macrophages and B cells, play in humoral responses induced by PorB and compare 
responses to other TLR-dependent (MPLA and CpG) and TLR-independent (Alum and 
MF59) adjuvants. 
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Aim 2: Examine how PorB stimulation of antigen presenting cell types in vivo modulates 
the Th1/Th2 type adjuvant-induced immune responses compared to other adjuvants.  
 
Aim 3: Examine the ability of PorB to induce antigen specific T cell mediated immune 
responses. 
 
To explore our hypothesis, we compared the adjuvant activity of PorB to other 
well-characterized adjuvants that are MyD88 dependent or independent. The requirement 
for MyD88 in TLR signaling for the adjuvant activity of PorB in specific cell types is 
essential for our study. Abrogating MyD88 signaling in specific cell types and 
investigating how this affects the vaccine adjuvant activity will help us understand the 
role of these immune cells in PorB’s adjuvant activity in a vaccine-induce immune 
response compared to other well-studied adjuvants. We generated conditional knockouts 
of the MyD88 gene in specific cells by crossing MyD88flox/flox mice with mice expressing 
Cre recombinase under the control of cell specific promoter for dendritic cells, B-Cells or 
macrophages as described in methods section below.  
The observations made from investigating these aims are described in Chapter 3 
and 4. It is important to use the right type of adjuvants in vaccine preparations to generate 
the appropriate immune responses to provide protective immunity against various 
pathogens. A better understanding of the mechanisms of adjuvant activity is essential for 
the development of highly efficacious vaccines. Solving the unknowns from this proposal 
will help us better understand how some of these adjuvants works. This knowledge could 
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be use to target adjuvants to specific cell types to induce a specific type of response to 
provide protection against pathogens. This will increase vaccine efficacy and potency. 	
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CHAPTER TWO: MATERIALS AND METHODS 	 	
Methods for Chapter Three: 	
Animals 
All mice including Wild Type (WT) C57BL6J were purchased from Jackson 
Laboratories. MyD88 flox/flox (MyD88tm1Defr, stock # 008888) (Hou, Reizis, & DeFranco, 
2008) mice were bred with CD19 Cre (Cd19tm(cre)Cgn, stock # 006785) (Rickert, Roes, & 
Rajewsky, 1997), CD11c Cre (Tg(Itgax-cre)1-1Reiz, stock # 008068) (Caton, Smith-
Raska, & Reizis, 2007) or Lysm Cre (Lyz2tm1(cre)Ifo, stock # 004781) (Clausen, Burkhardt, 
Reith, Renkawitz, & Forster, 1999) mice then crossed again with MyD88flox/flox to 
generate MyD88flox/flox homozygous and heterozygous Cre mice. MyD88flox/flox CD19Cre 
mice have a MyD88 deletion in CD19+CD3- B cells (B-Cell-MyD88-/- mice). 
MyD88flox/flox CD11cCre mice have MyD88 deletion in CD11c+CD11b- dendritic cells 
(DC-MyD88-/- mice). MyD88flox/flox LysmCre mice have MyD88 deletion in 
CD11b+F4/80+ macrophages (Mac-MyD88-/- mice). All mice were maintained in the 
Association for Assessment and Accreditation of Laboratory Animal Care International 
accredited facility at Boston University School of Medicine Laboratory Animal Science 
Center (LASC). All animal experiments were conducted under the approved IACUC 
protocol for Dr. Wetzler’s Laboratory at Boston University School of Medicine. Mice 
were genotyped by PCR using primer sequences recommended by Jackson Laboratories. 
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Genotyping 
 Separate breeding colonies were maintained for MyD88 flox/flox, these mice were 
used as control and for breeding with the different Cre-recombinase mice. Tails were cut 
at weaning date, digested using RedExtract-N-Amp Tissue PCR Kit (Sigma, Cat# E7526, 
T3073 and N3910) according to the manufacturers protocol. PCR reaction was prepared 
using RedExtract-N-Amp Tissue PCR Kit (Sigma, Cat# R4775) according to 
manufacturers protocol. 
MyD88 flox/flox : 
Primers: 
GTT GTG TGT GTC CGA CCG T – Forward 
GTC AGA AAC AAC CAC CAC CAT GC – Reverse 
Both primers are used at a final concentration of 1 µM 
PCR Program: 
1. 94°C for 5:00 
2. 94°C for 0:30 
3. 60°C for 1:00 
4. 72°C for 1:00 
5. Go to Step #2 for 35 times 
6. 72°C for 10:00 
7. 4°C forever 
Expected Results: 
Mutant = 353 bp 
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Heterozygous = 266bp and 353bp 
 
MyD88 flox/flox CD11cCre: 
Primers: 
ACT TGG CAG CTG TCT CCA AG – Forward Transgene 
GCG AAC ATC TTC AGG TTC TG – Reverse Transgene 
CAA ATG TTG CTT GTC TGG TG – Internal positive control Forward 
GTC AGT CGA GTG CAC AGT TT -- Internal positive control Reverse 
All primers are used at a final concentration of 1 µM and transgene PCR reaction need to 
be run separately from internal positive control. 
PCR Program: 
1. 94°C for 3:00 
2. 94°C for 0:30 
3. 67°C for 1:00 
4. – 0.5°C per cycle 
5. 72°C for 1:00 
6. Go to Step #2 for 34 times 
7. 72°C for 2:00 
8. 4°C forever 
Expected Results: 
Transgene = 313 bp 
Internal positive control = 200 bp 
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MyD88 flox/flox CD19Cre: 
Primers: 
GCG GTC TGG CAG TAA AAA CTA TC– Forward Transgene 
GTG AAA CAG CAT TGC TGT CAC TT – Reverse Transgene 
CCT CTC CCT GTC TCC TTC CT – WT Forward 
TGG TCT GAG ACA TTG ACA ATC A -- WT Reverse 
All primers are used at a final concentration of 1 µM and transgene PCR reaction need to 
be run separately from WT. 
PCR Program: 
1. 94°C for 4:00 
2. 94°C for 0:30 
3. 65°C for 0:30 
4. – 0.5°C per cycle 
5. 72°C for 0:30 
6. Go to Step #2 for 10 times 
7. 94°C for 0:30 
8. 60°C for 0:30 
9. 72°C for 0:30 
10. Go to Step #7 for 24 times 
11. 72°C for 2:00 
12. 4°C forever 
Expected Results: 
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Mutant = 100 bp 
Heterozygous = 100 bp and 477 bp 
WT =477 bp 
 
MyD88 flox/flox LysmCre 
Primers: 
CCC AGA AAT GCC AGA TTA CG– Mutant 
CTT GGG CTG CCA GAA TTT CTC – Reverse Transgene 
CCT CTC CCT GTC TCC TTC CT – Common 
TTA CAG TCG GCC AGG CTG AC -- WT 
All primers are used at a final concentration of 1 µM except for Mutant, which is used at 
0.5 µM. Mutant PCR reaction need to be run separately from WT reaction.. 
PCR Program: 
1. 94°C for 4:00 
2. 94°C for 0:45 
3. 64°C for 1:00 
4. – 0.3°C per cycle 
5. 72°C for 1:00 
6. Go to Step #2 for 35 times 
7. 72°C for 5:00 
8. 4°C forever 
Expected Results: 
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Mutant = 700 bp 
Heterozygous = 700 bp and 350 bp 
WT =350 bp 
 
All PCR products were visualized on a 1.5% Agarose (Fisher Bioreagent, Cat# BP164-
500) in 1X TAE buffer prepared in house and add 1X SYBR Safe DNA gel stain 
(Invitrogen Cat# S33102). 
 
50X TAE Buffer: 
24.2 g Tris Base + 5.71 Glacial acetic acid + 0.5M EDTA (pH8.0) + adjust to 100 ml 
with distilled water. 
 
Neisseria meningitidis Porin B (PorB) Isolation 
PorB was purified from Neisseria meningitidis strain H44/76 Δ-1/4, that lacks 
PorA and Rmp (Mackinnon et al., 1999b) using protein extraction and column 
chromatography as it has been described in detailed previously (Massari et al., 2005). 
Neisseria meningitidis strain H44/76 Δ-1/4 was grown on gonococcal agar plates 
supplemented with 1% IsoVitaleX (Becton Dickinson, Cat#211876) and cultured 
overnight at 37˚C with 5% CO2. Colonies from GC plates were sub-cultured at 37˚C with 
shaking for seven hours in 50ml of GC broth (Wetzler et al., 1992) supplemented with 
1.5% peptone (Becton Dickinson), 1% IsoVitaleX, 0.5% sodium chloride, 0.4% 
potassium phosphate dibasic and 0.1% potassium phosphate monobasic (Reagents from 
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Sigma). The seven-hour liquid cultures were then divided into 4 new culture tubes with a 
final volume of 50 ml of new liquid GC medium. It was then incubated for seven hours at 
37˚C on an orbital shaker. Another 1.5 ml of liquid GC media was added to each 50 ml 
tube and incubated on the shaker at 37˚C overnight. Using a centrifuge (Sorvall RC-5C 
Plus Centrifuge, Sorvall Products, Newton, CT, USA) at 5000 rpm for 20 minutes, the 
bacteria were pelleted.  The bacterial pellet was re-suspended in sodium acetate 
(Concentration: 1M) with the anti-protease dimercaptopropanol (Sigma). The 
suspensions were mixed with 5% Zwittergent (Calbiochem, San Diego, CA, USA) and 
0.5 M calcium chloride in a water bath equipped with a sonicator (Branson 3200 
Ultrasonic Cleaner, Branson Ultrasonics Company, USA). DNA, Neisserial LOS, and 
other bacterial debris were precipitated with ethanol. The mixture was centrifuged as 
describe above. All proteins were precipitated with the addition of 100% ethanol to the 
supernatant with a final concentration of 80% of ethanol and incubated overnight at 4˚C.  
The precipitate was pelleted and re-suspended in loading buffer which consists of 
50 mM Tris, 10 mM EDTA, 5% Zwittergent and 0.02% sodium azide, adjusted to pH 
8.0. Using DEAE-Sepharose and CM-Sepharose (Amersham, GE Healthcare, UK) 
columns (2.5 × 10 cm, Econo column; Bio-Rad, Hercules, CA, USA) the sample was 
purified by ion-exchange at a flow rate of 1.8 ml/min. (Massari et al., 2005). All flow-
through was collected until the 280 nm absorbance indicated that the level of protein has 
returned to baseline. The flow-through was precipitated as described above in 80% 
ethanol and re-suspended in washing buffer containing 100 mM Tris, 10 mM EDTA, 0.2 
M sodium chloride, 0.05% Zwittergent, and 0.02% sodium azide, brought to pH 8.0.  
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Using a Sephacryl S-300 (Amersham) column (2.6 x 180 cm) at a flow rate of 
0.25 ml/min, the sample were further purified by gel filtration chromatography. The 
collected fractions containing PorB protein were identified by Coomassie staining of 
SDS–PAGE gels. All fractions containing PorB were pooled and precipitated, followed 
by re-suspension in loading buffer, but at pH 7.6. Endotoxin and lipoproteins was 
removed by using a Matrex Cellufine Sulfate (Millipore, USA) column (2.5 x 10 cm) 
(Massari et al., 2005). The Matrex column was cleaned with washing buffer at pH 7.5, 
and a linear gradient of 0.2 to 0.5 M NaCl was applied. Fractions with PorB were 
detected and precipitated again, followed by re-suspension in 10% d-octyl-glucoside 
(DOG) (Annatrace, Affymetrix, USA) with 10 mM Hepes, pH 7.2. Samples were 
dialyzed for three days at room temperature with three changes of PBS with 0.02% azide 
(>5 × 1010 times the original volume of the sample over 72 hours) to remove the 
detergent (Massari et al., 2005). During dialysis process, PorB forms lipid-free micelles 
termed “proteosomes” (Wetzler et al., 1992). The concentration of PorB was measured 
using a BCA protein assay reagent kit (ThermoFisher Scientific, Waltham, MA, USA) 
according to the manufacturer’s protocol.  
 
Ovalbumin (OVA) 
  Ovalbumin protein was isolated from chicken egg whites, purchased locally from 
Shaws grocery store, by freeze-drying followed by lyophilization (Singleton et al., 2005). 
The lyophilized powder is kept at 4˚C. OVA was re-suspended in sterile PBS and filtered 
through a 0.22 µm filter. OVA concentration was measured by the BCA assay as 
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described above and confirmed on a Nanodrop. Endotoxin contamination of OVA was 
screened by Silver staining of SDS-PAGE gels, LAL assay, HEK cell and BMDM 
stimulation.  
 
Coomassie Staining 
 Coomassie solution was prepared according the manufacturers protocol by mixing 
45 ml dH2O with 45 ml methanol, 10 ml acetic acid, and 0.25 g Coomassie Brilliant Blue 
(Sigma). The mixture was sonicated to solubilize the Coomassie dye, and filtered through 
Whatman 3MM filter paper (Whatman, UK) to remove any particulates.  
PorB preparations were loaded at 10µg per lane and analyzed using non-
denaturing and denaturing 12% polyacrylamide gel electrophoresis (PAGE). Samples 
used in a non-denaturing PAGE were separated on a 12% PAGE with loading buffer that 
contained 20% glycerol with bromophenol blue. Samples for denaturing SDS-PAGE 
were boiled for 5 minutes in 5% of β-mercaptoethanol (BME) in SDS containing loading 
buffer. SDS-PAGE gels were stained with Coomassie solution at room temperature for 4 
hours, then washed with dH2O four times and de-stained with a solution of 25% propanol 
and 10 % acetic acid in dH2O until bands were clear. Gels were preserved in 4% glycerol 
and 10% ethanol, then dried on a frame (Owl Separation System, NH) between two 
sheets of drying film (Promega, WI, USA) (Liu et al., 2008). Images were acquired on a 
Biorad Gel Doc XR imaging system (Biorad, USA). 
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Silver Staining 
 SDS-PAGE gels containing known amount of PorB as well as LPS and LOS were 
placed in petri dish with 50 ml solution containing 40% methanol, 10% acetic acid and 
soaked on a shaker at room temperature for 30 minutes. Gels were washed twice for 15 
minutes with a solution containing 10% ethanol and 5% acetic acid. Silver stain oxidizer 
concentrate (Bio-Rad) was diluted according to the manufacturer’s protocol with a final 
volume of 20 ml of dH2O and incubated for 5 min. Gels were washed twice for 5 minutes 
each with dH2O. Silver stain reagent (Bio-Rad) was diluted with dH2O to a total volume 
of 20 ml, and incubated with the gel for 20 min according the manufacturer’s protocol. 
Gels were washed with dH2O for 1 min. Developer solution was prepared by mixing 5g 
of silver stain developer (Bio-Rad) with 150 ml dH2O. The wash solution was removed 
from the dish and 25 ml developer solution was added. As the developer solution started 
to turn cloudy, it was removed, and fresh developer solution added. This process was 
repeated until bands were visible on the gels. Adding 25 ml of 5% acetic acid stopped the 
reaction and the gel was soaked in dH2O and then preserved in a similar way as the 
Coomassie gel preservation process described above. This assay is not very sensitive and 
cannot consistently detect 100ng/ml of LPS, which is the minimum amount this assay 
seems to be able to detect. Since LPS has biological activity at 50 ng/ml or less, we used 
the LAL assay to further rule out any endotoxin contamination.  
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Limulus Amebocyte Lysate Assay (LAL Assay) 
 The amount of endotoxin in our PorB and OVA preparations was quantitated 
using a very sensitive, fast and accurate assay called the LAL Assay (ThermoFisher 
Scientific, Cat#88282). This assay was performed according to the manufacturers 
protocol using the same amount of proteins used in our immunization studies 10 µg/ml. 
 
Activity and Endotoxin Content: 
Purified PorB’s activity and endotoxin content were further examined using HEK 
cells that over express TLR2 or 4, Bone Marrow Derived Macrophages (BMDM) from 
WT, MyD88, TLR2 or TLR4 knock out mice and LAL assay as a more sensitive measure 
for the endotoxin content. 
 
HEK Cells Assay 
The activity of purified PorB was evaluated by stimulating HEK cells that had 
been stably transfected with a vector expressing TLR2, TLR4 or an empty vector 
(pcDNA) (Chow, Young, Golenbock, Christ, & Gusovsky, 1999) (Toussi et al., 2012). 5 
x 105 cells were plated in each well of a 12 well plate (Corning) and stimulated with 10 
µg/ml PorB for 24 hours. Pam3CSK4 (Invivogen), LPS or N. meningitidis 
lipooligosaccharide (LOS) at 100 ng/ml were used as a positive control. OVA 10 µg/ml 
was also used to stimulate HEK cells expressing TLR4 to determine potential LPS 
contamination. TNFα (Sigma Aldrich) treatment was also used as a positive control for 
all cell lines. The level of IL-8 production by HEK cells was measured from the 
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supernatant, using an ELISA kit (BD OptEIA, Becton Dickson) following the 
manufacturer’s protocol.  
 
Bone Marrow Derived Macrophages (BMDM) 
PorB activity and endotoxin content were examined by stimulation of BMDM 
generated from the femurs and tibias of WT, MyD88-/-, TLR2-/- and TLR4-/- mice 
(Zhang, Goncalves, & Moser, 2008). Muscle tissues were removed and bone marrow was 
flushed out from the bones with RPMI 1640 (Gibco, Life Technologies, USA) using a 27 
1/2G needed. Single cell suspensions were prepared by disruption using a 70µm nylon 
mesh (ThermoFisher Scientific). Erythrocytes were removed using 1ml of Ammonium-
Chloride-Potassium lysis buffer (ACK Lysis buffer) (4.15g NH4Cl, 2.5g KHCO3, 500 µl 
of 0.5M EDTA, and bring final volume to 500ml for 1X ACK lysis buffer). The cells 
were washed in PBS, pelleted, and then plated in RPMI 1640 supplemented with 10% 
FBS (Cellgro), 100 U/ml penicillin (Sigma-Aldrich, St. Louis, MO, USA), 100 µg/ml 
streptomycin (Sigma-Aldrich) and 25% 0.22 µm-filtered L929 supernatant (a M-CSF 
secreting cell line) supplemented media. Cells were plated in un-coated petri dishes 
(ThermoFisher) with a total volume of 11 ml incubated at 37 ˚C for 7 days. On day 7, 
plates were washed with PBS and cells lifted with 3 ml of lidocaine solution (4mg/ml and 
10mM EDTA). Cells were washed, re-suspended and plated at the appropriate density for 
experiments.  
	  
		
32 
Immunizations 
WT, B-Cells MyD88-/-, DC-MyD88-/- and Mac-MyD88-/- mice between the 
ages of six to twelve weeks were immunized subcutaneously at the base of the tail three 
times at two-week intervals (Figure 2.1) with a 28g 1/2 insulin syringe (Becton Dickinson 
Cat# 329461 containing 100 µl of the vaccine. Mice were immunized with 10 µg of 
Neisseria meningitidis Porin B (PorB), MPL-A (Invivogen, Cat# tlrl-MPL), or CpG 
(Invivogen, Cat# ODN1826) admixed with 10 µg of Ovalbumin (OVA, prepared in 
house). Alum vaccinations contained 200 µg of Aluminium Hydroxide, Alum, (Sigma, 
Cat# A8222) mixed with 10µg of OVA. MF-59 based vaccines were prepared by mixing 
50µl of MF-59 (gift from Anja Seubert, Novartis Vaccines & Diagnostics) with 50µl PBS 
containing 10µg of OVA and the 100µl vaccine was administered subcutaneously. Mice 
were immunized with either PBS (Corning, Cat# 21-040-CV) or 10µg of (OVA) as 
controls. There were at least 4 mice per group and single experiments were repeated to 
obtain a total of 8 to 12 mice per group. The amount of adjuvants and OVA antigen 
utilized were based on previously published studies and falls within the best range of 
their efficacy (Calabro et al., 2011; Chen et al., 2001; Massari et al., 2006; Needham et 
al., 2013; Seubert et al., 2011).  
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Figure 2.1. Immunizations and tail bleed schedule. 
 
Murine Phlebotomy from Tail Vein 
Mice were warmed under heating lamp and put in a restrainer. The tail was nicked 
with a blade and blood was collected in heparin containing tubes (40µl of 1X heparin). 
Sera were isolated from the blood collected prior to each immunization and two weeks 
after the last immunization. For serum cytokine measurements, pre-immune sera as well 
as sera from 4 hours post immunization were collected (Figure 2.1). This time point was 
selected based on our examinations of other time points and previously published study 
(Valensi, Carlson, & Van Nest, 1994). 
 
Measurement of Antigen Specific Antibodies 
Sera were assayed for OVA-specific immunoglobulin by Enzyme-Linked 
Immunosorbent Assay (ELISA) as previously described (Liu et al., 2008; Platt et al., 
2013). Briefly, wells were coated with OVA (5 µg/mL) in carbonate buffer and incubated 
overnight at 4°C. Sera were sequentially diluted starting at 1:50 and added to the 
previously coated wells, and incubated overnight at 4°C. Alkaline phosphatase-
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conjugated anti-mouse total IgG or IgG1, 2b, 2c or 3 subclasses (Sigma Aldrich, St 
Louis, MO) were added. After washing, the ELISA was developed with one-step p-
nitrophenyl phosphate (Pierce, Rockford, IL) and the optical density (OD) at 405 nm was 
measured on a SpectraMax190 Microplate Reader (Molecular Devices, Sunnyvale, CA). 
Colorimetric values were converted to nanograms/milliliter, according to standard curves 
generated by known amounts of IgG as previously described (Mackinnon et al., 1999b) 
using GraphPad Prism. End point titers were determined for IgG subclasses. 
 
Sectioning for Fluorescent Microscopy 
Harvested spleens of immunized mice were embedded in Optimal Cutting 
Temperature (OCT) medium (Richard Allan Scientific, Kalamazoo, MI, USA) in molds 
(ThermoFisher) and flash frozen in an isopropanol and dry ice bath and stored at -80ºC. 
Sectioning was performed on a cryostat (Microm HM 550, Microm International GmbH, 
Walldorf, Germany). Embedded spleens were removed from molds, placed on mounts 
and allowed to equilibrate to the -20˚C internal temperature of the cryostat for about 15 
minutes. For initial trimming 20 µm slices were made until the tissue was visible at the 
surface of the block. Sections of 8 µm thickness were obtained and placed on lysine 
treated slides (Colorfrost Plus, ThermoFisher). Six sections were cut per mouse and a 
total of 18 sections for the three mice per immunization group (Figure 2.2). About 24µm 
or more of tissue were cut between the collected sections and special attention was given 
to the location of the germinal center upon imaging to prevent quantitation of the same 
germinal centers. 
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Figure 2.2. Frozen spleen-sectioning scheme. 
Six sections were examined per mouse and there were 3 mice per immunization group. 
 
Confocal Microscopy 
Mice were immunized as describe above. Spleens from mice (N=3) were 
harvested 7 days after the second immunization, frozen and sectioned as described above. 
For positive control WT mice were immunized with sheep red blood cells via retro-
orbital injections and seven days after injection spleen sections were analyzed (Figure 
2.3). Sections were air dried for 15 minutes at room temperature, then fixed in acetone at 
-20˚C for 10 minutes and air dried for 10 minutes. Afterwards, sections were re-hydrated 
in Tris-Buffered Saline solution (TBS) with 0.05% Tween-20 (TBS-T) then blocked for 
20 minutes at room temperature with TBS-T with 5% BSA. Sections were rinsed with 
TBS-T and then stained with antibodies for 1 hour followed by two rinses with TBS-T 
and incubated in a TBS-T bath for 5 minutes on an orbital shaker. The following 
antibodies were used at 1 to 200 dilution: FITC Rat anti-Mouse B and T cell Activation 
Antigen Clone: GL-7 (Beckton Dickinson Biosciences, San Jose, CA), PE anti-Mouse 
IgD Clone: 11-26c.2a (BioLegend, San Diego, CA) and Alexa Fluor 647 anti-Mouse 
TCR-β Clone: H57-597 (BioLegend, San Diego, CA). Stained sections were mounted in 
Spleen 	
24µM	
8µM 	
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Fluoroshield mounting medium with DAPI (Abcam, Cambridge, MA), covered with a 
cover glass and dried overnight. A Leica TCS Sp5 DMI6000 confocal microscope (Leica 
AG, Wetzlar, Germany) was used to examine the sections using the Leica Application 
Suite Advanced Fluorescence (LAS AF) software. Four separate lasers were used to 
excite the 4 different fluorochromes used and the appropriate gating was applied to 
prevent emission spectral overlap during capture. The 10x objective (HC PL FLUOTAR 
10.0x0.3 Dry) with a numerical aperture of 0.3 was used to capture the images with 4 
lines average at 200Hz with a resolution of 1024x1024 and at 16 bit. The images were 
analyzed and area measured using Image processing analysis in Java (ImageJ, NIH). 
Areas less than 400µm2 were excluded, as they could not be measured accurately using 
the freehand selection feature in the software (Figure 2.3).  
 
Figure 2.3. Germinal center staining. 
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Spleen sections stained for germinal center from a mouse injected with sheep red blood 
cells via a retro-orbital route. This image was capture using the 64x objective. This 
mouse was used as a positive control to identify germinal center and to titrate antibody 
before use. All other experimental mouse received subcutaneous immunization and 7 
days after the 2nd immunization spleens were harvested, stained and analyzed and as 
describe in methods. Germinal center B cells were stained with FITC GL-7, T cells with 
Alexa Fluor 647 TCR-β and follicular B cells PE IgD. 
 
Flow Cytometry 
Germinal Center cells were examined using a BD LSRII Flow Cytometer 
(Beckton Dickinson Biosciences, San Jose, CA) in the Boston University Flow Core. 
Spleens and draining lymph nodes from mice (N=3) were harvested 7 days after the 
second immunization and single cells suspension were prepared. Red blood cells were 
lysed with ammonium-chloride-potassium lysis buffer prepared in house (ACK Lysis 
Buffer). Cells were washed with cold FACS buffer (0.5% FBS + 2mM EDTA in PBS) 
then stained for 30 minutes at 4°C with fluorescently labeled antibodies in 40 µl of FACS 
buffer in 96 well plate then washed and transferred in FACS cluster tube for analysis. The 
following antibodies were used: FITC Rat anti-Mouse B and T cell Activation Antigen 
Clone: GL-7, APC Rat anti-Mouse CD4 Clone RM4-5, Biotin Rat anti-Mouse 
CD45R/B220 Clone: RA3-6B2 (Beckton Dickinson Biosciences, San Jose, CA) and 
PE/Cy7 anti-Mouse CD19 Clone: 6D5 and PE Strepavidin (BioLegend, San Diego, CA). 
Forward and Side Scatter gates were used to identify live cells (gating strategies were 
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similar to Figure 3.4) and cells that were CD4-, B220+, CD19+, and GL7+ were gated as 
germinal center B cells as illustrated in Figure 2.4. All gates were based on PBS 
immunized as negative control (Figure 2.4). Single cell suspensions from spleens and 
inguinal, axillary and brachial lymph nodes from WT, B-Cell-MyD88-/-, DC-MyD88-/- 
and Mac-MyD88-/- mice were prepared as described above. Cells were stained with 
fluorescently labeled antibodies and the number of CD8+ T-cells, CD11b+F4/80+ 
macrophages, CD19+ B cells, CD11c int B220+ Ly6C+ CD19- pDCs, CD11c+B220- 
DCs, CD11b+Ly6G+ PMNs, NK1.1+CD4- T-cells and CD4+ T-cells were measured by 
flow cytomteric analysis. Differences between the number of cells in WT and the 
different MyD88 Floxed mice were calculated using One Way ANOVA with Bonferroni 
test. Analysis was performed using FlowJo (Tree Star, Ashland, OR, USA). 
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Figure 2.4. Germinal center cells gating strategy by Flow Cytometry. 
Percentage of germinal center cells from spleen was measured by Flow Cytometry 7 days 
after the 2nd immunization and gating for B220+CD4-CD19+GL7+ germinal center 
cells. The results shown here are just representative FACS plots. This was done for at 
least two experiments with a total N = 8 mice per immunization group for the Flow 
Cytometry analysis experiment. One-way ANOVA with Tukey test were used (ns: not 
significant P>0.05, *P<0.05, **P<0.01, ***P<0.001 and ****P<0.0001).  
 
Measurements of Cytokines 
Cytokine levels were measured from sera obtained 4 hours post each 
immunization and compared to pre-immune sera. Sera from similar immunization group 
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were pooled together (N=8 mice), used in duplicate and screened on a MAGPIX XMAP 
instrument (Luminex, Austin, TX) in duplicate using Mouse 20-plex cytokines kits (Life 
Technologies). Individual standard curves were generated for individual cytokines and 
analyzed using the Luminex Xponent software. Unknown sample concentration was 
extrapolated from standard curves for single analytes. All values outside of the standard 
curve limit were rejected. 
 
Statistics 
Statistics were calculated using GraphPad Prism. Differences in OVA-IgG 
concentration between WT and the different MyD88 Floxed mice were calculated using 
One Way ANOVA with Tukey test. Differences in percentage of germinal center cells 
and area of germinal centers were calculated using the non-parametric Mann-Whitney U 
test. In all experiments significance levels were defined as ns = p>0.05, *=P<0.05, 
**=P<0.01, ***=P<0.001 and **** P<0.0001.  
 
Methods for Chapter Four: 
Animals and Immunizations 
All Wild Type (WT) C57BL/6J mice were purchased from Jackson Laboratories. 
All mice were maintained in the Association for Assessment and Accreditation of 
Laboratory Animal Care International accredited facility at Boston University School of 
Medicine Laboratory Animal Science Center (LASC). All animal experiments were 
conducted under approved IACUC protocol for Dr. Wetzler’s Laboratory at Boston 
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University. WT mice between the ages of six to twelve weeks were immunized 
subcutaneously two or three times at two-week intervals. Mice were immunized with 
10µg of Neisseria meningitidis Porin B (PorB) admixed with 10µg of ovalbumin (OVA). 
Mice were immunized with either PBS or 10µg of OVA as controls. There were at least 4 
mice per group and single experiments were repeated to obtain a total of 8 mice per 
group. PorB was purified from N. meningitidis strain H44/76 Δ-1/4 (Mackinnon et al., 
1999b) using protein extraction and column chromatography as previously described 
(Massari et al., 2005) and as thoroughly described in Chapter 3 above. Activity of PorB 
and endotoxin content were examined by stimulation of WT, MyD88-/-, TLR2-/- and 
TLR4-/- BMDM and analysis of supernatant for TNF-α, silver staining and LAL assay 
(Pierce Endotoxin Kit from Life Technologies) as described in Chapter 3 above, no 
endotoxin was found in any preparations. The amount of adjuvant PorB and OVA antigen 
utilized were based on previously published studies and falls within the best range of 
their efficacy (Massari et al., 2006). Sera were collected via tail bleed for serum cytokine 
measurements, pre-immune sera as well as sera from 4 hours or 12 hours post 
immunization were collected. This time point was selected based on our examinations of 
other time points and previously published study (Valensi et al., 1994).  
 
Chemokine and Cytokine Screening 
Cytokine levels were measured from sera obtained 4 hours or 12 hours post each 
immunization and compared to pre-immune sera. Sera from similar immunization groups 
were pooled together (N=8 mice), used in duplicate and screened on a MAGPIX XMAP 
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instrument (Luminex, Austin, TX) using Mouse 20-plex cytokines kits (Life 
Technologies). Individual standard curves were generated for each cytokines and 
analyzed using the Luminex Xponent software. Unknown sample concentration was 
extrapolated from standard curves for single analytes. All values outside of the standard 
curve limit were rejected. 
 
Antigen Specific T cells 
WT mice were immunized as described above and spleens harvested on day 11 
after the 2nd immunization. This was also done for 14 days after the 3rd immunization and 
7 days after the 3rd immunization. There were 3 to 4 mice per group and experiments 
were repeated with a total of 6 to 8 mice per group. Single cell suspensions were 
prepared. Red blood cells were lysed with ammonium-chloride-potassium lysis buffer 
(ACK Lysis Buffer) as described above, prepared in house. Cells were counted using a 
hemocytometer. ELISPOT plates (Cat# MAIPS4510, Merck Millipore, Ireland) were 
coated for 3 hours at room temperature with anti-mouse IFN-γ (5 µg/ml) (mAb AN18, 
Mabtech, Sweden) or anti-mouse IL-4 (7.5 µg/ml) (mAb 11B11, Mabtech, Sweden) or 
PBS. Plates were washed with PBS. Cells were plated at a density of 5x104 and 5x105 
cells per well in 4 replicates per mouse per condition in RPMI 1640 media (Corning, 
Corning NY) supplemented with 8% fetal bovine serum (Corning, Corning NY). Cells 
were stimulated with OVA323-339 CD4 peptide (ISQAVHAAHAEINEAGR, ANASPEC, 
Fremont, CA), OVA257-264 CD8 peptide (SIINFEKL, ANASPEC, Fremont, CA) or 
OVA257-254 scrambled peptide (FILKSINE, ANASPEC, Fremont, CA). All peptides were 
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used at 5 µg/ml. Cells from each mouse were also plated with media alone or with 
purified α-CD3/CD28 (1.5 µg/ml) (Affymetrix eBioscience, San Diego, CA). All 
stimulations were performed overnight at 37°C. Plates were then washed with PBS 
containing 0.1% Tween (PBST) then incubated with secondary antibodies (mAb R4-6A2 
Biotin IFN-γ at 1 µg/ml or mAb BVD6-24G2-Biotin IL-4 at 2 µg/ml)  (Mabtech, 
Sweden) for 1.5 hours at room temperature. Plates were then washed and incubated with 
alkaline phosphatase-conjugate streptavidin (Jackson Immuno Research Lab, West 
Grove, PA) (1:1000) for 30 minutes. Plates were washed and developed with Vector Blue 
Substrate Kit (Vector Lab, Burlingame, CA) until spots are clearly visible. Plates were 
read on an ImmunoSpot CTL Reader instrument and using the ImmunoSpot software 
(CTL Worldwide, Shaker Heights, OH) where the spots were quantified for each well 
and were put through a quality control check, data analyzed and graphed using GraphPad 
Prism.  
 
Bacterial Infection 
WT mice were immunized as described above and infected with recombinant 
Listeria monocytogenes expressing OVA with resistance to erythromycin (rLmOVA) via 
retro-orbital injection two weeks after the 3rd immunization. rLmOVA was a generous 
gift from Hao Shen (University of Pennsylvania) (Foulds et al., 2002). Frozen aliquots of 
rLmOVA were streaked on BHI plates (prepared in house according to manufacturer’s 
protocol) (Remel BHI Cat# R452452) supplemented with erythromycin at 50 µg/ml. A 
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single colony from the streaked plate was selected and Gram stain performed as 
illustrated in Figure 2.5.  
 
Figure 2.5. Gram stain of recombinant Listeria monocytogenes expressing OVA 
(rLmOVA). 
This is a Gram stain of recombinant Listeria monocytogenes expressing OVA 
(rLmOVA). rLmOVA is a Gram positive rod shaped bacterium. 
 
This colony was expanded in 5 ml of brain heart infusion (BHI) broth (Beckton 
Dickinson Cat# 221812, 221813) and frozen aliquots prepared. rLmOVA (100µl of 
frozen aliquot) was cultured overnight in 5 ml of BHI broth (Beckton Dickinson Cat# 
221812, 221813) with erythromycin at 50µg/ml. Subculture was performed by 
transferring 10 µl, 20 µl or 50 µl of overnight culture to 5 ml of BHI broth and culture for 
3 hours then the optical density at 600nm was measured on a SmartSpec 3000 
spectrophotometer. The O.D closest to 0.1 was used to prepare the infectious doses 
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during bacterial log phase and used to infect mice. Colony forming units (CFU) of each 
injectable dose was determined by plating injectable doses of bacteria before and after 
injection in mice to get an accurate CFU per mouse. Mice received either a low dose of 
1x105 or 5x105 bacteria per mouse for bacterial burden experiments, or a high dose of 
1x106 bacteria per mouse for survival experiment as illustrated in Figure 2.6. Three days 
after a low dose infection, mice were euthanized, organs perfused with PBS and spleen 
and liver harvested. Single cells suspensions were prepared from the spleen and the total 
number of cell was quantitated using a hemocytometer. The weight of each liver was 
recorded. The organs were permeabilized using 0.5% TritonX-100 (MP Biomedicals, 
France) and homogenized in stomacher bags. The processed tissues were diluted for 
plating on BHI Agar (prepared in house with Erythromycin). Un-diluted, 1:10, 1:1 000, 
1:10 000 and 1:100 000 diluted samples were plated in triplicate and incubated overnight 
at 37°C. CFU were calculated and normalized to the weight of the livers or number of 
cells in spleen. Mice receiving a high dose infection were monitored multiple times 
throughout the 24-hour period until they succumbed to the infection. 
 
Figure 2.6. Immunization and infection schedule. 
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Mice were immunized as described and infected with a low or high dose of rLmOVA. 
Day 3 after the low dose infection, bacterial burden was measured in liver and spleen as 
described in Methods. Mice receiving a high dose of rLmOVA were monitored multiple 
times a day until they succumb to the infection. 
 
Statistics 
Statistics were calculated using GraphPad Prism. When comparing more that two 
immunization groups at time, One Way ANOVA with Tukey test was used. For 
comparing OVA/PorB with OVA alone for bacterial burden, the non-parametric Mann-
Whitney U test was used. In all experiments significance levels were defined as ns = 
p>0.05, *=P<0.05, **=P<0.01, ***=P<0.001 and **** P<0.0001. The Mantel-Cox Test 
was used to compare the survival distributions of OVA/PorB and OVA alone 
immunization group (*** P = 0.0001). 
 
Methods for Appendix 
Hock Injections 
We used a hock immunization model to examine recruitment of DCs to draining 
lymph nodes (Kamala, 2007) and presence of OVA in the draining lymph node. This was 
done in accordance with the BU IACUC. This is an ideal model because the vaccine 
content is able to drain to a known lymph node (popliteal node) while injection in the 
opposite leg can be use as a control. The mice were restrained, and a 31g needle was used 
to inject 10 µl of the vaccine preparation into the hock (lateral part of the ankle), an area 
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with minimum blood vessels. Extra precautions were taken to avoid hitting any blood 
vessels. The mice were vaccinated with 5 µg Ova-A594 (Life technologies) in one ankle 
and 10 µg PorB + 5 µg Ova-A594 in the second hock area. This allowed the contralateral 
ankle of each mouse to be used as an internal control. 
 
Frozen Lymph Node  
24 hours after hock vaccinations, mice were euthanized, and the draining popliteal 
lymph nodes (pLNs) were removed and cleaned in PBS. pLN were quickly rolled on kim 
wipes to remove excess PBS and fat. The pLN was oriented appropriately in optimum 
cutting temperature (OCT) medium with the hilar blood vessels pointing sideways in the 
mold and flash frozen as describe in Chapter 3 above. The pLN were cut vertically on a 
cryostat as described above. 
 
In vivo and in vitro Microarray Analysis of PorB Adjuvant Activity 
C57BL/6J (WT) mice were given three immunizations at two weeks interval. 
There were 10 groups of three mice each. The vaccine formulations contained 10 µg 
OVA, 10 µg PorB or 10 µg OVA admixed with 10 µg PorB. Control mice were mock 
immunized with three injections of PBS only. All vaccines were administered in 100 µl 
of PBS subcutaneously. 24 hours after the specific vaccinations, mice were euthanized 
and spleens collected. Spleens were harvested in 1 ml RNAlater (Qiagen, Venlo, 
Netherlands) to avoid RNA degradation. RNA was extracted using RNEasy kits (Qiagen) 
according to the manufacturer’s instructions. Approximately one third of the spleen was 
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diced with sterilized scissors and then disrupted using a tissue homogenizer (PRO 
Scientific, Oxford, CT, US) for the initial processing steps. Purified RNA was checked 
for quality and concentration on a Nanodrop system (Thermo Fisher Scientific). RNA of 
known concentration and purity was delivered to the Boston University School of 
Medicine Microarray Core for reverse transcription and analysis on Affymetrix Mouse 
Gene 1.0 microarray chips (Affymetrix, Santa Clara, CA, US). Preliminary data analysis 
was performed by Adam Gower of the Clinical and Translational Science Institute 
(CTSI) of BUSM. 
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CHAPTER THREE 
Intact MyD88 Signaling in Macrophages is Required for Antibody and Germinal 
Center Induction by TLR-Ligand Based Adjuvants. 	
Abstract 
Vaccines are vital in the fight against infectious diseases and immune stimulating 
adjuvants are essential for enhancing vaccine efficacy. However the precise mechanisms 
of action of most adjuvants are unknown. We have investigated the role of cell specific 
MyD88 signaling in vaccine adjuvant activity in vivo, using Neisserial PorB, a TLR2-
ligand based adjuvant, along with a variety of TLR-dependent (CpG, MPLA) and 
independent (Alum, MF59) adjuvants. We found that intact MyD88 signaling is essential, 
separately, in all three APC types (B cells, macrophages and DCs) for optimal TLR-
ligand based adjuvant activity. However, the immune response was reduced to the 
greatest extent in mice with macrophage specific MyD88 deletion (Mac-MyD88-/-). We 
demonstrated that TLR-dependent adjuvants are potent inducers of germinal center (GCs) 
responses, but GCs are nearly absent in Mac-MyD88-/- mice upon immunization with 
TLR-dependent adjuvants PorB or CpG, but not with TLR-independent adjuvants MF59 
or Alum. In addition, intact MyD88 signaling in macrophages is crucial for the induction 
of cytokines important for GC formation when immunized with TLR-ligand based 
adjuvants. Our findings, reveal a unique and here-to-for unrecognized importance of 
intact MyD88 signaling in macrophages, to allow for a robust vaccine induced immune 
responses when TLR-ligand based adjuvants are used.  
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Introduction  
Immune adjuvants are necessary in most, if not all, vaccines, to enhance efficacy 
by increasing the immunogenicity of poorly immunogenic antigens. Adjuvants can be 
either exogenously added or are inherent in the vaccine preparations, e.g. live attenuated 
or killed whole organism vaccines. The majority of adjuvants originate from microbial 
components, referred to as Pathogen Associated Molecular Patterns (PAMPs). Our 
immune system has evolved to respond to these PAMPs and stimulate innate immune 
responses through germ-line Pattern Recognition Receptors (PRRs). TOLL-like 
Receptors (TLRs) are some of the best-studied PPRs used by the immune system to 
respond to PAMPs. Vaccines containing TLR-ligand based adjuvants activate this 
mechanism of innate immunity to enhance a potential protective immune response 
induced by vaccines (Janeway, 1989).   
Adjuvants vary in their character and intensity of responses triggered in vivo.  
Moreover, the mechanism of action for most adjuvants is not very well understood. 
Therefore, in this study, a variety of well-characterized TLR-dependent (TLR2 PorB, 
TLR9 CpG, TLR4 MPLA) and TLR-independent adjuvants (Alum, MF59) were 
examined. Porin B (PorB) is the major outer membrane protein from Neisseria 
meningitidis (Wetzler, 2010). This protein has been investigated as a potential anti-
Neisserial vaccine candidate (Blake et al., 1989; Wetzler et al., 1992; Wetzler, 
Gotschlich, Blake, & Koomey, 1989), through this work it was found that this protein had 
potent immune stimulatory abilities beyond its own potential used as a vaccine. PorB 
stimulates antigen-presenting cells through direct interaction with TLR2/TLR1 
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heterodimers and requires the adaptor protein MyD88 for this stimulation to occur 
(Massari et al., 2002; Massari et al., 2003; Massari et al., 2006; Singleton et al., 2005). 
TLR2, a cell surface PRR, recognizes a wide range of bacterial, fungal and viral 
components and PorB is among the very few TLR2 ligands being investigated as a 
vaccine adjuvant. For comparison to PorB, an endosomal TLR9 dependent adjuvant, CpG 
DNA (CpG) was used in this study. CpG is composed of synthetic oligodeoxynuclotides 
and contains unmethylated bacterial DNA motifs. It binds to TLR9 and needs MyD88 as 
an adaptor protein to normally induce a Th1 type response (McCluskie et al., 2013). 
Monophosphoryl lipid A (MPLA) is a synthetic lipid A derived from E.coli. The 
bioactive part of LPS has been detoxified while maintaining its immune-stimulating 
activity (Johnson et al., 1987). MPLA adjuvant activity depends on TLR4 and signals 
through not just MyD88 but also TRIF adaptor proteins (Casella & Mitchell, 2008) for 
that reason it was used for comparison to PorB. MPLA is also the first licensed TLR-
ligand based adjuvant used in vaccine in United States, enhancing humoral and cellular 
immune responses when used in the human HPV vaccine (Maisonneuve et al., 2014). 
PorB was also compared to two TLR-independent adjuvants. Aluminum salt (Alum) is 
the first adjuvant approved by the FDA as part of a vaccine formulation and has been in 
use for over 80 years in millions of vaccine doses. Alum induces mainly Th2 type 
immune responses and its effect is MyD88 and TRIF independent (Gavin et al., 2006). 
MF59, consisting of an oil-in-water squalene solution, has been a licensed adjuvant in the 
formulation of the seasonal influenza vaccines since 1994 in Europe (manufactured by 
Novartis Vaccines, now GSK Vaccines). The adjuvanticity of MF59 appears to be 
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MyD88 dependent but TLR independent (Seubert et al., 2011).  
TLRs are commonly expressed in various cell types, especially in antigen 
presenting cells (APC), including dendritic cells (DCs), B cells and macrophages (Akira, 
Takeda, & Kaisho, 2001; Medzhitov, 2001). TLR-ligand based adjuvants are used in 
vaccines to stimulate these immune cells, providing appropriate signals (sometimes 
termed signal 3) to induce and boost protective immune responses, linking the innate and 
adaptive immunity (Janeway, 1989). Investigators have shown that incorporation of 
glucopyranosyl lipid adjuvant (GLA, binding to TLR4) in an oil/water emulsified malaria 
vaccine can greatly increase diversity of the antibody repertoire (Wiley et al., 2011). 
Another study, also utilizing GLA as TLR4-ligand based adjuvant, has shown that an 
investigative tuberculosis vaccine resulted in enhanced protection in animal models 
(Baldwin et al., 2012). The successful yellow fever vaccine has been shown to activate 
multiple subsets of DCs by signaling through a specific set of TLRs (TLR2, 7, 8 and 9) 
(Pulendran & Ahmed, 2006). Absence of one of these TLRs affected the type of 
responses induced by the vaccine on DCs in vitro (Pulendran & Ahmed, 2006). It has 
also been demonstrated that MyD88 signaling in B cells in vivo is critical for induction of 
antibody secreting cells upon vaccination (Kang et al., 2011). It is also important for 
induction anti-retroviral germinal center response (Browne, 2011) and required for 
induction of functional CD4 T cells producing IFN-γ for the control of IgG 2c subclass 
production (Barr, Brown, Mastroeni, & Gray, 2009). Another interesting study showed 
that generation of T cell-dependent (TD) antigen specific antibody responses requires 
TLR and MyD88 signaling in naïve human B cells and that TLR stimulation of DCs 
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alone is not sufficient to induce T cell-dependent B-cell responses (Pasare & Medzhitov, 
2005; Ruprecht & Lanzavecchia, 2006). Germinal center (GC) formation is crucial for 
the production of antibody secreting cells including memory B cells, which produce class 
switched isotypes and high affinity antigen specific antibodies, and is essential for a rapid 
recall response to antigens (De Silva & Klein, 2015). Intact TLR-MyD88 signaling in B-
cells and DCs has previously been shown to be important for induction of robust 
germinal centers and antibody production upon stimulation with TLR-ligand based 
adjuvants (DeFranco, Rookhuizen, & Hou, 2012). Intrinsic DC MyD88 signaling in vivo 
has been shown to be important for induction of Th2/Th1 cells that have functional helper 
functions (Sporri & Reis e Sousa, 2005), induction of robust humoral response with 
TLR9 ligand CpG (Hou et al., 2011) and activation of adaptive immune responses (Hou 
et al., 2008). However, the contribution of macrophage intrinsic MyD88 signaling in 
vaccine adjuvant responses in vivo has never been investigated. 
Altogether, these findings clearly demonstrate that TLR recognition and signaling 
via the MyD88 adaptor protein are crucial for immune responses triggered by TLR-ligand 
based adjuvant formulated vaccines (Hornung et al., 2002). A better understanding of the 
role of intact in vivo MyD88 signaling in specific immune cells, namely B cells, DCs or 
macrophages, in TLR-ligand based adjuvant immune enhancing activities and subsequent 
vaccine efficacy can aid in the more effective use of these adjuvants in vaccines. In this 
study, we used the loxP/cre recombinase system to conditionally knock out MyD88 in the 
individual APC types in vivo. Immunizations of these mice revealed the importance of 
proper MyD88 signaling in each APC type, individually, in the adjuvanticity of TLR 
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dependent and independent adjuvants. Our findings, reveal a vital role for macrophages, 
in general, as well as intact in vivo MyD88 signaling in these cells, to trigger a robust 
vaccine induced immune responses including germinal center formation, when TLR-
ligands are used as adjuvants. 
 
Results 
Isolated PorB has TLR stimulating activity and is free of endotoxin. 
 PorB concentrations were determined using the BCA assay immediately after the 
purification process as described in (Massari et al., 2005). Afterwards PorB was analyzed 
using polyacrylamide gel electrophoresis (PAGE) denaturing and non-denaturing. PorB 
forms larger aggregates above the 95kDa band on the gel, also termed “proteosome”, 
which are the nanoparticle form of PorB as shown in Figure 3.1(A) in lane 2 to 5 in the 
non-denaturing gel. These likely represent the proteosomes, protein micelles formed from 
the porins, which we use for cell stimulation (see methods and Figure 1.1). When boiled 
and examined on a denaturing gel, PorB can be observed in its denatured form at 
~36kDa, as demonstrated in Figure 3.1(B). Various concentrations of OVA were also run 
on the gel for comparison. Figure 3.2 shows that purification process along with the use 
of the Matrex column successfully removed endotoxin from PorB, as determined by the 
silver-staining assay. In addition to silver staining, we validated the low endotoxin 
content using the very sensitive LAL assay. There was no endotoxin activity present in 
PorB or OVA used in our experiments. The above mentioned assays were performed on 
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every preparations of PorB to make sure it is a clean preparations and able to form its 
bioactive trimeric form. 
 
Figure 3.1 Purified PorB preparations analyzed on non-denaturing and denaturing 
12% PAGE gel. 
PorB preparations were examined on A) Non-denaturing PAGE, samples (10µg/lane for 
PorB and varying concentrations for OVA) were separated in a 12% PAGE. B) 
Denaturing SDS-PAGE where samples were boiled for 5 minutes in 5% of β-
mercaptoethanol in SDS containing loading buffer. Sample loading buffer contained 20% 
glycerol and bromophenol blue. The gels were stained in Coomassie Blue staining 
solution as described in methods. Images were acquired on a Biorad Gel Doc XR 
imaging system (Biorad, USA). C) Table indicating which sample was loaded in the 
A)	
B)	
C)	
		
56 
specific wells. This figure is representative of different PorB preparations that originated 
from one bacterial growth. This particular PAGE was performed by Michael Reiser in the 
laboratory. 
 
 
Figure 3.2 Purified PorB preparations analyzed on a silver stained gel for endotoxin 
content. 
PorB samples at 5µg/lane were loaded in lane 1 to 8 and Neisserial LOS in lane 9. Lane 1 
to 7 demonstrates that the purification steps were able to remove the endotoxin; lane 8 
shows a positive control sample that contained LPS or LOS. 
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Figure 3.3. Purified PorB has TLR stimulating activity and lacks endotoxin activity. 
The activity of purified PorB was analyzed using BMDMs originating from WT, TLR2-/-
, TLR4-/- and MyD88-/- mice. These cells were also stimulated with Pam3CSK4 and LPS 
to directly compare their stimulating ability to PorB. TNF-α from the supernatant was 
assessed as surrogate for activation of the respective BMDM type. Concentrations of 
TNF-α in pg/ml from supernatant of stimulated BMDMs interpolated from known 
standards. The symbol (-) indicates that the TNF-α was below detectable level. This 
figure was prepared in Prism and displayed as the mean with SEM. 
 
The activity of the purified PorB was analyzed in vitro by examining its ability to 
stimulate BMDM generated from WT, TLR2-/-, TLR4-/- and MyD88-/- mice and 
comparing this activity to un-stimulated control, a TLR2 ligand (Pam3CSK4) or a TLR4 
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ligand (LPS) used as positive control. PorB stimulated WT BMDM, inducing high 
amounts of TNF-α, greater than Pam3CSK4 and comparable to LPS (Figure 3.3). This 
activity was TLR2 dependent, as TNF-α was not detected in the supernatants from 
BMDMs generated from TLR2-/- or MyD88-/- mice. TLR2-/- mice still express normal 
levels of TLR4, as we did not detect TNF-α using these cells, this further confirms that 
the PorB preparations do not contain a biologically active amount of LPS (Figure 3.3). In 
TLR4-/- BMDM, LPS was unable to induce TNF-α as expected, while PorB induced a 
greater amount, as compared to un-stimulated or LPS stimulated BMDM (Figure 3.3). 
 
The Requirement of in vivo MyD88 Signaling in Macrophages, B-cells and Dendritic 
Cells, individually, for TLR-ligand Based Adjuvant Function.  
We have previously demonstrated that PorB lacks adjuvant activity in MyD88 
KO mice (Massari et al., 2002) and were unable to stimulate BMDM from MyD88-/- 
mice (Figure 3.3). In this study, we examined the effect of deficient MyD88 signaling, 
separately, in each type of APC on the adjuvant activity of PorB and other TLR-ligand 
based adjuvants. We used MyD88 conditional KO mice, with MyD88 deletion in specific 
APC types (B-cells, dendritic cells or macrophages). MyD88flx/flxCD19Cre, 
MyD88flx/flxCD11cCre or MyD88flx/flxLysmCre mice (termed B-cells MyD88-/-, DC-
MyD88-/- and Mac-MyD88-/- mice respectively) were generated by breeding 
MyD88flx/flx mice with mice expressing Cre recombinase under cell specific promoter as 
described in the methods. Previous studies have shown efficient deletion of MyD88 in 
dendritic cells and B cells from the DC-MyD88-/- mice and B-cells MyD88-/- mice, 
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respectively (Hou et al., 2008) and macrophages from the Mac-MyD88-/- mice (Hoshi et 
al., 2012) utilizing this method. Congruent with past studies, MyD88 was efficiently 
deleted as measured by quantitative real time (qRT) PCR (Figure 3.5) from genomic 
DNA isolated from sorted cells (Figure 3.4). CD3-CD11c+CD11b- (DCs), CD3-CD19+ 
(B-cells) and CD11b+F4/80+ (macrophages) were sorted from WT, DC-MyD88-/-, B-
cells MyD88-/- and Mac-MyD88-/- mice as shown in Figure 3.4 A to G. Deletion of 
MyD88 was confined to a specific cell type while the other APC types expressed high 
level of MyD88 (Figure 3.5). Percentages and numbers of the CD8+ T-cells, 
CD11b+F4/80+ Macrophages, CD19+ B cells, CD11c int B220+ Ly6C+ CD19- 
plasmacytoid DCs, CD11c+B220- DCs, CD11b+Ly6G+ PMNs, NK1.1+CD4- T-cells 
and CD4+ T-cells from spleen (Figure 3.6A-H) and six different lymph nodes (Figure 
3.7A-H) in these three transgenic mice were also examined. There were no significant 
differences in the major cell types as compared to WT mice suggesting that deletion of 
MyD88 in the specific cell types did not affect these cell populations in the lymphoid 
organs. 
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Figure 3.4. Gating strategies for Flow Cytometry analysis for sorting of B-cells 
(CD3-CD19+), DCs (CD11b-CD11c+) and macrophages (CD11b+F4/80+).  
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Spleens from WT, B-Cell-MyD88-/-, DC-MyD88-/- and Mac-MyD88-/- mice were 
harvested, single cell suspensions were prepared and red blood cells lysed. The 
splenocytes were analyzed with the live/dead stain (Zombie Aqua viability kit), Pacific 
Blue anti-CD3, PerCP-Cy5.5 anti-CD19, FITC anti-CD11b, APC anti-CD11c, and PE 
anti-F4/80 fluorescently labeled antibodies all purchased from Biolegend. B-cells (CD3-
CD19+), DCs (CD11b-CD11c+) and macrophages (CD11b+F4/80+) were sorted on a 
FACS ARIA II SORP Cell Sorter by their specific cell markers. Dead cells and CD3+ 
cells were gated out. There were two mice per genotype. 
 
 
Figure 3.5. Efficient deletion of MyD88 in specific cell types.  
Amount of MyD88 deletion in various cell types purified from spleens was determined 
by measuring the amount of residual MyD88. DNA from samples sorted as described in 
Figure 3.4 was isolated using DNeasy DNA isolation kit (Qiagen, Hilden, Germany) and 
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quantitated on Nanodrop 2000 (Thermo Scientific, USA). Using quantitative real time 
PCR (qRT-PCR) (Qiagen SYBR Green kit) with the ABI Prism 7000 Sequence Detection 
System, the amount of residual MyD88 was measured in B-cells (CD3-CD19+), 
Macrophages (CD3-CD11b+F4/80+) and Dendritic cells (CD3-CD11b-CD11c+). There 
were two mice per group. The qRT-PCR analysis was done with the threshold cycle (Ct) 
of MyD88 gene normalized to β-actin (internal control) by the Livak method. Each test 
sample was also normalized to the WT samples (calibrator). MyD88 deletion efficacy 
was calculated where 2- ΔΔCt gives us the fold change normalized to the internal control 
and calibrator sample. Percent deletion was calculated.  
		
63 
 
WT
DC
 M
yD
88
-/-
Ma
c M
yD
88
-/-
B 
Ce
lls
 M
yD
88
-/-
0
4000
8000
12000
N
um
be
r o
f C
D
8+
 c
el
ls
pe
r 2
50
00
 C
el
ls
WT
DC
 M
yD
88
-/-
Ma
c M
yD
88
-/-
B 
Ce
lls
 M
yD
88
-/-
0
4000
8000
12000
16000
N
um
be
r o
f 
C
D
19
+ 
B 
ce
lls
pe
r 2
50
00
 C
el
ls
WT
DC
 M
yD
88
-/-
Ma
c M
yD
88
-/-
B 
Ce
lls
 M
yD
88
-/-
0
100
200
300
400
500
N
um
be
r o
f 
C
D
11
c+
B2
20
- D
C
pe
r 2
50
00
 C
el
ls
WT
DC
 M
yD
88
-/-
Ma
c M
yD
88
-/-
B 
Ce
lls
 M
yD
88
-/-
0
500
1000
1500
2000
2500
N
um
be
r o
f 
C
D
4-
 N
K1
.1
+ 
 c
el
ls
pe
r 2
50
00
 C
el
ls
WT
DC
 M
yD
88
-/-
Ma
c M
yD
88
-/-
B 
Ce
lls
 M
yD
88
-/-
150
200
250
300
350
N
um
be
r o
f 
C
D
11
b+
 F
4/
80
+ 
M
ac
ro
ph
ag
es
 
pe
r 2
50
00
 C
el
ls
WT
DC
 M
yD
88
-/-
Ma
c M
yD
88
-/-
B 
Ce
lls
 M
yD
88
-/-
0
40
80
120
160
N
um
be
r o
f C
D
11
c 
in
t B
22
0+
Ly
6C
+ 
C
D
19
- p
D
C
pe
r 2
50
00
 C
el
ls
WT
DC
 M
yD
88
-/-
Ma
c M
yD
88
-/-
B 
Ce
lls
 M
yD
88
-/-
0
200
400
600
800
N
um
be
r o
f 
C
D
11
b+
 L
y6
G
+ 
PM
N
s
pe
r 2
50
00
 C
el
ls
A) B)
C) D)
E) F)
G)
WT
DC
 M
yD
88
-/-
Ma
c M
yD
88
-/-
B 
Ce
lls
 M
yD
88
-/-
0
1000
2000
3000
4000
5000
N
um
be
r o
f C
D
4+
 c
el
ls
pe
r 2
50
00
 C
el
ls
H)
		
64 
Figure 3.6. Deletion of MyD88 in DCs, macrophages or B-cells did not affect the 
different cell populations in the mouse spleen.  
Spleens from WT, B-Cell-MyD88-/-, DC-MyD88-/- and Mac-MyD88-/- mice were 
harvested, single cells suspensions were prepared and red blood cells lysed. Splenocytes 
were stained with fluorescently labeled antibodies and the number of A) CD8+ T-cells, 
B) CD11b+F4/80+ Macrophages, C) CD19+ B cells, D), CD11c int B220+ Ly6C+ 
CD19- pDCs E) CD11c+B220- DCs, F) CD11b+Ly6G+ PMNs, G) NK1.1+CD4- T-cells 
and H) CD4+ T-cells were measured by Flow Cytomteric analysis. There were two mice 
per genotype.  
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Figure 3.7. Deletion of MyD88 in DCs, macrophages or B-cells did not affect the 
different cell populations in the mouse inguinal, axillary and brachial lymph nodes 
combined.  
Single cell suspensions from these 6 draining lymph nodes were prepared and stained 
with fluorescently labeled antibodies and the number of A) CD8+ T-cells, B) 
CD11b+F4/80+ Macrophages, C) CD19+ B cells, D) CD11c int B220+Ly6C+CD19- 
pDCs, E) CD11c+B220- DCs, F) CD11b+Ly6G+ PMNs, G) NK1.1+CD4- T-cells and 
H) CD4+ T-cells were measured by Flow Cytomteric analysis. There were two mice per 
mouse genotype. 
 
WT, B-cells MyD88-/-, DC-MyD88-/- and Mac-MyD88-/- mice were immunized 
with OVA antigen alone or admixed with TLR dependent or independent adjuvants. Two 
weeks after the third immunizations, the vaccine induced antibody responses were 
measured (Figure 3.8 A and B). WT mice mounted a robust antibody response to any 
adjuvant formulation, while immunizations of the transgenic mice revealed that intact 
signaling through MyD88 was required in B cells, macrophages and DCs for optimal 
adjuvant activity of the TLR2 dependent adjuvant PorB, which binds to a cell surface 
TLR (Figure 3.8A). Similar results were observed with CpG, an endosomal TLR9 ligand, 
in the vaccine formulation. This indicates that intact MyD88 signaling is crucial for TLR-
ligand based adjuvants acting through either a surface receptor or an endosomal receptor 
that are dependent on the MyD88 adaptor protein for the induced antibody responses 
(Figure 3.8A). The vaccine containing TLR4 based adjuvant MPLA was able to trigger a 
high level of antigen specific antibody response as compared to PorB or CpG, in all three 
		
67 
different MyD88 conditional knockout mouse strains (Figure 3.8A). However, this 
antibody response was still significantly lower than what was observed in WT mice. This 
data suggests even though TLR4 TRIF signaling is adequate to allow for MPLA adjuvant 
activity, intact MyD88 signaling in all three APC types is required for induction of a 
robust MPLA induced humoral response (Figure 3.8A). In contrast, vaccine formulations 
containing the TLR-independent adjuvants, MF59 or Alum, were able to induce a robust 
humoral response against OVA in mice lacking MyD88 in any of the three APC types 
(Figure 3.8B). This suggests that the decrease in the humoral response when PorB or 
CpG were used as adjuvants is not due to an intrinsic defect in these mice, but, rather, a 
robust humoral response is specifically dependent on a successful MyD88 signaling by 
these TLR-ligand based adjuvants in all these APC types. 
OVA specific antibodies were undetectable two weeks after the first 
immunization. The humoral responses two weeks after the second immunization were 
lower (Figure A2.1 in the Appendix section) as compared to two weeks after the third 
immunization (Figure 3.8A and B). However, a similar trend of decreasing IgG levels 
was observed for B cells-MyD88-/-, DC-MyD88-/- and Mac-MyD88-/- mice as 
compared to WT mice. 
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Figure 3.8. Intact in vivo MyD88 signaling in B cells, DCs or macrophages is 
absolutely required for robust vaccine induced humoral responses by TLR based 
adjuvants.  
Total OVA-IgG concentrations were measured in sera by ELISA following immunization 
with (A) PBS, OVA alone or mixed with TLR-dependent adjuvants PorB, CpG or MPLA 
or (B) with TLR-independent adjuvant MF-59 or Alum. WT, Mac-MyD88-/-, DC-
MyD88-/- and B-cell MyD88-/- mice respectively were immunized three times at two- 
week intervals. The results shown are from samples collected two weeks after the third 
immunization and representative of two experiments with a total of 8 mice per 
immunization group except for PBS and OVA alone where a total of 4 mice were 
immunized. One-way ANOVA with Tukey test were used (ns: not significant P>0.05, 
*P<0.05, **P<0.01, ***P<0.001 and ****P<0.0001). Symbol (-) indicates that IgG 
levels were below detectable level. 
 
One of the interesting finding in the course of this study was that the humoral 
response was affected most in mice with macrophage specific MyD88 deletion following 
immunization with vaccines containing TLR-ligand based adjuvants, as compared to 
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immunization of B cells MyD88-/- and DC MyD88-/- mice (Figure 3.8A). This trend was 
also observed with formulations containing the TLR4-ligand based adjuvant MPLA, but 
the decrease in the anti-OVA antibody levels was less dramatic. This is likely due to 
MPLA’s ability to signal through both the MyD88 and the TRIF pathway, which might 
be able to compensate for the lack of MyD88 signaling. Similar to adjuvant PorB and 
CpG, the antibody levels were most dramatically decreased in the Mac-MyD88-/- mice 
with MPLA in the vaccine formulation. These results indicate the importance of MyD88 
signaling in the different APCs and, importantly, it demonstrates a novel role for MyD88 
signaling in vivo in macrophages for the induction of antigen specific antibodies with 
TLR-based adjuvants.  
 
In vivo Th2/Th1 Type Associated Response Requires Intact MyD88 Signaling in 
Macrophages.  
Given the findings above, the previously examined role of TLR/MyD88 signaling 
in B cells and DCs for antibody production (DeFranco et al., 2012; Pasare & Medzhitov, 
2005) and the presence of unique types of macrophages at specific locations within the 
lymphoid organs (Gray & Cyster, 2012), further studies were performed to characterize 
the role of MyD88 signaling in macrophages in vivo upon immunization with TLR-ligand 
based adjuvants. Th2/Th1 type associated responses, as measured by antigen specific 
antibody subclasses and cytokines levels were dramatically decreased in Mac-MyD88-/- 
mice, when immunized with PorB/OVA; Th2 associated anti-OVA IgG1 levels were 
greatly diminished as compared to WT mice (Figure 3.9A). A similar decrease in OVA-
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IgG1 levels was observed when either MPLA or CpG were used as an adjuvant. In 
contrast, vaccines containing TLR independent adjuvants MF59 or Alum mixed with 
OVA induced high levels of antigen specific IgG1 antibody in both WT mice and Mac-
MyD88-/- mice (Figure 3.9B). This suggests that MyD88 signaling in macrophages is 
required for the induction of Th2 type associated antibody responses induced by TLR 
dependent but not by TLR independent adjuvants. In addition, PorB/OVA also induced a 
robust Th1 type associated response, represented by the induction of Th1 associated IgG 
subclasses, IgG2b, 2c and 3 in WT mice (Figure 3.9C, E, G). However, immunizations of 
Mac-MyD88-/- mice with PorB/OVA were unable to induce any of these subclasses. 
Similar decreases in the Th1 type associated antibody responses were observed when 
these mice were immunized with CpG/OVA. Interestingly, MPLA failed to induce a Th1 
associated antibody responses in both WT and Mac-MyD88-/- mice (Fig 3.9C, E, G). The 
TLR independent adjuvants Alum or MF59 induced low amounts of Th1 type associated 
antibody subclasses as expected, and deletion of MyD88 in macrophages did not affect 
the levels of these antibodies (Figure 3.9D, F, H).  
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Figure 3.9. Antigen specific antibody subclasses associated with Th2/Th1 type 
responses require MyD88 signaling in macrophages for TLR-ligand based vaccine 
adjuvants activity.  
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(A-B) OVA-IgG1 (Th2 type associated responses) and (C-H) OVA-IgG2b, OVA-IgG2c 
and OVA-IgG3 respectively (Th1 type associated responses) endpoint titers were 
measured by ELISA from sera of WT and Mac-MyD88-/- mice immunized three times at 
two week intervals with TLR-dependent and independent adjuvants. The results shown 
are from samples collected two weeks after the third immunization and representative of 
two experiments with a total N = 8 mice per immunization group. One-way ANOVA 
with Tukey test were used (ns P>0.05, *P<0.05, **P<0.01, ***P<0.001 and 
****P<0.0001). Symbol (-) indicates that the antibody levels were below detectable 
level. 
 
We then measured the Th1 and Th2 type cytokines in pooled sera of vaccinated 
mice, four hours after the second immunization to determine if these correlate with our 
antibody findings. Formulations containing PorB induced high levels of IL-4, IL-5 and 
IL-13 (Th2 type cytokines, Figure 3.10A-C) as well as IFN-γ and IL-12 (Th1 type 
cytokines, Figure 3.10D-E) in WT mice. Selective deletion of MyD88 in macrophages 
resulted in a profound decrease in most of these cytokines except for IL-4 and IFN-γ, 
which remained unchanged (Figure 3.10A & D). As expected TLR dependent adjuvant 
CpG induced mainly a Th1 type response as determined by cytokine and IgG subclass 
responses (Figure 3.10A-E) (McCluskie et al., 2013). Lack of macrophages-MyD88 
signaling in macrophages in vivo, resulted in a decrease in IL-12, but not IFN-γ, when 
CpG was used as an adjuvant (Figure 3.10D & E), similar to the results obtained with 
PorB. The TLR independent adjuvant Alum mainly induced Th2 type cytokines in WT 
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mice, and deletion of MyD88 in macrophages, in vivo, did not affect the cytokine 
induction to the same extent as with TLR dependent adjuvants (Figure 3.10A-C). Alum 
was still able to induce IL-4, IL5 and IL-13 in the Mac-MyD88-/- mice, as compared to 
TLR-ligand based adjuvants, although reduced compared to levels in WT mice. 
Interestingly, IL-4 was also decreased when alum was used as an adjuvant in the vaccine 
given to Mac-MyD88-/- mice. This is in contrast to TLR-ligand based adjuvant, PorB. 
The heterogeneity in the different adjuvant responses is probably due to the different 
mechanism of action of each of these adjuvants. 
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Figure 3.10. In vivo MyD88 signaling in macrophages differentially affects the 
induction of Th2 and Th1 type cytokines upon immunization with TLR-ligand 
based adjuvants.  
(A-C) Th2 type (IL-4, IL-5 and IL-13) and (D and E) Th1 type (IL-12 and IFN-γ) 
cytokines level in pooled sera of WT and Mac-MyD88-/- mice immunized two times at 
two weeks interval and serum collected 4 hours after of the 2nd immunization with PBS, 
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OVA, OVA/PorB, OVA/CpG or OVA/Alum measured by Luminex magnetic bead-based 
multiplex assay. The results shown are representative of two experiments with a total of 8 
mice per immunization group. Sera from 8 mice were pooled and plated in duplicate. 
Symbol (-) indicates that cytokine levels were below detectable level. 
 
Intact in vivo MyD88 Signaling in Macrophages is Required for Germinal Center 
Formation Induced by TLR-ligand Based Adjuvants.  
The total OVA specific antibody level in Mac-MyD88-/- mice was almost 
completely abolished, as compared to WT, B-cells-MyD88-/- or DC-MyD88-/- mice 
immunized either with PorB or CpG given with OVA (Figure 3.8A). This was also true 
for antigen specific IgG1, 2b, 2c and 3 subclasses from Mac-MyD88-/- mice immunized 
with TLR-ligand based adjuvant. Production of these antibody subclasses occurs through 
a process known as Class Switch Recombination (CSR) and this occurs in germinal 
centers. Also, importantly, there are the unique types of macrophages in and around the 
lymphoid follicles where germinal centers form. These unique sets of macrophages 
whose function cannot be replicated by DCs or B cells may explain the significant effect 
on the humoral response upon immunization with PorB/OVA in the Mac-MyD88-/- mice.   
Given the importance of germinal centers, WT and Mac-MyD88-/- mice were 
immunized as described above and the germinal center formation in the spleen was 
assessed.  Germinal centers were measured as indicated in Figure 3.11B, at various time 
points after immunizations. Seven days after the second immunization yielded large 
amounts of germinal centers in WT mice and was therefore used to assess GC area. A 
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significant decrease in the area of germinal center in the spleens of Mac-MyD88-/- mice 
was observed, as compared to WT mice, when immunized with TLR-ligand based 
adjuvant PorB or CpG (Figure 3.11A & C). Interestingly, Mac-MyD88-/- mice form 
equivalent germinal center areas, as compared to WT mice, when immunized with TLR 
independent adjuvant Alum (similar to the antibody responses) or when injected with 
sheep red blood cells as a positive control (Figure 3.11A & C). This demonstrates that the 
decrease in germinal center formation was not due to an intrinsic defect in the Mac-
MyD88-/- mice, but rather due to the lack of signaling through MyD88. The presence of 
germinal centers was examined in six different frozen spleen 6 µm sections per mouse 
that were 40 µm apart, with a total of three mice per immunization group, providing an 
adequate assessment of splenic germinal center formation. The area of germinal centers 
was measured using ImageJ as shown in Figure 3.11B. The extent of the germinal center 
response was also examined by flow cytometric analysis. Deletion of MyD88 in 
macrophages dramatically decreased the ability of TLR-ligand based adjuvants requiring 
MyD88, to induce splenic CD4-B220+CD19+GL7+ germinal center B-cells (GC B cells) 
formation (Figure 3.11D). The difference in GC area measured by confocal microscopy 
between WT and Mac-MyD88-/- mice immunized with OVA/PorB was larger compared 
to the difference in the percentage of GC cells measured by flow cytometric analysis. 
This is likely because flow cytometric analysis allowed for the assessment of the whole 
spleen and there might be variations between immunized mice. Vaccine containing CpG 
induced large germinal center areas compared to any other adjuvants. There was a 
significant decrease of these large germinal centers in Mac-MyD88-/- mice. However, 
		
77 
many of these small GC areas in Mac-MyD88-/- mice were larger than 400 µm2 therefore 
measurable by ImageJ, unlike what was observed with PorB. That's likely contributing to 
the residual amount of GC area present on Mac-MyD88-/- with the use of CpG in the 
vaccine formulations. Regardless, there was still a significant decrease in GC with TLR-
ligand based adjuvant in Mac-MyD88-/- mice. In contrast, there were very few GL7+ 
areas within the B cell follicle from PBS or OVA immunized mice as measured by 
confocal microscopy. However since these areas were less than 400 µm2 they were not 
easily measurable by freehand selection in ImageJ. Flow cytometric analysis of whole 
spleens allowed for a more accurate assessment of the presence of these germinal center 
B-cells (B220+CD4-CD19+GL7+), which were present to a much lower extent in the 
PBS or OVA immunized mice as compared to the mice receiving OVA plus adjuvant. 
The residual germinal center cells in non-immunized mice are likely due to baseline 
responses to other antigens that the mice are exposed to in the facility and background 
staining of the cells. Notably, there was no decrease in GC area and cell numbers with 
vaccines containing TLR independent adjuvants in these Mac-MyD88-/- mice (Figure 
3.11D). These findings demonstrate a major role of intact MyD88 signaling in 
macrophages for robust germinal center formation when TLR ligands are used as 
adjuvants. 
 
 
 
 
		
78 
 
Figure 3.11. Formations of germinal centers in the spleen are dependent on in vivo 
MyD88 signaling in macrophages upon immunization with TLR-ligand based 
adjuvants.  
A) Germinal center responses examined by confocal microscopy 7 days after the 2nd 
immunization, 8µm thick spleen sections were prepared and examined as describe in the 
method section. Sections were stained for IgD follicular B cell marker (red), germinal 
center B cell marker GL-7 (green) and T cell marker TCR-β (cyan). B) Shows a spleen 
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section with the GC area measured using the freehand selection tool in ImageJ, here the 
area of GC (green) is encircled in white. C) Quantitation of germinal center areas by 
ImageJ. There were three mice per immunization group, 6 sections per spleen that are at 
least 40µm apart and a total of 18 sections were examined per group. D) Percentage of 
germinal center cells from spleen was measured by Flow Cytometry 7 days after the 2nd 
immunization and gating for B220+CD4-CD19+GL7+ germinal center cells. The results 
shown are representative of at least two experiments with a total N = 8 mice per 
immunization group for the Flow Cytometry analysis experiment. One-way ANOVA 
with Tukey test were used (ns: not significant P>0.05, *P<0.05, **P<0.01, ***P<0.001 
and ****P<0.0001).  
 
Intact MyD88 Signaling in Macrophages is Required for Induction of Germinal 
Center Cytokines by TLR-ligand Based Adjuvants.  
Deletion of MyD88 in macrophages significantly decreased the amount of 
germinal centers formed upon immunization with TLR-ligand based adjuvants (Figure 
3.11A-C). Germinal center formation and maintenance involves specific cytokines such 
as IL-1α, IL-1β, IL-6 and IP-10. To address whether those cytokine levels are affected in 
WT and Mac-MyD88-/- mice, we immunized mice with OVA admixed with TLR 
dependent adjuvants PorB, CpG or the TLR independent adjuvant Alum. Serum cytokine 
levels were measured 4 hours after the second immunization. Mice immunized with 
PorB/OVA triggered high levels of IL-1α, IL-1β, IL-6 and IP-10 and all were profoundly 
decreased in MacMyD88-/- mice, except for IL-6 (Figure 3.12A-D). WT and Mac-
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MyD88-/- mice immunized with CpG/OVA had a similar pattern of expression for these 
cytokines except for IL-6; IL-6 levels were low in WT mice, but these levels were even 
further decreased in the Mac-MyD88-/- mice.  
In contrast, the effect of deletion of MyD88 in macrophages on the induction of 
cytokines by the TLR independent adjuvant Alum was different, as compared to the TLR 
dependent adjuvants; IL-1α and IL-1β levels remained the same as compared to WT mice 
(Figure 3.12A & B). However, Alum/OVA induced high levels of IL-6 (Figure 3.12C) 
and low levels of IP-10 (Figure 3.12D) in WT mice. Interestingly, these cytokines were 
decreased in Mac-MyD88-/- mice, indicating that their induction by Alum might be 
dependent to some extent on MyD88 signaling in macrophages. Deletion of MyD88 in 
macrophages resulted in a more profound decrease in IL-1α, IL-1β, and IP-10 cytokines 
when TLR-ligand based adjuvants were used compared to TLR independent adjuvants 
(Figure 3.12A-D). A summary of the results is illustrated in Figure 3.13. 
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Figure 3.12. In vivo MyD88 signaling is important for induction of cytokines 
involved in germinal center formation.  
(A) IL-1α, (B) IL-1β (C) IL-6 and (D) IP-10 cytokine levels in pooled serum of WT and 
Mac-MyD88-/- mice immunized two times at two weeks interval and serum collected 4 
hours after of the 2nd immunization with PBS, OVA, OVA/PorB, OVA/CpG or 
OVA/Alum measured by Luminex magnetic bead-based multiplex assay. The results 
shown are representative of at least two experiments and a total of 8 mice; pooled sera 
were analyzed in duplicate wells. Symbol (-) indicates that cytokine levels were below 
detectable level.  
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Discussion 
In the present study, we provide detailed insight into the in vivo role of TLR 
signaling through MyD88 in B cells, DCs or macrophages for TLR-ligand based vaccine 
adjuvant activity. MyD88 is an essential adaptor-signaling molecule for all TLRs except 
TLR3 and the TRIF/TRAM signaling pathway for TLR4 (Akira et al., 2001). We found 
that separate in vivo MyD88 signaling in all three different antigen presenting cell types 
(B cells, macrophages or DC), was essential for the adjuvant activity of PorB and CpG, 
both TLR ligands that signal through MyD88, and partially involved in MPLA adjuvant 
activity, which signals through both MyD88 and TRIF/TRAM adaptor proteins. The most 
striking finding of this study was that mice harboring a macrophage specific MyD88 
deletion have the greatest decrease in T-cell dependent antibody responses upon 
immunization with vaccines formulated with TLR-ligand based adjuvants PorB, CpG or 
MPLA, as compared to B-cell MyD88-/- or DC-MyD88-/- immunized mice. In contrast, 
TLR-independent adjuvants Alum and MF59 were able to induce a robust antibody 
response in mice with MyD88 deletion in specific APC types (however, they were always 
characterized by limited IgG subclasses, mainly induced Th2 related IgG1 as also 
observed in WT mice).  
Previous studies have shown the importance of TLR/MyD88 signaling in B cells 
and DCs for the induction of antibodies in vivo (DeFranco et al., 2012; Pasare & 
Medzhitov, 2005), so it was not as surprising to observe a decrease in the humoral 
response in the DC-MyD88-/- and B-cells MyD88-/- mice in our experiments. This was 
especially evident in studies where MyD88 signaling in B cells in vivo was shown to be 
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critical for induction of antibody secreting cells upon vaccination (Kang et al., 2011), 
important for induction anti-retroviral germinal center responses (Browne, 2011) and 
required for induction of functional CD4 T cells producing IFN-γ for the control of IgG2c 
subclass production (Barr et al., 2009). Initially, it was suggested that there are no 
differences between TLR signaling in B cells or DCs resulting in the induction of T-cell 
dependent antigen specific antibody responses. This was demonstrated by adoptive 
transfer of MyD88 deficient B-cells or DCs in specific recipient mice followed by 
immunization with TLR-ligand based adjuvant (Pasare & Medzhitov, 2005; Ruprecht & 
Lanzavecchia, 2006). More recent studies have shown that TLR-MyD88 signaling in 
DCs is required for induction of antibodies when immunized with vaccine containing 
TLR9 ligands using DC-MyD88-/- mice (Hou et al., 2011). The same study also 
demonstrated that TLR ligands contained within vesicle like particle (VLPs) required 
intact MyD88 signaling in B cells for the induction of antibody responses (Hou et al., 
2011). Our observations of a decrease in T-cell dependent antibody responses in DC-
MyD88-/- and B-cell MyD88-/- mice with different TLR-ligand based adjuvants were 
consistent with these previous results. However, the requirement of MyD88 signaling in 
macrophages for in vivo TLR-ligand based adjuvant activity has never been previously 
investigated. Understanding how these adjuvants work and how signaling in the different 
cell types affects the vaccine-induced immune responses are important for vaccine 
adjuvant design. In this set of studies we have revealed a unique and, here-to-for, 
unknown role of macrophage TLR/MyD88 signaling in in TLR-ligand based adjuvant 
function.  
		
84 
We found that sorted DCs and B cells expressed normal levels of MyD88 in the 
Mac-MyD88-/- mice (Figure 3.5). MyD88 signaling is likely intact in DCs and B cells 
from these mice, though further studies are needed to demonstrate this. However, normal 
DC or B cell function cannot “rescue” the defect in MyD88 signaling in macrophages 
when TLR2 ligand PorB, TLR9 ligand CpG or TLR4 ligand MPLA were used as 
adjuvants. This highlights a unique and unrecognized role of macrophages in general and 
MyD88 signaling in macrophages, specifically, for the vaccine adjuvant activity of these 
TLR ligands. The level of OVA specific IgG was not completely abrogated in Mac-
MyD88-/- mice when TLR4 ligand MPLA was used in the vaccine formulation. This is 
likely due to intact TRIF/TRAM adaptor protein mediated signaling through TLR4 
induced by MPLA, unlike PorB and CpG, whose TLR signaling effects are solely 
dependent on MyD88 adaptor protein. However, this residual amount of antigen specific 
antibody induced by MPLA in Mac-MyD88-/- was still significantly lower than what was 
observed in WT, B-cell MyD88-/- and DC-MyD88-/- mice, indicating that some of the 
humoral response induced by MPLA is still MyD88 dependent. 
An essential immunological process that needs to occur to allow for the 
production of significant amounts of high affinity T-cell dependent antibodies is the 
generation of germinal centers.  Germinal centers are transient structures that form within 
lymphoid organs in response to antigens (De Silva & Klein, 2015) and are the main 
source of memory B cells, as well as plasma cells producing high levels of antigen 
specific antibodies of different subclasses (Nutt, Hodgkin, Tarlinton, & Corcoran, 2015). 
Previous studies have shown that mice with B cell specific MyD88 deletion have a 
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significant reduction in germinal center formation upon stimulation with endogenous 
nucleic acid recognized by TLR 9 or 7 in a lupus-like autoimmune disease model (Hua et 
al., 2014). Another study showed that TLR9 signaling in DCs and B cells controls the 
magnitude of the GC reaction upon immunization with vaccine formulated with the 
TLR9 ligand, CpG (Rookhuizen & DeFranco, 2014).  In the current study, we have 
demonstrated that Mac-MyD88-/- mice had a dramatic decrease in both germinal center 
formation and the percentage of germinal center B cells found upon immunization with 
vaccines containing TLR ligands PorB or CpG functioning as adjuvants. This finding is 
the likely reason why Mac-MyD88-/- mice had significantly lower antigen specific 
antibody levels upon vaccination with MyD88 dependent TLR-ligand based adjuvants, 
compared to WT mice. This suggests that MyD88-mediated signaling in macrophages in 
vivo is vital for inducing a strong adaptive humoral response, when PorB or CpG are used 
as adjuvant in vaccine preparations. Previous studies using complete MyD88-/- mice 
have reported defects in the induction of humoral responses using OVA and LPS in 
Complete Freund’s adjuvant (Pasare & Medzhitov, 2005), live virus infections (Guay, 
Andreyeva, Garcea, Welsh, & Szomolanyi-Tsuda, 2007; Koyama et al., 2007), with 
inactivated influenza virus (Koyama et al., 2007; Zhou et al., 2007) or with PorB/OVA as 
we have previously demonstrated (Platt et al., 2013). These studies investigated the 
effects of global MyD88 deletion. Our report specifically addresses the role of MyD88 
signaling in individual APC types using MyD88 conditional KO mice, immunized with 
vaccines containing TLR-ligand based adjuvants (requiring MyD88) and these studies 
have uncovered the essential role and overwhelming importance of macrophages in the 
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induced immune response. 
We have shown that removal of MyD88 signaling in macrophages resulted in a 
decrease in germinal center formation and antibody production upon immunization with 
vaccines containing the TLR-ligand based adjuvants PorB or CpG. Interestingly, Mac-
MyD88-/- mice form normal germinal centers and antigen specific antibody levels when 
TLR independent adjuvant Alum was used in the vaccine formulation, indicating that 
these mice are not inherently impaired in GC formation. Some aspects of MF59 (Seubert 
et al., 2011) and Alum (Kool, Soullie, et al., 2008) adjuvant activity have been shown to 
be partially MyD88 dependent and we do see a small role for MyD88 signaling on these 
specific cells for induction of antibodies by MF59 and Alum. However, the decrease in 
the antibody response was minimal when compared to the complete abrogation of antigen 
specific antibodies with TLR-ligand based adjuvants. Notably, there was no decrease in 
germinal center formation in Mac-MyD88-/- mice when TLR independent adjuvants 
were used in the vaccine. Furthermore, we showed that sheep red blood cells, a common 
control used to demonstrate induction of germinal centers in vivo, were able to induce 
germinal centers in Mac-MyD88-/- mice. This further reinforces our finding that these 
mice can mount a competent immune response. Therefore the decrease in germinal center 
formation upon vaccination is not an intrinsic defect in the Mac-MyD88-/- mice but it is 
rather an important and novel role for MyD88-mediated signaling in macrophages in vivo 
for the induction of germinal centers specifically by TLR-ligand based adjuvants. 
Many cytokines have been reported to play important roles in the induction and 
formation of germinal centers, along with antibody formation. We found that the TLR2 
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ligand PorB induces high serum levels of these cytokines, including pro-inflammatory 
cytokines (IL-1α, IL-1β and IL-6), chemokine (IP-10), Th2 type cytokines (IL-4, IL-5 
and IL-13) and Th1 type cytokines (IL-12 and IFNγ) in WT mice shortly after 
immunization. Interestingly, selective deletion of MyD88 in macrophages resulted in a 
profound decrease in most of these effector molecules except for IL-6, IL-4 and IFNγ, 
which remained unchanged. Pro-inflammatory cytokines IL-1α and IL-1β have been 
shown to be important during early immune responses and act directly on antigen specific 
T cells resulting in elevated IgG1 levels in the serum (Ben-Sasson et al., 2009). Our 
findings are in agreement with this observation where the systemic levels of IL-1α and 
IL-1β are increased along with IgG1 antibodies in WT mice. However, we observed a 
decrease in these cytokines and IgG1 titers in Mac-MyD88-/- mice upon immunization 
with TLR-ligand based adjuvants but not with TLR independent adjuvant Alum. This 
suggests that intact MyD88 signaling in macrophages is important for production of these 
cytokines with TLR-ligand based adjuvants. IL-1R signaling also needs the MyD88 
adaptor protein linked to IRAK kinases, for proper signaling in a cell (Warner & Nunez, 
2013). Therefore, IL-1R signaling in macrophages is likely defective in these mice. 
Interestingly when these Mac-MyD88-/- mice received vaccine formulated with TLR-
independent adjuvant, we observed normal level of these cytokines as well as antibody 
level. This suggests that signaling of these cytokines can take place in other cell types and 
not in macrophages, possibly compensating for MyD88 deficiency. However, further 
studies using IL1R KO mice are needed to prove this concept. 
Other studies have shown that Th2 type cytokine IL-4 had no effect on growth 
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and proliferation of B cells, whereas IL-1 enhanced proliferation of germinal center B 
cells in response to IL-5 (Rabinowitz, Tsiagbe, Nicknam, & Thorbecke, 1990; Tsiagbe, 
Nicknam, Fattah, & Thorbecke, 1992). Extra-follicular IL-4/IL-13 has been shown to be 
very important for germinal center formation by acting directly on follicular B cells for a 
robust germinal center formation (Turqueti-Neves et al., 2014). We observed an ample 
decrease in IL-5 and IL-13 in Mac-MyD88-/- immunized with the TLR2 ligand PorB. 
Interestingly, we do not see a decrease in IL-4 level in Mac-MyD88-/- mice upon 
immunization with vaccine containing TLR-ligand based adjuvants; instead we see a 
dramatic decrease in IL-13, which also signals through IL-4R. This decrease may cause 
an imbalance in IL-4/IL-13 cytokines level, decreasing signaling through IL-4R on B 
cells, which in turn may contribute to the dampening of the humoral response observed in 
Mac-MyD88-/- mice upon immunization with TLR2 ligand PorB. We observed a similar 
pattern of increasing and decreasing cytokine levels in WT and Mac-MyD88-/- mice with 
the endosomal TLR9 ligand CpG. The levels of Th2 cytokines were lower, when 
compared to PorB, in WT mice when CpG was used as an adjuvant, while Th1 cytokines 
had similar levels when both adjuvants were used. CpG is known to induce very low 
levels of these Th2 type cytokines but high levels of Th1 type cytokines (Coffman, Sher, 
& Seder, 2010). Given the importance of Th1 type cytokines (IL-12 and IFN-γ) in 
generating Th1 type associated antibody subclasses (IgG2b, 2c and 3), we examined 
whether these cytokines were affected in immunized Mac-MyD88-/- mice. DCs and 
macrophages are a major cellular source of Th1 type cytokine IL-12 upon TLR 
stimulation (Zundler & Neurath, 2015). IL-12 in turn has been shown to induce NK and 
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T cells to produce IFN-γ, which drives Th1 differentiation, promoting production of Th1 
type associated antibodies (Zundler & Neurath, 2015). IP-10 (CXCL10) produced by 
macrophages drives B cells differentiation into plasma cells and the production of IP-10 
is controlled by B-cell derived IL-6 (W. Xu et al., 2012). These previous studies clearly 
demonstrate that IL-1α/β, IP-10, IL-5, IL-13 and IL-12 effector molecules have important 
roles in germinal center formation and antibody production. Therefore, it is possible that 
the decrease in IL-1α/β, IP-10, IL-5, IL-13 and IL-12 levels from sera of Mac-MyD88-/- 
mice are related to the decrease that we observed in germinal center formation, and OVA 
specific IgG levels, upon immunization with TLR-ligand based adjuvants. 
Deletion of MyD88 in macrophages did not affect the cytokine induction by TLR-
independent adjuvant Alum to the same extent as TLR-dependent adjuvants. Lack of 
MyD88 signaling in macrophages did not affect the levels of IL-1α and IL-1β in 
Alum/OVA immunized mice. In addition, defective MyD88 signaling caused a smaller 
decrease in IP-10, IL-5 and IL-13 when Alum was used in the vaccine composition when 
compared to PorB or CpG as adjuvants. Interestingly, IL-4 and IL-6 were also decreased 
while IFNγ levels were increased when Alum was used in the Mac-MyD88-/- mice, 
unlike our observation with TLR-ligand based adjuvant PorB. Some aspects of Alum 
adjuvant activity have been shown to be partially MyD88 dependent (Kool, Soullie, et al., 
2008), and this could be contributing to the decrease in the cytokines. Adjuvants vary 
greatly in the character and intensity of induced responses (Coffman et al., 2010) and this 
is reflected in the heterogeneity of the observed cytokine levels with the different types of 
adjuvant used in our study. More studies and experiments are needed for each of these 
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adjuvants to address the cytokine profile and how it is affected upon inhibition of MyD88 
signaling in macrophages in vivo. Overall, deletion of MyD88 in macrophages resulted in 
a profound decrease in cytokines important for germinal center formation and generation 
of antibody secreting cells in our vaccination studies performed with TLR-ligand based 
adjuvants.  
Upon subcutaneous immunization the content of the vaccine is partly taken up by 
the resident DCs or macrophages at the immunization site, which then traffic to the 
draining lymph nodes and spleen. The vaccine components can also journey to the 
draining lymph nodes via vitreous pressure. Within the secondary lymphoid organs they 
encounter unique sets of macrophages (Gray & Cyster, 2012) including Metallophillic 
Macrophages (MM, CD169+ Macrophage), Marginal Zone macrophages (MZM, 
MARCO+), red pulp macrophages (CD206+) and white pulp macrophages (CD68+, 
tingible body macrophages), with a variety of functions depending on their locations in 
vivo (Gray & Cyster, 2012). MM CD169+ macrophages are a very important subset of 
macrophages that line the subcapsular sinus of the draining lymph nodes and also 
surround the follicular B cells in the spleen. Previous studies have shown that these 
subcapsular sinus MM CD169+ macrophages can capture antigens and present these 
antigens complexes directly to B cells and follicular DC (Phan, Grigorova, Okada, & 
Cyster, 2007). Interestingly, depletion of macrophages in the spleen resulted in an 
inability to form germinal centers (Nikbakht, Shen, & Manser, 2013). Here we show that 
mice with a cell specific deletion of MyD88 in macrophages led to a profound decrease 
in antibody production upon immunization with vaccine formulated with TLR-ligand 
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based adjuvants, as opposed to preparations containing TLR independent adjuvants. We 
feel that these findings are due to the inability of TLR-ligand based adjuvant components 
of the vaccine to signal through MyD88 in macrophages, especially MM CD169+ 
macrophages, in the spleen and draining lymph nodes. This, in turn, diminishes the 
vaccine induced humoral immune responses. Further work is ongoing to examine this 
hypothesis. 
In summary, our findings reveal the importance of all three APC types, but most 
especially macrophages, in the vaccine-induced immune responses when TLR-ligand 
based adjuvants are used in the vaccine formulation. More specifically, we found that 
intact in vivo MyD88 signaling in macrophages is required for robust germinal center 
formation and antigen specific antibody production with TLR-ligand based adjuvants 
(Figure 3.13). These insights will aid in vaccine development by allowing more 
intelligent and judicious use of these and other vaccine adjuvants to target specific cell 
types and induce specific type of responses. Vaccines containing TLR-ligand based 
adjuvants can be formulated and administered in a specific way so that they target these 
unique macrophages in the lymphoid organs and engage specific TLR or sets of TLRs in 
order to enhance types of immune responses needed for protection. 
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Figure 3.13. Summary of results for Chapter Three. 
This figure illustrates the summary of the results from Chapter three. Red arrow 
represents the decrease observed in the parameters measured as indicated in the figure 
following immunization of Mac-MyD88-/- mice. Black arrow represents the increased 
observed in the parameters measured as indicated in the figure following immunization of 
WT mice.   
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CHAPTER FOUR 
Induction of Robust and Diverse T Cell Responses by TLR2 Ligand Based 
Adjuvant, Meningococcal PorB  	
Abstract 
Vaccines formulated with adjuvant have been effective against numerous 
infectious diseases mainly by inducing antibody responses. However, there is an unmet 
clinical need for vaccine adjuvants that induce T cells responses to achieve protection 
against malignancies and intracellular pathogens such as HIV, TB and Hepatitis C virus 
where a humoral response is not adequate for protection. In this study, using a 
subcutaneous immunization model and a mouse recombinant Listeria infection model 
(expresses a truncated form of ovalbumin), we demonstrate that a TLR2 ligand based 
adjuvant, meningococcal PorB, has broad adjuvant activity with robust and diverse T cell 
responses. We show that a vaccine formulated with PorB admixed with ovalbumin 
induces a wide variety of effector molecules (MIG, MCP-1, IP-10, MIP-1α, KC & IL-2) 
with known roles for inducing T cell responses. Upon further investigation, we observed 
that PorB induced high level of Th1 and Th2 type cytokines after the 3rd immunization, 
suggesting an induction of T cell responses. We confirmed production of some of these 
cytokines by analyzing the antigen-specific T cells induced by PorB in vivo. Antigen-
specific CD4 and CD8 T cells were significantly increased in numbers and are highly 
functional producing IL-4 or IFN-γ just after two immunizations with vaccine formulated 
with PorB/OVA. Finally, in a mouse infection model, vaccine formulated with PorB 
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significantly reduced the bacterial burden upon a low dose infection and increased 
survival upon a high dose infection with rLmOVA, a pathogen that requires OVA-
antigen specific cytotoxic CD8 T cells for clearance. Thus, PorB is a potent new 
adjuvant, which is able to induce both a humoral response and strong diverse T cell 
response. 
 
Introduction 
Most vaccines have been successful, either because of adjuvants added to their 
formulations or in the case of live attenuated or killed whole organism vaccines because 
the adjuvants are inherent (Coffman et al., 2010; Plotkin, 2005a, 2005b). The majority of 
vaccines currently formulated with adjuvant mainly induce a humoral response (Plotkin, 
2010). This has worked well against many pathogens, especially those where neutralizing 
or bactericidal antibodies are known to be protective, such as diphtheria, tetanus, polio, 
Haemophilus influenza type B, hepatitis A and S, rabies, measles, mumps, rubella, 
varicella, pneumococcus and meningococcus (Robbins, Schneerson, & Szu, 1995; 
Robbins, Schneerson, Vann, Bryla, & Fattom, 1995). These pathogens are controlled and 
cleared by immunoglobulin in the serum (Robbins, Schneerson, & Szu, 1996). Many of 
these pathogens have low immune evading ability, low antigen variability and exist in the 
extracellular space (Coffman et al., 2010). Interestingly, some of the most effective 
vaccines contained endogenous adjuvants as components of the live or attenuated forms 
of the targeted pathogens. The immune system has responded well to these vaccines and 
mounts robust protection against some pathogens. Part of the reason for this success is 
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because our immune system has evolved to respond to Pathogen Associate Molecular 
Patterns (PAMPs), which stimulates the innate immune responses through Pattern 
Recognition Receptors (PRRs) (Akira et al., 2006). Effective vaccines exploit this 
property of the immune system to mount protection. Live attenuated or killed whole 
organism vaccines causes an asymptomatic infection and mounts robust humoral 
responses and cellular responses against some pathogens (Makela, 2000). However, for 
many other pathogens such as influenza, even a normal infection does not generate 
adequate adaptive immunity for all strains while other pathogens are too immunogenic 
and cannot be safely used as live attenuated vaccines (Bonduelle et al., 2014).  
The development of most vaccines and adjuvants happened without an 
understanding of vaccine immunity and their immunological mechanisms. There have 
been many failures to develop vaccines against pandemics such as human immune 
deficiency virus (HIV) infection, Mycobacterium tuberculosis (TB), Hepatitis C and 
Respiratory Syncytial Virus (Pulendran & Ahmed, 2011). These pathogens are 
intracellular, immune evading and some of them have high antigen variability. 
Traditional vaccines that induce mainly antibody responses have failed for pathogens that 
remain a threat today. They might require a more diverse type of response including T 
cell responses (Burton et al., 2004). Previous studies have demonstrated that T cell 
responses, especially CD8 T cell responses, have a vital role in controlling and clearing 
intracellular infections (Moore & Hill, 2004; Prieur et al., 2004; Robinson & Amara, 
2005; Seder & Hill, 2000). For example, T cells responses have been suggested to be a 
major contributor to immune protection provided by the varicella vaccine (Kimberlin & 
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Whitley, 2007). Similar observations have been made with the live attenuated influenza 
vaccine, where one dose has been shown to provide protection even though the antibody 
levels were much lower compared to the inactivated influenza vaccine (Belshe, 2007; 
Belshe et al., 2007). It has been suggested that CD8 T cells may be playing an important 
role in the protective immune responses induced by the vaccine (Belshe, 2007; Belshe et 
al., 2007). T cell responses have also been shown to have a critical role in 
immunotherapy for chronic hepatitis infections, HIV and cancers (Autran, Carcelain, 
Combadiere, & Debre, 2004; Autran, Costagliola, Murphy, & Katlama, 2004). This 
clearly demonstrates the unmet clinical needs for new novel adjuvants that can induce 
strong T cell immunity. To date, immunizations with specific live attenuated pathogens 
(such as smallpox virus, yellow fever virus and others) are the only approved way to 
induce T cell responses for vaccination purposes (Leroux-Roels, 2010). There are many 
different types of PRRs that have important roles in a vaccine induced immune responses 
such as immunizations with live attenuated vaccines where the endogenous adjuvant 
(PAMPs) are being recognized by PRRs. TOLL-like receptor 2 (TLR2) is an important 
PRR used in this study. TLR2 is special type of TLRs, among all the mammalian TLRs, 
this type of TLR is present on the surface of most cells, including T cells, and is able to 
recognize the most diverse repertoire of PAMPs such as cell walls of Gram-positive 
bacteria, bacterial glycolipids, structures from parasites (GPI-anchored structures from 
Trypanosomes), mycobacterial lipoprotein among many others (Dasari, Nicholson, 
Hodge, Dandie, & Zola, 2005; Hasan et al., 2005; Ozinsky et al., 2000; Takeuchi et al., 
2001). TLR2’s ability to detect a wide repertoire of PAMPs is the result of its potential to 
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heterodimerize with either TLR 1 or 6 in mice and TLR1, 6 and 10 in humans (Dasari et 
al., 2005; Hasan et al., 2005; Ozinsky et al., 2000; Takeuchi et al., 2001).  
Given the limitations of traditional vaccines, the success of PAMPs within live 
attenuated vaccines in inducing T cell responses, and the importance of TLR2, we 
investigated the ability of Neisseria meningitidis Porin B (PorB) protein, a TLR2 ligand 
based adjuvant, to generate vaccine-induced T cell responses. PorB is the major outer 
membrane protein from pathogenic Neisseria meningitidis (Wetzler, 2010) and has been 
thoroughly describe in chapter 1 and 2 of this thesis. To highlight the importance of using 
this TLR2 ligand in this study, we have summarized some of its important characteristics 
as an adjuvant. Gonococcal PorB has been used as an immune adjuvant for vaccines with 
a wide range of antigens including bacterial capsular polysaccharides, bacterial 
oligosaccharides and proteins (Chiavolini et al., 2008; Latz et al., 2004; Mackinnon et al., 
1999b). PorB is also a component of the Outer Membrane Proteins from Meningococcus 
(OMPC), which has been used as a carrier protein for the Haemophilus influenza type B 
(Hib) human vaccine (Chiavolini et al., 2008; Latz et al., 2004). This glycoconjugate 
vaccine has had a dramatic role in significantly decreasing Hib disease. Since PorB, as a 
component of OMPC, has been part of a safe human vaccine, it has great potential to 
become a licensed adjuvant for use in future vaccines. More recently, it was 
demonstrated that PorB requires intact in vivo MyD88 signaling in B cells, macrophages 
and dendritic cells for its adjuvant activity and also induced a robust germinal center 
reaction (Mosaheb et al. manuscript submitted) (Chapter 3 above), producing diverse 
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antigen specific antibody responses including IgG1, 2b, 2c and 3 antibody subclasses 
(Platt et al., 2013). 
In this study, we demonstrate that PorB can also induced strong and diverse T cell 
responses. To acquire insight into the ability of PorB to induce T cell responses, we 
employed in vivo immunization with OVA followed by infecting mice with L. 
monocytogenes expressing OVA wherein OVA-specific T cells can provide protective 
immunity. We found that vaccines formulated with PorB admixed with OVA induced 
diverse chemokines and cytokines associated with and vital for direct induction of T cell 
responses and for robust antigen specific CD4 and CD8 T cell responses. These cells 
were fully functional, in vivo, inducing high levels of cytokines in ELISPOT assays. 
Using a Listeria mouse infection model, we found that OVA CD8 T cells induced by 
PorB are likely decreasing the bacterial burden in immunized mice upon infection with a 
low bacterial dose and increasing the survival upon infection with a high bacterial dose of 
Listeria. This study provides important information into the adjuvant activity of TLR2 
ligand based adjuvant, PorB. Insights from this study will help in future vaccine design, 
where PorB could be use alone or in combination with other adjuvants to induce specific 
type of protective responses including T cell immunity. A good understanding of the 
mechanisms of adjuvant activity is essential for the development of highly efficacious 
vaccines very important for intelligent use of adjuvants in vaccines (Alving et al., 2012). 
 
 
 
		
99 
Results 
Neisserial PorB induces effector molecules important for cellular responses in vivo. 
 Mice were immunized three times at two-week intervals and sera were obtained 
either 4 hours or 12 hours after the third immunization. Sera were analyzed for IL-4, IL-
5, IL-13, IFN-γ and TNF-α cytokines, that are known to be produce by T cells 
(Aggarwal, 2003; Ohshima et al., 1999; Pennock et al., 2013; Ruddle, 1992; Smyth & 
Johnstone, 2000; Sung, Bjorndahl, Wang, Kao, & Fu, 1988; Yang, Chang, Parnes, & 
Fathman, 1998). These time points were used based on observations from previous 
studies, as well as our own investigations, where it was demonstrated that serum T cell 
cytokines peak during these periods in mice upon immunization (Nolz, Starbeck-Miller, 
& Harty, 2011; Valensi et al., 1994).  
Mice immunized with PBS (Control) had no detectable levels of IL-4, IL-5, IL-
13, IFN-γ and TNF-α cytokines in the sera 4 hours and 12 hours after immunization. 
Mice immunized with OVA alone had very low concentrations of IL-5 and IL-13 (Figure 
4.1B & C) 4 hours after the 3rd immunization. OVA alone did induce high levels of IL-5, 
IL-13 and very small amounts of TNF-α (Figure 4.1E) 12 hours after the third 
immunization. However IL-4 and IFN-γ were below the detection limits (Figure 4.1A & 
D). Interestingly, mice immunized with adjuvant PorB admixed with OVA induced 
higher levels of these cytokines as compared to PBS or OVA alone-immunized mice. 
Vaccine containing PorB induced very high amounts of IL-4, IL-5, IL-13 and TNF-α at 
the earliest time point (4 hours) after the 3rd immunization as compared to mice 
immunized with OVA alone (Figure 4.1A-C & E). However, IFN-γ was below the 
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detection limit at 4 hours after the 3rd immunization with OVA/PorB. Instead, we 
observed that IFN-γ peaked at 12 hours after the 3rd immunization with OVA/PorB 
(Figure 4.1D) and it was also induced only when the vaccine contained the adjuvant. Th2 
type cytokine IL-4 was noticeably lower at 12 hours compared to 4 hours after the 3rd 
immunization with OVA/PorB. There were very subtle increases in the level of IL-5, IL-
13 and TNF-α 12 hours after the 3rd immunization with OVA/PorB as compared to OVA 
alone. 
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Figure 4.1. Adjuvant PorB induces cytokines produced by T cells in vivo.  
(A-C) IL-4, IL-5, and IL-13 (Th2 type cytokines), (D) IFN-γ (Th1 type cytokine) and (E) 
TNF-α cytokine levels in pooled sera from WT mice immunized three times at two-week 
intervals. Sera were collected 4 hours (black border) or 12 hours (grey border) after the 
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3rd immunization with PBS, OVA or OVA/PorB. These cytokines were measured by 
Luminex magnetic bead-based multiplex assay. The results shown are representative of 
two experiments with a total of 8 mice per immunization group. Sera from 8 mice were 
pooled and plated in duplicate. Symbol (-) indicates that effector molecules levels were 
below detectable level.  
 
Next we measured IL-2 cytokine and chemokines (MIG, MCP-1, IP-10, MIP-1α 
and KC) 4 hours after each of the three immunizations. These effector molecules are 
known to peak early after each immunization and have been shown to play important 
roles in generating cellular responses in vivo, including T cell responses (Nolz et al., 
2011). Mice immunized with PorB admixed with OVA induced high levels of MIG 
(CXCL9), MCP-1 (CCL2), IP-10 (CXCL10), MIP-1α (CCL3) and KC (CXCL1) 
chemokines early (4 hours) after each of the three immunizations as compared to mice 
immunized with OVA alone or mock-immunized with PBS (Figure 4.2A-E). MIG and 
MIP-1α were highly induced 4 hours after the 1st immunization with PorB/OVA, whereas 
levels were decreased after the 2nd and 3rd immunizations (Figure 4.2A & D). MCP-1 was 
detected at its highest level after the 2nd immunization with the adjuvanted vaccine 
(Figure 4.2B). IP-10 and KC levels varied subtly after each immunization, with KC being 
induced and remained high (~500pg/ml) in comparison to all other chemokines after each 
of the three immunizations (Figure 4.2C & E). Vaccine formulations containing PorB 
also increased IL-2, 4 hours after the 2nd and 3rd immunizations; there were no detectable 
IL-2 after the 1st immunization (Figure 4.2F). Control mice immunized with PBS had no 
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detectable levels of MIG, MCP-1, IP-10, MIP-1α, KC and IL-2 in the sera. These 
chemokines and IL-2 cytokine levels were very low or undetectable for most analytes 12 
hours after immunization.  
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Figure 4.2. TLR2 ligand based adjuvant PorB induced effector molecules important 
for cellular responses in vivo.  
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(A-E) MIG, MCP-1, IP-10, MIP-1α, and KC chemokines and (F) IL-2 cytokine level in 
pooled sera from WT mice immunized three times at two weeks interval and sera 
collected 4 hours after each immunization with PBS, OVA or OVA/PorB measured by 
Luminex magnetic bead-based multiplex assay. X-axis labeling of 1st, 2nd and 3rd 
represent sera collected 4 hours after each of the three different immunizations. The 
results shown are representative of two experiments with a total of 8 mice per 
immunization group. Sera from 8 mice were pooled and plated in duplicate. Symbol (-) 
indicates that effector molecules levels were below detectable level. 
 
TLR2-ligand based adjuvant PorB induced a robust antigen specific CD4 T cell 
response. 
Our laboratory have shown that PorB increases antigen uptake, recruitment of DC 
to draining lymph nodes and antigen cross presentation (Reiser, Mosaheb, Platt and 
Wetzler, manuscript in preparation). PorB’s ability to induce cytokines and chemokines 
that are involved in induction of antigen specific T cell responses and enhance T cell 
specific cytokine production indicates that its adjuvant activity can certainly help initiate 
and improve antigen specific T cell responses. These responses were further 
characterized by immunizing mice with PorB/OVA, OVA alone, or PBS, (as control), 
twice, at two week intervals. Eleven days after the 2nd immunization the number of 
splenic antigen specific CD4 T cells producing either IFN-γ or IL-4 were quantified. 
Single cell suspensions were prepared from the spleen and stimulated overnight with a 
CD4 OVA specific peptide, scrambled OVA peptide or anti-CD3/CD28 as a positive 
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control in an ELISPOT assay. The MHC Class II restricted OVA peptides loaded on 
APCs were used to determine the relative number of OVA specific CD4 T cells induced 
by immunization with PorB. This assay is highly sensitive and reproducible, allowing not 
just the quantitation but also the secretory activity of the cells being screened (Lehmann 
& Zhang, 2012). Vaccine formulated with PorB induced a robust antigen specific CD4 T 
cells to the model antigen OVA (Figure 4.3A-B). The number of OVA specific CD4 T 
cells had significantly greater numbers as compared to mice immunized with OVA alone 
(Figure 4.3B). They were also highly functional, producing significantly more IFN-γ 
(OVA Th1 Cells) upon stimulation with OVA specific CD4 peptide as compared to mice 
that received OVA alone. Incubation with a scrambled OVA peptide stimulation induced 
very low levels of IFN-γ producing CD4 T cells when compared to PorB/OVA 
immunized mice. This demonstrated that production of the effector molecules were 
specific to the OVA MHC II restricted peptide. Splenocytes stimulated with anti-
CD3/CD28 induced a large number of IFN-γ productions by CD4 T cells non-specifically 
as expected. TLR2-ligand based adjuvant PorB also induced significantly more OVA 
specific CD4 T cells producing IL-4 (OVA Th2 Cells) compared to mice immunized with 
OVA alone (Figure 4.3C-D). OVA Th2 cells were at a lower frequency as compared to 
OVA Th1 cells.  
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Figure 4.3. Vaccine formulated with adjuvant PorB induced robust antigen specific 
CD4 T cell responses in vivo.  
WT mice were immunized two times at two-week intervals. Eleven days after the 2nd 
immunization single cell suspensions were prepared from the spleen and stimulated 
overnight with an OVA CD4 peptide, OVA scrambled peptide or anti-CD3/CD28 (α-
CD3/CD28) as a positive control. An ELISPOT assay, as described in Methods above, 
was used to quantitate the number of antigen specific CD4 T cells producing either A) 
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IFN-γ positive spots and B) quantitation of CD4 T cells producing IFN-γ or C) IL-4 
positive spots and D) quantitation of CD4 T cells producing IL-4 from the spleens of 
immunized mice. The results shown are representative of two experiments with a total N 
= 6 to 8 mice per immunization group. One-way ANOVA with Tukey test were used (ns 
P>0.05, *P<0.05, **P<0.01, ***P<0.001 and ****P<0.0001).  
 
Vaccine formulated with adjuvant PorB induced a strong antigen specific CD8 T 
cells response in vivo. 
We examined PorB’s ability to induce antigen specific CD8 T cell response in 
vivo, similar to analysis of antigen specific CD4 T cells described above. We used an 
OVA specific CD8 MHC Class I restricted peptide to determine the level of the antigen 
specific CD8 T cells induced by OVA/PorB immunization. The vaccine formulated with 
adjuvant PorB induced a significantly larger number of antigen specific CD8 T cells 
producing IFN-γ compared to mice immunized with OVA alone (Figure 4.4A-B). 
Minimal production of IFN-γ was seen when the OVA CD8 scrambled peptide was used. 
This demonstrates that the IFN-γ positive spots from the ex vivo assay produced by the 
cells from immunized mice after stimulation with OVA specific CD8 epitopes were being 
produced by OVA specific CD8 T cells induced by the vaccine.  
Vaccines prepared with PorB admixed with OVA induced a small but significant 
population of OVA specific CD8 T cells producing IL-4 (TC2 cells) in vivo 11 days after 
the 2nd immunization compared to mice vaccinated with OVA alone (Figure 4.4C-D). 
Non-specific signal was ruled out using a scrambled OVA peptide (as a negative control) 
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to stimulate the cells (Figure 4.4D) as well as cells stimulated without any peptide.  
OVA CD8 T cells secreting IFN-γ (OVA TC1 cells) (Figure 4.4B) was the largest 
population quantified per 106 splenocytes compared to the OVA Tc1 (Figure 4.4D), OVA 
Th1 (Figure 4.3B) and OVA Th2 cells (Figure 4.3D). 
  
Figure 4.4. Vaccine formulated with adjuvant PorB induced a robust antigen 
specific CD8 T cell response in vivo.  
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WT mice were immunized two times at two weeks interval and 11 days after the 2nd 
immunization single cell suspensions were prepared from the spleen and stimulated 
overnight with an OVA CD8 peptide, OVA scrambled peptide or anti-CD3/CD28 as 
positive control. An ELISPOT assay, as described in Methods, was used to quantitate the 
number of antigen specific CD4 T cells producing either A) IFN-γ positive spots and B) 
quantitation of CD8 T cells producing IFN-γ or C) IL-4+ spots and D) quantitation of 
CD8 T cells producing IL-4 from the spleens of immunized mice. The results shown are 
representative of two experiments with a total N = 6 to 8 mice per immunization group. 
One-way ANOVA with Tukey test were used (ns P>0.05, *P<0.05, **P<0.01, 
***P<0.001 and ****P<0.0001).  
 
Antigen specific CD8 T cells induced by TLR2-ligand based adjuvant PorB reduce 
bacterial burden and increase survival of mice infected with Listeria monocytogenes. 
There is a vital clinical need for adjuvants that induce antigen specific CD8 T cell 
responses for use in future vaccines. Adjuvant PorB induced a robust antigen specific 
CD8 T cell responses as demonstrated above. Therefore, the functionality of these OVA 
specific CD8 T cells induced by PorB, their ability to mitigate a bacterial infection in vivo 
was investigated. Mice were immunized three times at two-week intervals with either 
OVA alone or OVA/PorB. Immunized mice were then challenged with either low doses 
(~1x105 or 5x105 bacteria per mouse) or a high dose (~1x106 bacteria per mouse) of 
rLmOVA two weeks after the last immunization in order to assess bacterial burden and 
survival respectively. Upon infection with rLmOVA, mice vaccinated with PorB admixed 
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with OVA had noticeably less CFUs in the liver or spleen as compared to OVA-
immunized mice (Figure 4.5A-D). When quantitated, it was clear that PorB adjuvanted 
vaccine decreased the bacterial load dramatically in the liver (Figure 4.6A) and 
significantly in the spleen (Figure 4.6B), three days after infection with 5x105 rLmOVA. 
Mock-immunized mice with PBS or mice immunized with OVA alone had very high 
numbers of bacteria in both the liver and spleen. This experiment was repeated with 
1x105 CFU of rLmOVA per mouse and a similar decrease in bacterial burden in the liver 
(Figure 4.6C) and spleen (Figure 4.6D) was observed when PorB was present in the 
vaccine formulations. 
 
Figure 4.5. Decrease of Listeria monocytogenes CFUs in mice immunized with PorB. 
A)	 B)	
C)	 D)	
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WT mice were immunized three times at two-week intervals with PBS, OVA or 
OVA/PorB. Two weeks after the last immunization, the mice were challenged with 
5.4x105 CFU of rLMOVA per mouse and bacterial burden in A) Liver of OVA-
immunized mice, B) Liver of OVA/PorB-immunized mice, C) Spleen of OVA-
immunized mice, and D) Spleen of OVA/PorB-immunized mice were harvested and 
analyzed 3 days after the infection. Organs were processed, diluted and plated on BHI 
plates as described in methods. CFUs were counted when colonies were visible 24 hours 
and 48 hours later.  
 
 
Figure 4.6. TLR2-ligand based adjuvant PorB decreases bacterial burden in mice 
infected with Listeria monocytogenes.  
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WT mice were immunized three times at two weeks interval with PBS, OVA or 
OVA/PorB. Two weeks after the last immunization, the mice were challenged with 
5.4x105 CFU of rLMOVA per mouse and bacterial burden in A) Liver and B) Spleen 
were measured 3 days after the infection. Bacterial burden from mice challenged with 
1x105 CFU of rLMOVA per mouse were measured in the C) Liver and D) Spleen. The 
results shown are representative of two experiments with an N = 4 mice per 
immunization group per experiment. Total N = 8 mice. Mann Whitney U test were used 
(ns P>0.05 and *P<0.05) to compare OVA/PorB with OVA alone. 
 
Listeria monocytogenes infection in mice is known to cause a decrease in the 
number of cells in the spleen (Wang, Strugnell, Wijburg, & Brodnicki, 2011). Two weeks 
after the 3rd immunization the change in the total number of cells in the spleen of non-
infected mice remained unchanged (Figure 4.7). However, when these mice were 
challenged with rLmOVA two weeks after the 3rd immunization, there was a significant 
decrease in the number of cells in the spleen of mice immunized with PBS and a dramatic 
decrease in mice vaccinated with OVA alone three days after the infection (Figure 4.7). 
However, mice immunized with OVA admixed with PorB, when challenged with 
rLmOVA, did not have a decrease in the total cell numbers from the spleen, as compared 
to non-infected OVA/PorB immunized mice. The total cell numbers were significantly 
higher in mice that received the adjuvanted vaccine as compared to OVA alone-
immunized mice three days after a low dose of rLmOVA infection (Figure 4.7).  
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Figure 4.7. Infection with Listeria monocytogenes did not affect the total number of 
cells in the spleen of mice immunized with PorB adjuvanted vaccine.  
WT mice were immunized three times at two weeks interval with PBS, OVA or 
OVA/PorB. Two weeks after the last immunization, the mice were challenged with 1x105 
CFU of rLMOVA per mouse. Cell numbers in spleen were quantitated 3 days after the 
infection. The results shown are representative of two experiments with an N = 4 to 6 
mice per immunization group. One-way ANOVA with Tukey test were used (ns P>0.05, 
*P<0.05, **P<0.01, ***P<0.001 and ****P<0.0001). 
 
Mice infected with a high dose of rLmOVA were closely monitored multiple 
times a day by our laboratory personnel and veterinary services throughout the 
experiment. The specific time and number of mice that died were recorded. Some of the 
mice immunized with PBS succumbed to the infection after the first 24 hours and all of 
these mice perished three days after the high dose infection (Figure 4.8A). Some of the 
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mice immunized with OVA alone and challenged with a high dose of rLmOVA 
succumbed to the infection after 24 hours. About 60% of these mice died within three 
days of the infection. However, mice that received vaccine formulated with PorB were 
able to survive longer and the first mouse succumbed to the infection on day 4 after the 
high dose infection. About 70% of the OVA/PorB immunized mice were still alive five 
days after the high dose infection. The last mouse died 7 days post infection. Survival of 
mice immunized with vaccine formulated with PorB were significantly greater as 
compared to mice immunized with OVA alone as determine by Mantel-Cox test with 
95% confidence interval (Figure 4.8A).  
Figure 4.8. Vaccine formulation containing PorB increases mice survival upon a 
high dose infection with Listeria monocytogenes.  
WT mice were immunized three times at two weeks interval with PBS, OVA or 
OVA/PorB. Two weeks after the last immunization, the mice were challenged with high 
dose (1x106 CFU) of rLMOVA per mouse. A) Survival of infected mice was monitored 
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multiple times a day until the mice succumbed to the infection. The results shown are 
representative of two experiments with a total N = 8 mice per immunization group. The 
Mantel-Cox Test was used to compare the survival distributions of OVA/PorB and OVA 
alone immunization group (*** P = 0.0001). 
 
These results indicate that PorB has potent adjuvant activity, stimulating the 
production of chemokines and cytokines, either as a result of direct or in-direct 
stimulation of immune cells. This resulted in robust induction antigen specific CD4 and 
CD8 T cell responses. These antigen specific T cells were increased in numbers and were 
highly functional producing IL-4 and IFN-γ when PorB was used in the vaccine 
formulation. Listeria monocytogenes expressing OVA infection model is a well-
established model. It has been clearly demonstrated in multiple studies that this pathogen 
requires antigen specific CD8 T cells and not CD4 T cells, nor antibody responses, to 
control and clear the infection (Edelson & Unanue, 2000; Sanjabi, Mosaheb, & Flavell, 
2009; Shedlock et al., 2003; Wang et al., 2011; Zenewicz, Foulds, Jiang, Fan, & Shen, 
2002). Therefore in our model, it is likely that the OVA specific CD8 T cells induced by 
PorB reduced the bacterial burden and increased mice survival upon infection with a 
recombinant Listeria monocytogenes expressing OVA. 
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Discussion 
Adjuvants in current vaccines have been very successful at inducing responses 
that are protective against pathogens; most of these vaccines protect through induction of 
a pathogen specific antibody response (Rappuoli, 2007). Many of the current adjuvanted 
vaccines contain Alum, which is very good at inducing a Th2 associated IgG1 type 
response (Brewer, 2006). However, many of these diseases such as TB, HIV, malaria and 
cancer require a broader antibody response and, likely, a concomitant T cell responses 
(Rappuoli, 2007). There is still an unmet clinical need for new novel adjuvants for use in 
vaccines against organisms and diseases that are immune evading and that remain a threat 
today. Live attenuated vaccines such as the yellow fever and smallpox vaccines have 
been very successful because they contained endogenous adjuvants that are PAMPs 
capable of being recognized by PRRs such as TOLL-like Receptors (TLRs), among many 
others. Previous studies have demonstrated the potential for PAMPs to be used as 
adjuvants in vaccine formulation, for example a TLR4-ligand based adjuvant has been 
shown to be able to enhance T cell proliferation and survival of these T cells during 
clonal expansion and contraction (Gandhapudi, Chilton, & Mitchell, 2013). In our 
previous work, we have shown that the TLR2-ligand Neisseria meningitidis PorB has 
adjuvant properties, increasing the antibody response to a wide range of antigens, 
including polysaccharides, proteins, and LPS (Chiavolini et al., 2008; Singleton et al., 
2005). This adjuvant activity was dependent on PorB’s signaling through TLR2/1 
heterodimers (Massari et al., 2006), and MyD88 adaptor protein (Singleton et al., 2005). 
TLR2-ligand based adjuvant PorB is excellent at shaping the vaccine-induced immune 
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responses, enhancing antigen uptake in vivo (Reiser, Mosaheb, Platt and Wetzler, 2016 
manuscript in preparation) and inducing robust germinal center formation and diverse 
types of antigen specific antibody subclasses (Figure 3.9 and 3.11) (Mosaheb, Reiser and 
Wetzler, 2016 manuscript under review). 
In the present study, we set out to provide detailed insight into the ability of this 
TLR2 agonist, meningococcal PorB, to induce T cell responses as part of its adjuvant 
activity in vivo using a subcutaneous immunization model. We screened for IFN-γ, IL-4, 
IL-5, IL-13 and TNF-α cytokines produced by T cells after immunizations. Previous 
studies have demonstrated that mRNA encoding TNF-α increases dramatically within 
naïve CD8 T cells upon TCR engagement in both humans and mice (Ohshima et al., 
1999; Sung et al., 1988; Yang et al., 1998). CD8 T cells produced TNF-α within 5 hours 
of TCR engagement and this promotes DC maturation, CD8 T cell differentiation and 
proliferation (Aggarwal, 2003; Brehm, Daniels, & Welsh, 2005; Ruddle, 1992; Smyth & 
Johnstone, 2000). CD8 T cells producing TNF-α are also able to mediate infection in vivo 
(Grivennikov et al., 2005; L. Xu et al., 2004). We demonstrated that the TLR2-ligand 
based adjuvant PorB induced high levels of Th1 type (IFN-γ), Th2 type (IL-4, IL-5 and 
IL-13) and TNF-α T cell cytokines 4 or 12 hours after the 3rd immunization. These time 
points were used based on observations from previous studies, as well as our own 
investigations, where it was demonstrated that serum T cell cytokines peak early, at these 
time points in mice upon immunization (Nolz et al., 2011; Valensi et al., 1994). The 
induction of Th2 and Th1 type cytokines are consistent with the fact that PorB induced 
antigen specific IgG1 (Th2 type associated antibody) and antigen specific IgG2b, 2c and 
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3 (Th1 type associated antibody) responses (Platt et al., 2013).  
We demonstrated that vaccine formulated with PorB induced an increase in 
effector molecules (MIG, MCP-1, IP-10, MIP-1α, KC and IL-2) that are vital for the 
induction of T cell responses (Figure 4.2A-F). PorB increases the level of these 
chemotactic cytokines in sera very early (4 hours) after each of the three immunizations. 
MIG and IP-10 chemokines have been shown to act directly on CD8 T cells, which 
express high level of CXCR3, the receptor for these chemokines (Groom & Luster, 
2011). Other studies have shown that cells producing IFN-γ, including CD4 T cells, have 
an important role in controlling the level of MIG and IP-10 in vivo for the recruitment of 
CD8 T cells to lymphoid organs (Nakanishi, Lu, Gerard, & Iwasaki, 2009; Nolz et al., 
2011). IP-10 is also known to promote the retention of T cells in the draining lymph 
nodes for enhance APC-T cell interactions and a robust clonal expansion (Gandhapudi et 
al., 2013). Induction of these chemokines by PorB’s direct or in-direct adjuvant 
stimulating ability on immune cells in vivo suggest that it is likely playing a role in 
generating vaccine-induced T cell responses. Another important chemokine, MIP-1α, is 
induced upon immunization with a DNA based vaccine and has been shown to be able to 
increase the number of antigen specific CD8 T cells (Oynebraten, Hinkula, Fredriksen, & 
Bogen, 2014). MIP-1α signals through its receptor CCR1 and CCR5 and it has been 
previously demonstrated that this results in macrophages and NK cell migration, however 
even more importantly it leads to enhance T cell-DC interactions (Griffith, Sokol, & 
Luster, 2014). MIP-1α signaling on CD8 T cells induces these cells to migrate towards 
CD4/APC clusters, this enhances the contact of CD8 T cells with CD4 T helper cells-
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licensed DCs (Castellino et al., 2006). This type of interaction promotes the increase in 
number and quality of memory CD8 T cells (Hugues et al., 2007). Vaccines formulated 
with PorB induced MIP-1α after each of the three immunizations, this further fuels our 
interest in characterizing these antigen specific T cells induced by PorB. Other 
investigators have studied the adjuvant properties of biglycan ligands (TLR2 and 4 
agonists) and through these studies they showed that these ligands increase the level of 
KC (CXCL1), which in turns increase cells recruitment including T cells to the site of 
inflammation in mice (Moreth et al., 2014). MCP-1 (CCL2) is another chemokine that we 
screened because it signals through CCR2 which is express on monocyte, macrophages 
and Th1 type cells, signaling through this receptor results in enhance Th1 type adaptive 
immunity (Griffith et al., 2014). Induction of these important T cell chemokines upon 
vaccination with PorB promotes and enhances the T cell responses. It ensures the 
recruitment of specific cells and induces production of important effector molecules, 
which likely results in enhanced cross-presentation and APC-T cell interactions. One 
vital molecule for T cell responses is IL-2, which promotes the differentiation of T cells 
into effector and memory T cells (Liao, Lin, & Leonard, 2011). Previously, we have 
shown that PorB induced a robust germinal center reaction (Mosaheb, Reiser and 
Wetzler, 2016 Manuscript in review) (Chapter 3 above) and antigen specific antibody 
responses (Platt et al., 2013). PorB’s stimulating ability to induce these specific 
chemokines and T cell cytokines suggest that it’s adjuvant activity might also consist of a 
T cell response. 
We further identified the source of some of these Th2 and Th1 types cytokines. 
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PorB induced significantly more OVA specific CD4 T cells producing IL4 or IFN-γ as 
compared to OVA alone. (Figure 4.3A-D). Previous studies showed that the presence of 
CD4 T cells (Th1 type cells) producing IFN-γ enhance the differentiation of CD8 T cells 
into Tc1 type cells (Mosmann, Li, & Sad, 1997). This type of cellular response is crucial 
to prevent and delay the progression of infectious diseases (especially intracellular 
pathogens) as well as other pathologies like cancer (He & Falo, 2006). The increase in 
the level of IFN-γ, IL-2 and the various chemokines upon immunization with PorB, likely 
generated an environment conducive for the robust induction of OVA specific CD8 T 
cells producing IFN-γ by this adjuvant. We investigated all the different types of T cell 
responses induced by PorB and demonstrated that PorB induced antigen specific CD8 T 
cells producing IL-4 (Tc2 type response). The number of OVA specific Tc2 cells induced 
by PorB/OVA was much smaller as compared to the other type of T cell responses 
measured. However it was still significantly higher than mock-immunized or OVA-alone 
immunized mice (Figure 4.4C &D). These types of antigen specific Tc2 cells producing 
IL-4 have been shown to be able to provide B cell help (Maggi et al., 1994). In mice, they 
are able to be cytotoxic via the perforin pathway, however they are less cytotoxic than 
Tc1 type cells (Mosmann et al., 1997; Sad et al., 1997; Sad, Marcotte, & Mosmann, 
1995). In humans, Tc2 type cells have been shown to counteract the overproduction of 
pro-inflammatory cytokines in old age and are important for induction of humoral 
response upon immunization (Schwaiger, Wolf, Robatscher, Jenewein, & Grubeck-
Loebenstein, 2003). Older adults who fail to mount a protective humoral response upon 
immunization lack these Tc2 cell subset (Schwaiger et al., 2003). The elderly population 
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has an increase risk in acquiring infections with an increase in severity, which has been 
shown to be due to immune senescence (Schwaiger et al., 2003; Weinberger, Herndler-
Brandstetter, Schwanninger, Weiskopf, & Grubeck-Loebenstein, 2008). Using an 
adjuvant like PorB in vaccine formulations could enhance the vaccine-induced immune 
responses in the elderly, including an increase in the number of antigen specific Tc2 cells 
producing IL-4, which will in turn aid in inducing a robust humoral response. These types 
of responses induced by PorB-adjuvanted vaccine would be very beneficial to the 
growing aging population in today’s world. 
Previous studies demonstrated that the induction of CD8 T cells upon 
immunization or infection might be important for the control and clearance of various 
pathogens such as HIV, malaria, or tuberculosis (Coffman et al., 2010). After 
vaccination, naive T cells undergo clonal expansion followed by contraction, where the 
effector CD8 T cells die off while a smaller population of the antigen specific memory 
CD8 T cells are maintained (Sanjabi et al., 2009). A vaccine that induces antigen specific 
CD8 T cells could aid in inducing protective immunity against intracellular pathogens. 
Here, we demonstrated that our adjuvant PorB induced robust antigen specific CD8 T cell 
responses. We showed that these OVA specific CD8 T cells are not just increased in 
numbers upon immunization with vaccine formulated with PorB but they are highly 
functional producing IFN-γ in an ex vivo ELISPOT assay upon engagement of its TCR 
with OVA CD8 (MHC Class I restricted) peptide presented by antigen presenting cells.  
Using a bacterial infection model (recombinant Listeria monocytogenes 
expressing OVA, rLmOVA), we demonstrated that the antigen specific CD8 T cells 
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induced by vaccine formulated with PorB are likely functional in vivo as well. Infection 
with the Gram-positive rLmOVA is a well-established model to study T cell responses in 
mice because of the bacterium’s unique life cycle in vivo (Edelson & Unanue, 2000). 
Pathogen specific (in this case, OVA, since these bacteria have been engineered to 
express OVA) CD8 T cell responses have been shown to be required for clearance of this 
bacterium (Foulds et al., 2002; Zenewicz et al., 2002). Once inside the cell, rLmOVA 
replicates in the cytosol and spreads from cell to cell via actin polymerization, without 
having to expose itself to the outside of the cell (Gedde, Higgins, Tilney, & Portnoy, 
2000; Steffen et al., 2000). OVA expression by the bacteria is under the control of the 
listeriolysin promoter in the bacteria and bacterial proteins from the cytosol are presented 
on MHC I & II (Shedlock et al., 2003). Upon infection with rLmOVA, its is known that 
the infection caused lymphopenia by day three post infection (Wang et al., 2011). In our 
Listeria infection model, we observed a decrease in the number of cells from the spleen 
of mock-immunized or OVA-alone immunized mice. However, mice immunized with 
PorB/OVA did not have a significant decrease in splenocytes upon infection (Figure 4.7). 
rLmOVA is known to cause apoptosis of cells via its pore-forming toxin listeriolysin O 
and also through activation of death pathways (Carrero & Unanue, 2012; Unanue & 
Carrero, 2012). This happens early during the infection and together with its ability to up-
regulate IL-10 in DCs and macrophages, this allows the bacteria to spread quickly and 
become a systemic infection (Carrero & Unanue, 2007, 2012). The normal number of 
cells from OVA/PorB immunized and infected mice is likely due to the effect of antigen 
specific CD8 T cells controlling the rLmOVA infection, decreasing apoptosis of the 
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splenocytes. This is even more evident when the bacterial load from the spleen and liver 
were measured three days after infection, where we demonstrated that mice immunized 
with PorB admixed with OVA had a significantly lower bacterial burden (Figure 4.7A-
D). Multiple previous studies have used the same Listeria infection model and shown that 
this pathogen requires antigen specific CD8 T cells and not CD4 T cells nor antibody 
responses to control and clear the infection (Edelson & Unanue, 2000; Sanjabi et al., 
2009; Shedlock et al., 2003; Wang et al., 2011; Zenewicz et al., 2002). The induction of 
antigen (OVA) specific CD8 T cells in vivo induced by PorB/OVA immunization was 
associated with increased survival of mice infected with a high dose of rLmOVA and is 
the likely protective mechanism of this survival (Figure 4.8).  
TLR2 ligand based adjuvant Neisseria meningitidis PorB has broad adjuvant 
activity with a wide range of antigens (Chiavolini et al., 2008; Mackinnon et al., 1999b; 
Singleton et al., 2005). It induced a strong humoral response (Platt et al., 2013), robust 
germinal center formation and this adjuvant signals through B cells, dendritic cells and 
macrophages in vivo for its adjuvant activity (Figure 3.8 and Figure 3.11) (Mosaheb, 
Reiser and Wetzler, 2016 Manuscript in review). In this study, we demonstrated that 
PorB induced unique and robust diverse T cell responses, capable of decreasing the 
bacterial burden and increasing the survival of mice upon infection with a bacterium that 
depends on antigen specific CD8 T cells for clearance. The types of T cell responses 
induced by PorB promote antibody formation as well as strong antigen specific CD8 
cytotoxic T cell responses. PorB will be useful in future vaccine development alone or in 
combination with other adjuvants to induce responses that's needed for protection. 
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Conclusion 
Summary of Results 
In the first part of this thesis, we investigated the TLR2 ligand PorB’s adjuvant 
activity in vivo and compared its immune stimulating activity to other well-studied 
adjuvants. We found that intact MyD88 signaling is essential, separately, in all three APC 
types investigated (B cells, macrophages and DCs) for optimal TLR-ligand based 
adjuvant activity including PorB. However, the immune response was reduced to the 
greatest extent in mice with macrophage-specific MyD88 deletion. We demonstrated that 
TLR-dependent adjuvants are potent inducers of GC responses, but GCs were nearly 
absent in Mac-MyD88-/- mice upon immunization with TLR-dependent adjuvants PorB 
or CpG, but not with TLR-independent adjuvants MF59 or Alum. In addition, intact 
MyD88 signaling in macrophages is crucial for the induction of cytokines important for 
GC formation when immunized with TLR-ligand based adjuvants. These findings, reveal 
a unique and here-to-for unrecognized importance of intact MyD88 signaling in 
macrophages, allowing robust vaccine induced immune responses when TLR-ligand 
based adjuvants are used.  
In the second part of this thesis, we investigated PorB’s ability to induce T cell 
responses. Using a subcutaneous immunization model and a mouse recombinant Listeria 
infection model, we demonstrated that PorB has broad adjuvant activity with robust and 
diverse T cell responses. We showed that a vaccine formulated with PorB induced a wide 
variety of chemokines and cytokines with essential roles for inducing T cell responses 
very early after each of the three immunizations. We confirmed production of some of 
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these cytokines by identifying and quantitating the antigen specific T cells induced by 
PorB in vivo. PorB induced impressive quantity and quality of antigen specific CD4 and 
CD8 T cells that were significantly increased in numbers and are highly functional, 
producing IL-4 or IFN-γ just after two immunizations. Finally, in a mouse Listeria 
infection model, vaccine formulated with PorB significantly reduced the bacterial burden 
upon a low dose infection and increase survival upon a high dose infection with 
rLmOVA, a pathogen that requires antigen specific cytotoxic CD8 T cells for clearance. 
Therefore, PorB is a potent novel adjuvant, capable of inducing not only a robust humoral 
response but also a strong diverse T cell response. 	
Future Directions 
Findings from these investigations have enhanced our understanding of the 
immune stimulating ability of PorB, a novel TLR2 agonist, and its use as a vaccine 
adjuvant. Furthermore, through this process we also gained a better understanding of the 
mechanism of action of other adjuvants in vivo and the role of specific immune cells in 
vaccine-induced immune responses. 
In the immediate future we are in the process of further examining the draining 
lymph nodes and spleen in mice with MyD88 deletion in macrophages upon 
immunization with adjuvants and investigate:  
1. PorB’s effect on induction of various tissue chemokines and cytokines that are 
important for generation of germinal centers and robust humoral responses. So far 
we have examined the effector molecules profile in the serum, it is likely that the 
local environment has different levels of chemokines and cytokines that's 
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affecting the humoral responses induced in these transgenic mice. 
2. Identify the antigen specific T cells producing these cytokines in vivo in both WT 
and Mac-MyD88-/- mice. The biological relevance of sera cytokines is not clear 
however quantitating and identifying the number of T cells producing the Th2 and 
Th1 type cytokines might help us understand what is going on in the 
microenvironment of the lymphoid organs. These cytokines as described in 
discussion section (Chapter three) have important role in germinal center 
formation. 
3. As described in the discussion section of chapter three, there are different types of 
unique macrophages within the lymphoid organs, each with unique functions that 
cannot be substituted by DCs. We have shown in a hock immunization model that 
when immunized, the leg that received the antigen along with the adjuvant PorB 
has an increase in the number of DCs in the draining lymph node. Interestingly, 
most of these DCs contained the fluorescently labeled antigen OVA and there 
were clear co-localization of the antigen with CD169 subcapsular sinus 
macrophages that line the subcapsular sinus of the draining lymph node as 
illustrated in Figure A9.1 and A9.2. In contrast, the opposite hock immunized 
with OVA alone had very few DCs with OVA and little OVA co-localization 
within the CD169+ macrophages. We are in the process of using a fluorescently 
labeled PorB and examined its interaction with the various cell types in the 
draining lymph nodes by confocal microscopy. 
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4. Previous studies have demonstrated that TLR signaling in the CD169 
macrophages lining the subcapsular sinus of the lymph node actually leads to the 
movement of these cells, the lining around the lymph node gets disrupted (Gaya et 
al., 2015). The underlying reason for this is to allow influx of DCs into the 
draining lymph nodes (Gaya et al., 2015). A previous study actually demonstrated 
that among the different types of DCs that is recruited to the lung draining lymph 
node upon LPS stimulation, is a significant population that are non-lymphoid 
tissue derive DCs that expresses CD103 (Jakubzick et al., 2008). Both CD103+ 
and CD103- DCs are recruited to the draining lymph node in a subcutaneous 
mouse immunization model, similar to our model (Stary et al., 2015). The 
CD103+ DCs have been shown to express PDL1 and IL-10, molecules that have 
role in anti-inflammatory pathways upon immunization with a UV-inactivated 
Chlamydia strain (Stary et al., 2015). This has been shown to dampen the vaccine-
induced immune responses in this mouse infection model. We plan to immunize 
WT and Mac-MyD88-/- mice and sort the CD103+ and CD103- DCs and check 
their expression of PDL1 and PDL2. These anti-inflammatory pathways could be 
playing a role in decreasing the humoral response in the Mac-MyD88-/- mice 
since we do detect an increase in anti-inflammatory cytokine IL-10 in these mice 
upon immunization with TLR-ligand based adjuvant. 
5. T Follicular Helper cells (TFH) have vital role in germinal center formation and 
homeostasis. We have looked at TFH (CD4+PD1+CXCR5+) percentages and 
number pre and post immunization in WT and Mac-MyD88-/- and there were no 
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difference. We plan to further examine the presence and location of TFH by 
confocal microscopy in the spleens and draining lymph nodes. The number of 
TFH within a germinal center or in the proximity of germinal center in WT vs 
Mac-MyD88-/- mice might help us understand the decrease in humoral response 
observed in the Mac-MyD88-/- upon immunization. 
 
Our laboratory has an interest in further characterizing PorB’s induction of germinal 
centers by investigation germinal center persistence, plasmablast formation, and antibody 
affinity maturation and B cell somatic hypermutation. Other ongoing studies involve the 
use of clodronate to remove marginal zone associated macrophages in an attempt to 
better understand their role in the adjuvant activity of PorB. 
 
 PorB’s ability to induce a robust and diverse T cells responses is vital for future 
use in vaccine. It would be interesting to see if we observe similar results with the use of 
other antigens or in other infection models. Future directions should also include further 
characterization of the memory CD8 T cell population and its ability to continue to be 
highly functional. Induction of antigen specific T cells in the mucosa is important for 
control of pathogens that affect these specialized tissues. In the future, it would be 
important to investigate PorB’s ability to induce a CD8 cytotoxic T cell response in the 
different mucosal sites.  
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Significance 
I set out to better understand the adjuvant activity of a novel TLR2-ligand, PorB, 
and in the process I discovered a previously un-described novel role of in vivo MyD88 
signaling in macrophages for the induction of antibody and germinal centers upon 
immunization with TLR-ligand based adjuvants. More specifically, findings from this 
study demonstrate that intact MyD88 signaling in all three APC types in vivo was 
important for induction of a strong humoral response. As described in the discussion 
section of chapter 3, multiple studies have previously demonstrated the importance of 
intact MyD88 signaling in B cells and DCs. However, intact in vivo MyD88 signaling in 
macrophages upon immunization with TLR-ligand based adjuvants have not been 
described. I demonstrated in detail that macrophages were required for induction of 
antigen specific antibodies including the highly functional antibody subclasses and robust 
germinal center formation with TLR-dependent but not TLR-independent adjuvants. 
Intact MyD88 signaling in B-cells and DCs in these mice could not compensate for the 
deficient MyD88 signaling in the macrophages for the vaccine-induced responses. This 
observation was consistent for the various TLR-ligand based adjuvants studied, including 
PorB. Therefore, in vivo signaling of TLR-ligand based adjuvants in macrophages could 
be vital to induce the type of robust responses needed for therapy. Vaccines containing 
TLR-ligand based adjuvants can be formulated and administered in a specific way so that 
they encounter unique types of macrophages in the lymphoid organs to induce specific 
responses. These insights will aid in vaccine development by allowing more intelligent 
and judicious use of these and other vaccine adjuvants. 
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During these investigations I also discerned that PorB does not just induce a 
robust humoral response but also a strong and diverse CD4 and CD8 T cell response. I 
demonstrated that these antigen specific T cells are likely functional in vivo. This type of 
T cell immunity to immunization is vital for two significant reasons. First, most 
adjuvanted vaccines induce some neutralizing antibody, though this is the reason these 
vaccines have been successful, this approach may not be effective when considering 
vaccination against more complex and immune evading pathogens that remains a threat 
today such as HIV, malaria, Mycobacterium tuberculosis, hepatitis and pathologies like 
cancer. These types of pathogens and pathologies likely require an additional cellular 
immune response for protection. Secondly, for many vaccines, even those that induce 
good neutralizing antibodies, the immunobiology of the pathogens (for example high 
antigen variability, intracellular pathogen with minimum exposure outside of a cell) make 
the addition of pathogen specific cellular T cell responses important to induce.  
Finally another significant and interesting finding is the ability of vaccine 
formulated with PorB to induce a small but statistically significant population of antigen 
specific CD8 T cells producing IL-4 (Tc2 Type cells). As described in the discussion 
section of chapter four, these types of antigen specific Tc2 cells producing IL-4 have 
been shown to be able to provide B cell help (Maggi et al., 1994). In humans, they have 
been shown to counteract the overproduction of pro-inflammatory cytokines in old age 
and correlates with the induction of humoral response upon immunization or infection 
(Schwaiger et al., 2003). The elderly population has an increase risk in acquiring 
infections with an increase in severity and that's has been shown to be because of the 
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decline in the immune responses (Schwaiger et al., 2003; Weinberger et al., 2008). Using 
an adjuvant like PorB in vaccine formulation can enhance the vaccine-induced immune 
responses including an increase in the number of antigen specific Tc2 cells producing IL-
4, which will in turn induce a robust humoral response. These types of responses induced 
by PorB-adjuvanted vaccine would be very beneficial to the growing aging population.  
There are many types of adjuvants being studied to induce specific responses such 
as humoral responses (PorB, CpG, Alum), CD8 T cells responses (CpG, PorB), Th1 
(CpG, PorB), Th2 (Alum, PorB) and/or Th17 (Cationic Liposome adjuvant). My 
investigations of PorB immune stimulation ability as well as other adjuvants are 
important for future vaccine designs, where vaccines can be formulated with adjuvant, or 
combination of adjuvants, designed to target specific cell type to engage specific TLR or 
sets of TLRs to shape the vaccine-induced immune responses needed for protection. My 
findings provide novel conceptual insight into immunology. It has broad implications and 
clear in vivo relevance for vaccine design, cancer therapy and autoimmune disease 
treatments where specific responses are needed for successful treatment.  
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APPENDIX 
A1. Lack of MyD88 in macrophages increased anti-inflammatory cytokine IL-10 
upon immunization with TLR-ligand based adjuvant. 
 
Figure A1.1. Lack of MyD88 signaling in macrophages increases anti-inflammatory 
cytokine IL-10. 
Mice were immunized and serum IL-10 measured by Luminex. TLR-ligand based 
adjuvant induced the highest level of IL-10 four hours after the second immunization.  
 
The IL-10 cytokine is an anti-inflammatory effector molecule with pleiotropic 
effects and plays an essential role in establishing a competent infection by limiting the 
immune response (Saraiva & O'Garra, 2010). IL-10 is also known to dampen the immune 
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response to avoid damage to the host (Saraiva & O'Garra, 2010). IL-10 signaling in DCs 
and macrophages inhibits the development of Th1 type responses (Saraiva & O'Garra, 
2010). None of the adjuvants used in these studies (both TLR dependent or independent) 
induced production of IL-10 in WT mice; however deletion of MyD88 in macrophages 
caused a large increase of IL-10 after the second immunization (Figure A1.1). We intend 
to further dissect what is going on in the draining lymph nodes, we plan to screen these 
tissues for IL-10 and also identify which cell types are producing this anti-inflammatory 
cytokine. This could be contributing to the decrease in GC formation and antibody 
production that we observe in the Mac-MyD88-/- immunized with PorB or CpG. 
  
A2. Humoral responses two weeks after the 1st and  2nd immunizations. 
Immunization route and schedule are described in the methods sections. Adjuvant 
PorB admixed with OVA does not induce any detectable level of total OVA IgG two 
weeks after the first immunization. 
  However, two weeks after the 2nd immunization, vaccine formulated with PorB 
induced higher levels of total OVA specific IgG compared to OVA alone-immunized 
mice. MF59 or Alum was better at inducing a higher antibody level after the second 
immunization in WT mice. B-cells MyD88-/-, DC-MyD88-/- or Mac-MyD88-/- had a 
significant defect in producing antigen specific antibody after the 2nd immunization. Mac-
MyD88-/- mice did not produce any detectable level of OVA specific IgG two weeks 
after the second immunization as illustrated in Figure A2.1 below.  
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Figure A2.1. Humoral responses two weeks after the 2nd immunizations. 
WT, B cell-MyD88-/-, DC-MyD88-/- and Mac-MyD88-/- mice were immunized as 
described in the methods section. Two weeks after the 2nd immunization, total serum IgG 
were measured by ELISA. Note that there were 3 mice per immunization group. “X” is to 
indicate that Alum was not used for Mac-MyD88-/- mice. 
 
None of the TLR-ligand based adjuvant induced a detectable level of OVA 
specific IgG in the transgenic mice with the exception of CpG, which induced a minute 
amount in the B-cell MyD88-/- mice. 
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Figure A2.2. OVA IgG subclasses in WT two weeks after the second immunization. 
OVA IgG1, 2c, 2b, and 3 subclasses were measured from WT mice two weeks after the 
second immunization via ELISA as described in methods. 
 
Since we detected some OVA IgG (Figure A2.1), we screened for IgG subclasses. 
Two weeks after the second immunization was too early to detect subclass responses. 
Thus, total OVA IgG and IgG subclasses described in Chapter three were only detected 
two weeks after the third immunization. 	
A3. Humoral response induced by MF-59 is MyD88 dependent. 
MF-59, a Novartis patented adjuvant, has been shown to be MyD88 dependent 
and TLR independent (Calabro et al., 2011). However, in data described in Chapter 
Three, MF59 was still able to induce high levels of OVA specific IgG in B cell-MyD88-/-
, DC-MyD88-/- and Mac-MyD88-/- mice. This suggest that its adjuvant activity might be 
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dependent on MyD88 signaling in other cell types or defective signaling through one of 
the APCs is not enough to affect the humoral responses using MF59. We therefore 
investigated whether MF59 was able to induce a robust humoral response in complete 
MyD88-/- mice. We observed similar results as described in the literature that MF59 is 
not able to induce a strong humoral response in complete MyD88-/- mice as illustrated in 
Figure A3.1. 
 
Figure A3.1. MF59 adjuvant activity is MyD88 dependent. 
Complete MyD88-/- mice were immunized as described in the methods section. In these 
mice, MF59 failed to induce a strong humoral response as observed in WT mice. 
 
A4. Tissue sectioning and staining for germinal centers and CD169 macrophages. 
We first tried immunohistochemistry (IHC) (Figure A4.1) and quickly found out 
the immunofluorescence would allow us to look at a wider variety of antigen with 
antibodies that we already had in our lab. Multiple antibodies were tried and FITC Rat 
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anti-Mouse B and T cell Activation Antigen Clone: GL-7 (Beckton Dickinson 
Biosciences, San Jose, CA), PE anti-Mouse IgD Clone: 11-26c.2a (BioLegend, San 
Diego, CA) or Biotin B220 (BioLegend, San Diego, CA) and Alexa Fluor 647 anti-
Mouse TCR-β Clone: H57-597 (BioLegend, San Diego, CA) worked the best. 
 
Figure A4.1. Immunohistochemistry of frozen spleen section for B cells and CD169 
macrophages. 
Spleens were flash frozen and sectioned (8 µm thick) as described in methods and stained 
with B220 and CD169 antibodies. 
 
This experiment was designed to determine which antibodies would work best for 
tissue staining and determine if sectioning was being done properly. Figure A4.1 
demonstrated B cell and CD169 macrophages staining. Marginal zone B cells can also be 
seen as labeled on the images. Higher magnification shows the layers of CD169 clearly 
around the follicles (Figure A4.2). Biotin anti-B220 and FITC anti-CD169 worked best 
SP,	B220+	CD169,	3-13-14,	E10,	10x	SP,	B220+	CD169,	3-13-14,	Exposure	10,		
Mag	=	4x	
B	cell	rich	
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CD169+	
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CD169	
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for this experiment and were further tested via immunofluorescense (IF) staining (Figure 
A4.3).  
 
 
Figure A4.2. Higher magnification of spleen section stained for B220 and CD169. 
Spleen sections prepared as describe in Figure A4.1, here we are using the 20x and 40x 
objective to examine the B cell follicle closely. 
 
SP,	B220+MOMA,	3-13-14,	E20,	20x	
SP,B220+	MOMA,	3-13-14,	E40,	40x	
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Figure A4.3. Immunofluorescence staining of spleen section. 
Spleen sections were prepared as described in chapter three methods section and stained 
for CD169, TCR-β and B220 listed above. 
 
Figure A4.4. Germinal center staining. 
CD169	TCR-β	B220	
WT	OVA+PorB	 Mac	MyD88-/-	OVA+PorB		
GL-7	 B220	 TCR-β	 40x	
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Spleen sections were prepared as described in chapter three methods section and stained 
with GL-7, TCR-β and B220. 
 
Even though the B220 antibody worked very well (Figure A4.4), we decided to 
use an antibody against IgD (PE anti-Mouse IgD Clone: 11-26c.2a (BioLegend, San 
Diego, CA)) to stain the follicular B cells and because germinal center B cells are IgD 
negative (Figure A4.5). This allows for clearer distinction of germinal centers and allows 
for IgM staining in the future. 
 
 
Figure A4.5. Optimization of germinal center staining. 
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This is a spleen section from a mouse that received sheep red blood cells via retro-orbital 
injection. This section is stained with GL7, IgD and TCR-β as listed above. 
 
A5. Germinal center formation in lymph nodes of WT mice compared to Mac-
MyD88-/- mice. 
After our observations in the decrease of germinal center B cells in the spleen, we 
repeated a small set of experiment to look at the lymph nodes of mice immunized with 
PorB and a variety of other adjuvants. In this experiment, we investigated the presence of 
germinal center cells by flow cytometry in the six draining lymph nodes (dLN) (2 
inguinal, 2 axillary and 2 brachial nodes) of mice immunized with various vaccine 
compositions as described in the methods section. TLR-independent adjuvants (Alum and 
MF-59) induced a much higher percentage of germinal center cells in the lymph nodes 
(Figure A5.1) as compared to what was observed in the spleen (Figure 3.11D). There 
were no differences in percentage of germinal center cells between WT and Mac-
MyD88-/- mice immunized with TLR-independent adjuvants. The opposite was also 
observed in dLN of mice immunized with vaccine formulated with TLR-dependent 
adjuvant. These mice had lower percentages of germinal cells in the dLN (Figure A5.1) 
as compared to the spleen (Figure 3.11D) in both WT and Mac-MyD88-/- mice. Mac-
MyD88-/- mice immunized with vaccine formulation containing CpG had a significant 
decrease in the percentage of GC in the dLN when compared to WT mice. 
		
143 
 
Figure A5.1. Percent of germinal center B cells in the draining lymph nodes of WT 
compared to Mac-MyD88-/- mice. 
Single cell suspensions from inguinal, axillary and brachial lymph nodes from WT and 
Mac-MyD88-/- mice were prepared as described above for spleen without the use of 
ACK lysis buffer. FITC Rat anti-Mouse B and T cell Activation Antigen Clone: GL-7, 
APC Rat anti-Mouse CD4 Clone RM4-5, Biotin Rat anti-Mouse CD45R/B220 Clone: 
RA3-6B2 (Beckton Dickinson Biosciences, San Jose, CA) and PE/Cy7 anti-Mouse CD19 
Clone: 6D5 and PE Strepavidin (BioLegend, San Diego, CA). Forward and Side Scatter 
gates were used to identify live cells (gating strategies were similar to Figure 3.4) and 
cells that were CD4-, B220+, CD19+, and GL7+ were gated as germinal center B cells as 
illustrated in Figure 2.4. All gates were based on PBS immunized as negative control 
(Figure 2.4). One-way ANOVA with Tukey test were used (ns: not significant P>0.05, 
*P<0.05, **P<0.01, ***P<0.001 and ****P<0.0001). 
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Interestingly, we did not observe a decrease in the percentage of germinal center 
B cells in the dLN of the four PorB/OVA immunized Mac-MyD88-/- mice as compared 
to WT mice. This is likely due to a technical issue; we are in the process of repeating this 
experiment. Further investigations are needed to look at the germinal center formation in 
the draining lymph nodes as compared to the spleen for the different MyD88 transgenic 
mouse as compared to WT mice. 
 
A6. CD169 macrophage staining in WT compared to Mac-MyD88-/- mice. 
 
Figure A6.1 CD169 positive macrophages staining in WT compared to Mac-MyD88-
/- mice. 
Mice were immunized as described in methods section. Seven days after the 2nd 
immunization spleen were harvested and processed for sectioning and staining. Sections 
were stained for CD169 subcapsular sinus macrophages, B220 positive cells and TCR-β 
for T cells. 
Mac-MyD88-/-	
OVA+PorB	
WT	
OVA+PorB	
Mac-MyD88-/-	
OVA	
CD169	
TCR-β	
B220	
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In this experiment we set out to investigate how the architecture of the spleen 
changes following immunization in WT mice compared to Mac-MyD88-/- mice. CD169 
macrophages surround the follicles in the spleen and have a very important role in 
antigen capture and presentation as described in chapter three discussion section. Figure 
A6.1 is a very preliminary experiment and it shows the CD169 macrophages surrounding 
the lymph nodes. There seem to be a more prominent layer of these cells around the 
follicles in WT mice compared to Mac-MyD88-/- mice. However, the staining for CD169 
macrophages and sectioning of these sections did not work very well. Since then, we 
have optimized this assay and are in the process of further investigating the role of these 
cells in vivo. 
 
A7. Germinal center formation in spleen of WT mice compared to DC-MyD88-/- 
mice. 
The purpose of this experiment was to compare percentage of germinal center B 
cells in the spleen of WT and DC-MyD88-/- mice. Spleens were harvested, processed and 
stained as described for Mac-MyD88-/- and WT in Chapter three above. We observed a 
slight decrease in the percentage of germinal center B cells in the spleen of DC-MyD88-/- 
mice when immunized with TLR-dependent adjuvant PorB or CpG (Figure A7.1). We 
are in the process of repeating this experiment so that proper statistics can be done. 
Previous published studies have demonstrated a need for intact MyD88 signaling in DCs 
for induction of germinal center and antibody-secreting cells as thoroughly describe in 
chapter 3 discussion section above. 
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Figure A7.1. Percentage of germinal center B cells in spleen of WT mice compared 
to DC-MyD88-/- mice. 
Percentage of germinal center cells from spleens was measured by flow cytometry 7 days 
after the 2nd immunization by gating for B220+CD4-CD19+GL7+ germinal center B 
cells. The results shown are representative of at least one experiment with a total N = 2 to 
5 mice per immunization group for the Flow Cytometry analysis experiment. 
 
A8. BAFF and IL-21 cytokines level in WT vs. Mac-MyD88-/- upon immunization.  
BAFF and IL-21 are two very important effector molecules for the formation of 
germinal centers. IL-21 is secreted by T follicular helper cells and this cytokine also 
controls the differentiation of T follicular helper cells (Eto et al., 2011). BAFF is B cell 
lymphocyte stimulator activating factor and plays a vital role in B cell development, GC 
initiation and production of antibody secreting cells (Goenka, Scholz, Sindhava, & 
Cancro, 2014). BAFF is both secreted or exist in a membrane bound form (Goenka et al., 
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2014).  In this experiment we screened for secretory BAFF and IL-21 by ELISA from the 
serum collected or homogenized tissue samples from immunized mice. There were no 
differences between WT and Mac-MyD88-/- mice in the level of BAFF in dLN or spleen 
tissue homogenate or in the serum of immunized mice 4 hrs after the 2nd immunization. 
This needs to be repeated because of the high background in PBS immunized mice. We 
did observe a statistical difference in the level of BAFF from the sera of OVA/PorB 
immunized mice as compared to OVA vaccinated mice (Figure A8.1) 7 days after the 
second immunization. The level of BAFF in the sera was also significantly lower in Mac-
MyD88-/- mice compared to WT mice immunized with vaccine formulated with PorB. 
 
 
Figure A8.1 Sera BAFF level in WT vs Mac-MyD88-/- mice. 
Mice were immunized as describe in chapter three and 7 days after the 2nd immunization 
blood were collected via tail bleed and serum isolated. BAFF level were screened via 
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ELISA. One-way ANOVA with Tukey test were used (ns: not significant P>0.05, 
*P<0.05, **P<0.01, ***P<0.001 and ****P<0.0001). 
 
Figure A8.2 IL-21 levels in the spleen of WT vs Mac-MyD88-/- mice. 
Mice were immunized as describe in chapter three and 4 hours after the 2nd immunization 
spleen were harvested and homogenized. IL-21 levels were screened via ELISA. This is 
representative of two different experiments with an N of 5. One-way ANOVA with 
Tukey test were used (ns: not significant P>0.05, *P<0.05, **P<0.01, ***P<0.001 and 
****P<0.0001). 
 
 IL-21 was not detectable in sera isolated from blood collected 4 hours or 7 days 
after the second immunization. Figure A8.2 shows the level of IL-21 in WT and Mac-
MyD88-/- mice 4 hours after the second immunization. There were no difference 
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between WT mice immunized with OVA alone compared to WT mice immunized with 
OVA admixed with adjuvant. There were also no significant differences between WT and 
Mac-MyD88-/- immunized mice. Similar results were observed when IL-21 was screened 
in the draining lymph nodes as illustrated in Figure A8.3. However, interestingly the 
levels detected in the dLN were higher by 10 fold as compared to what’s observed in the 
spleen tissues. In the future, we plan to look at localized IL-21 in the spleen and draining 
lymph nodes in a more detailed manner with quantitation of cells producing this 
important germinal center cytokine. 
 
Figure A8.3 IL-21 draining lymph node levels in WT vs Mac-MyD88-/- mice. 
Mice were immunized as describe in chapter three and 4 hours after the 2nd immunization 
spleen were harvested and homogenized. IL-21 levels were screened via ELISA. This is 
representative of two different experiments with an N of 5. One-way ANOVA with 
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Tukey test were used (ns: not significant P>0.05, *P<0.05, **P<0.01, ***P<0.001 and 
****P<0.0001). 
 
A9. TLR2-ligand based adjuvant PorB increase the number of antigen positive DCs 
in the draining lymph nodes of WT mice. 
For a more detailed investigation of APC and antigen trafficking to draining 
lymph nodes following vaccination, fresh frozen sections of popliteal lymph nodes from 
mice vaccinated as described above, were examined via confocal microscopy. 8 µm 
sections were prepared and acetone fixation was used to preserve tissue structures as 
described in the methods above. Draining popliteal lymph nodes from the leg immunized 
with only OVA-A594 showed sparse antigen positive cells with little antigen uptake in 
DCs and CD169 macrophages (Figure A9.1A). In contrast, draining lymph nodes from 
the leg of mice immunized with Ova-A594 + PorB had a dramatic increase in the number 
of DCs and increased co-localization of OVA with the prominent layers of CD169 
macrophages around the subcapsular sinus of the lymph node. Most of the DCs contained 
high amount of OVA as observed by the co-localization of OVA-A594 with CD11c 
staining (Figure A9.1B & A9.2). We also see a wider distribution of CD169 macrophages 
(also termed metallophilic macrophages) in the periphery extending in the follicle area. 
Some of these CD169 macrophages also co-localize with OVA, suggesting that CD169 
macrophages may play a role in PorB’s adjuvant activity. Previous studies have 
suggested that these macrophages act as sentinel cells with important functions in 
detecting pathogens, presenting antigens by extending in the follicle area, and that the 
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antigen taken up is not degraded rapidly and gets presented for a longer period of time 
(Phan et al., 2007). In the future, we shall further characterize the role of these cells in 
TLR-ligand based adjuvant activity. 
 
Figure A9.1. Confocal microscopy confirms PorB inclusion increases antigen 
positive dendritic cells in draining lymph nodes.  
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C57BL6J mice received hock immunization with 5µg OVA-A594 alone in the right leg 
and 5µg OVA-A594 with 10 µg PorB in the left leg. Draining lymph nodes were 
obtained 24 hrs after immunization and prepared for confocal microscopy. A) 8 µm thick 
section of draining lymph node from a mouse immunized with OVA-A594 (red) alone 
were stained with CD169 (green) and CD11c (purple). B) 8 µm thick section of draining 
lymph node from a mouse immunized with OVA-A594 (red) plus PorB were stained with 
CD169 (green) and CD11c (purple). For each lymph node, the whole sample were 
sectioned and analyzed on the Leica Sp5 confocal microscope, representative sections are 
shown. The lymph node draining the site vaccinated with PorB + OVA demonstrates 
increased numbers of antigen positive DCs. There were two mice per immunization 
group, this figure represent one mouse. For both A) and B) the upper panels were 
captured using the 20x objective and lower panels using the 63x objective. 
 
Figure A9.2. Confocal microscopy confirms PorB inclusion increases antigen 
positive dendritic cells in draining lymph nodes of the second mouse immunized 
with OVA+PorB.  
This is the same experiment as described for Figure A8.1. Here we are displaying 
representation sections from the second mouse that received OVA+PorB vaccination in 
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the right leg. Unfortunately, the draining popliteal lymph node of the left leg receiving 
OVA alone was damaged during sectioning. Our laboratory is in the process of repeating 
this experiment to quantitate the number of OVA positive DCs that are recruited to the 
draining lymph node. 
 
A10. In vivo and in vitro microarray analysis for further understanding of PorB’s 
adjuvant activity. 
 I performed this experiment in collaboration with Andrew Platt, former PhD 
Candidate in the Wetzler Laboratory. Andrew elegantly discussed the mRNA gene 
expression in his thesis so we wont go into these details here. I am in the process of 
confirming some of the genes that were differentially affected in these experiments by 
RT-PCR. We have further analyzed this data looking at the microRNA induced in the 
spleen by PorB in vivo 24 hours the 1st, 2nd or 3rd immunization comparing OVA, PorB or 
OVA/PorB immunized mice. The data was sorted base on the FDR value, followed by P-
value and log2 expression or fold change. From this analysis we observed multiple 
microRNA (miR) that were upregulated when the 2nd immunization were compared to the 
1st or 3rd vaccination as illustrated in Figure A10.1 below. The functions of most of these 
microRNA are not known. Next, we compared the expression of these miRs between 
OVA/PorB and OVA alone-immunized mice after each of the three immunizations as 
illustrated in Figure A10.2 below. 
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Figure A10.1. In vivo microRNA induction by OVA/PorB formulated after the 2nd 
immunization compared to the 1st or 3rd vaccinations. 
These data were derived from an mRNA microarray that also detected some miRNA as 
described in the methods section in the appendix. 
 
 
 
 
 
 
 
 
Upregulation of miRNA after 2 immunization 
vs 
1 or 3 immuization with O+P
0
2
4
6
8
10
Mir19a
Mir181b-2
Mir423
Mir24-1
Mir186
Mir15a
Mir181b-1
Mirlet7f-1
Mir148b
Mir29a
Mir701
Mir697
Mir374
Mir687
Unknown
Lo
g2
 e
xp
re
ss
io
n
		
155 
 
Figure A10.2. In vivo microRNA induction by OVA/PorB compared to OVA alone.  
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For most of the miRs there were no differences between OVA alone and 
OVA+PorB immunized mice 24 hours after the first or third immunizations. The 
differences between these miRs were mainly observed at 24 hours after the 2nd 
immunization, however the differences were very small. This is likely due to three main 
reasons. First, these samples were prepared to preserve mRNA and not microRNA; this is 
likely affecting our results. Secondly, even though the mRNA microarray detected some 
miRs, it was not optimized for such assay. Finally, spleen samples contained a wide 
variety of cell types. MicroRNA in these cell types would be expressed at different levels. 
Screening of the whole spleen for microRNA is likely the reason why we are seeing 
minute differences between mice receiving the adjuvanted vaccine verses un-adjuvanted 
vaccine. In the future, we need to sort specific cell type, prepare the samples to preserve 
microRNAs and use microRNA specific chips for screening.  
To further characterize PorB’s adjuvant activity, we went back to investigate 
PorB’s ability to induce microRNAs in vitro. We generated Bone Marrow Derived 
Macrophages (BMDM) from WT and TLR2-/- mice as described in methods section and 
either stimulated with 10µg/ml of the TLR2 ligand PorB or the synthetic TLR2 ligand 
Pam3CSk4 for 6 hours. Pro-inflammatory cytokines were measured by ELISA. PorB is a 
TLR2-ligand based adjuvant and previous studies from our laboratory seem to suggest 
that PorB might have some TLR2 independent activity. This is due to PorB’s ability to 
induce some antibodies in TLR2-/- mice. 
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Figure A10.3. In vitro generation and stimulation of bone marrow derived 
macrophages.  
(A) TNF-α (B) IL-6 and (C) RANTES (CCL5) cytokines were measured by ELISA of in 
vitro stimulated BMDM from WT or TLR2-/- mice, either stimulated with TLR2 ligand 
PorB or the synthetic TLR2 ligand Pam3CSk4. 
 
We observed an increase in the cytokines measured with PorB and Pam3CSk4 in 
WT mice (Figure A10.3). This confirmed that our adjuvant were able to stimulate these 
cells at a similar level or higher than the positive control Pam3CSk4, while the control un-
stimulated cells did not have any detectable level of these cytokines. In TLR2-/- BMDM, 
Pam3CSk4 failed to induce a detectable level of these cytokines as expected (Figure 
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A10.3). However, PorB were able to induce very low level of these cytokines in TLR2-/- 
BMDM. We did not observe a complete abrogation in the cytokines production as 
observed with Pam3CSk4.  
RNA was isolated, purity checked on nanodrop, and quantified as described in 
methods. BUSM microarray core performed a microRNA microarray on these samples 
and did preliminary analysis of the data. MicroRNA expressions were sorted based on P 
value and fold change and WT was compared to TLR2-/- BMDM. 
 
Figure A10.4. In vitro microRNA expression from WT and TLR2-/- BMDM upon 
stimulation with PorB. 
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(A) WT or TLR2-/- BMDM stimulated with PorB were compared to control and in (B) 
PorB or control stimulated TLR2-/- BMDM were compared to WT. The expression 
values were sorted based on their P value and fold change. 
 
 PorB induced a wide array of microRNA in WT BMDM and expression of these 
microRNA is dramatically decreased in TLR2-/- BMDM (Figure A10.4). MicroRNA 155 
have been previously shown to be induced my multiple TLR agonist including TLR2 
ligand Pam3CSk4. This is the first time PorB has been shown to be able to induce this 
microRNA. MicroRNA 155 expression is dependent on an NFkB mechanism and it has 
anti-bacterial and anti-viral properties (O'Connell, Taganov, Boldin, Cheng, & Baltimore, 
2007). Our laboratory is in process of confirming some of the microRNA by Taqman RT-
PCR, repeating this type of assays in BMDC as well as in cells sorted from immunized 
mice and further characterize the functions of some of these microRNA. 
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Sorter, CFSE labeling of cells, infection model in mice, microarray.  
o Isolation of different antibodies 2C11, CD28, 11B11. 
Merck & Co (West Point, PA) (February 2007 to November 2008) 
§ Virology Technician Position  
§ Vaccine Testing  (Measles, Mumps, Rubella and Varicella) 
§ Identity and Stability Testing 
§ Potency testing of vaccines and other experimental samples 
§ LIMS, GLP, GMP, Plaque Assay, SOP design. 
§ MRC-5 cell line infection and trypsinization. 
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§ Macroscopic and Microscopic evaluation of infected cells. 
§ Supervisor (Christopher Milano & Michael Nuzzolo) 
 
Thomas Jefferson University, Department of Human Virology and Biodefense (July 
2005 – May 2007)  
§ Graduate Master’s Student Research Thesis  
§ Thesis title: “Identification of HLA-A2 and HLA-A3 restricted Adenovirus 
Specific Cytotoxic T Lymphocyte Epitopes from the Hexon Capsid Protein.” 
§ Techniques:
o Cell counting, ELISPOT, Plaque Assay, CTL Assay, Flow Cytometry, 
Buffy coat processing, Dendritic Cell isolation and stimulation, EBV 
transformation of PBMC, Adenoviral infection of cells, CD 8 T-cell 
isolation and culture, Generate peptide specific T Cell lines, Peptide 
identification and Analysis, Media/buffer preparations.  
Thomas Jefferson University Hospital Clinical Laboratory (April 2006 – May 2007) 
Graduate Master’s Student Clinical Clerkship 
§ One year Clinical Clerkships in the area of Bacteriology, Mycology, Parasitology 
and Virology.   
§ Acquired hands-on experience, and gained a full understanding (and appreciation) 
of an integrative approach to the clinical microbiology laboratory.  
§ Learned different techniques for isolation, identification and drug susceptibility 
testing of many organisms from different samples, including urine, feces, blood, 
sputum, bone marrow and spinal fluid. 
§ Techniques:
o Bacterial Isolation & identification, Microscan bacterial screening, Sample 
processing , PCR , API test, Gram stain, plates streaking, techniques used 
in a daily clinical microbiology hospital laboratory. 
 
University of Minnesota (August 2001 – May 2005) 
§ Undergraduate Research 
§ Title: “In Vitro Effects of Betulin, Betulinic Acid and β-Cyclodextrin Alone and 
in Combination against HSV-1 And HSV-2 infection in HEP-2 Cells” 
§ Herpes Simplex Virus 1 & 2 infection 
§ Human Epithelial Cell, African Green Monkey Kidney cells 
§ Techniques: 
o Aseptic techniques for tissue culture, Plaque Assay, ELISA, Virus 
expansion & titration.
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§ Title: “In Vitro Combination of Tea Extracts and Antibiotics Against Different 
Species of Bacteria and Yeast” 
§ Culture of Staphylococcus aureus, Salmonella paratyphi, Proteus vulgaris, 
Escherichia coli, Bacillus megaterium, Bacillus subtilis, Streptococcus 
pneumoniae, Candida albicans, etc. 
§ Techniques: 
 
o Kirby-Bauer susceptibility testing, Tea extract preparation, Organism 
isolation and dilution, Agar preparation, sterilization of equipment, Basic 
aseptic techniques involved when working with microorganism. 
 
Publications 
 
“Intact MyD88 Signaling in Macrophages is Required for Antibody and Germinal Center 
Induction by TLR-Ligand Based Adjuvants.”   
Munir Mosaheb, Michael Reiser, Lee Wetzler. This manuscript has been submitted, 
addressing reviewers comments. 
  
“The TLR-2 Ligand, Meningococcal PorB, Has Broad And Unique Adjuvant Activity, 
Inducing Humoral And CD4 And CD8 Cellular Responses.” 
Munir Mosaheb and Lee Wetzler (In Preparation) 
 
“The TLR2 Ligand based adjuvant, Neisserial Porin PorB, Enhances Antigen Uptake and 
Antigen Presenting Cell Trafficking as a Mechanism of its Potent Adjuvant Activity.” 
Michael Reiser, Munir Mosaheb, Andrew Platt and Lee Wetzler. (In Preparation) 
 
"Truncated form of TGFβRII, but not its absence, induces memory CD8+ T cell 
expansion and lymphoproliferative disorder in mice."  
Harumichi Ishigame, Munir Mosaheb, Shomyseh Sanjabi, Richard Flavell. Journal of 
Immunology 2013 Jun 15;190(12):6340–50. PMID: 23686479 
 
“Abrogated transforming growth factor beta receptor II (TGFβRII) signaling in dendritic 
cells promotes immune reactivity of T cells resulting in enhanced atherosclerosis.” 
Lievens D ,  Habets K L,  Robertson A K, Laouar  Y, Winkels H , Rademakers T , 
Beckers L, Wijnands E, Boon L, Munir Mosaheb, Ait-Oufella H, Mallat Z, Flavell RA, 
Rudling M, Binder CJ, Gerdes N, Biessen EA, Weber C, Daemen MJ, Kuiper J, Lutgens 
E. European Heart Journal 2012 May 21, PMID: 22613345 
 
“Opposing Effects of TGF-B and IL-15 Cytokines Control the Number of Short-Lived 
Effector CD8+ T Cells” 
Shomyseh Sanjabi, Munir Mosaheb and Richard Flavell. Immunity 31, 131–144, July 
17, 2009, PMID: 19604492	 	
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Presentations and Abstracts 
 
The TLR-2 Ligand, Meningococcal PorB, Has Broad And Unique Adjuvant Activity, 
Inducing Humoral and CD4 and CD8 Cellular Responses. 
Munir Mosaheb , X. Liu, D. Toussi, P. Massari, L. Wetzler. (Poster Presentation, TOLL 
Meeting 2015) 
 
“The Essential Role of Macrophages in Vaccine Induced Immune Responses upon 
Immunizations with TLR-based Adjuvants.”  
Munir Mosaheb, Lee Wetzler (Poster presentation, Cold Spring Harbor Laboratory 
Meeting: Fundamental Immunology and Its Therapeutic Potential 2015)  
“Examination of the Role of Dendritic Cells, Macrophages and B Cells in the Function of 
Vaccine Adjuvants, Including Meningococcal PorB.” 
Munir Mosaheb, Deana Toussi, Xiuping Liu, Paola Massari, Lee Wetzler. (Poster 
presentation, Keystone Vaccine Meeting 2014 The Modes of Action of Vaccine 
Adjuvants) 
“Expression of microRNAs in response to a TLR dependent adjuvant PorB from 
Neisseria meningitides.”  
Munir Mosaheb, Andrew Platt, Michael L Reiser, Yazdani Shaik-Dasthagirisaheb, 
Deana Toussi, Xiuping Liu, Lee Wetzler. (Poster Presentation, American Association of 
Immunologist Meeting 2014) 
“Examination of the Role of Dendritic Cells, Macrophages and B cells in the Function of 
Vaccine Adjuvants.”   
Munir Mosaheb, Michael Reiser, Deana Toussi, Xiuping Liu, Paola Masari, Lee 
Wetzler. (Oral and Poster Presentation, American Association of Immunologist Meeting 
2014) 
 
“Examination of the Role of Dendritic Cells, Macrophages and B Cells in the Function of 
Vaccine Adjuvants, Including Meningococcal PorB.”   
Munir Mosaheb, Deana Toussi, Xiuping Liu, Paola Massari, Lee Wetzler. (Poster 
presentation, Immunotherapy & Vaccine Summit 2014) 
 
“Selective MyD88 Signaling in Macrophages is Required for Germinal Centers 
Formation and the Subsequent Vaccine-Induced Responses upon Immunization with 
TLR-based Adjuvants.” 
Munir Mosaheb, Xiuping Liu, Deana Toussi, Lee Wetzler (Poster Presentation Boston 
University EVANS Day 2014) 
 
 “In Vitro Combination of Tea Extracts and Antibiotics Against Different Species of 
Bacteria and Yeast” 
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Munir M. Mosaheb and Reza-ul(Raj) Karim (Poster presentation, University of 
Minnesota, Published in the Journal of National Conference On Undergraduate 
Research 2005, also Presented at Virginia Military Institute and Washington and Lee 
University for the 19th National Conference on Undergraduate Research). 
Other Relevant Experiences 
 
Boston University School of Medicine (August 2015 – December 2015) 
§ Teaching Assistant for Infectious Disease Module (Medical school courses 
Vista Research Society for Industry Leaders (Guidepoint Global) (April 2007 – 
November 2008) 
§ Consultant 
§ Used my expertise and experience to advise professionals on technology and 
investment trends in the scientific field. 
Thomas Jefferson University Hospital Infectious Disease Department (May 2006 – 
March 2007) 
§ Volunteer 
o Assisted Phyllis Flomenberg, M.D. during her weekly rounds at Thomas 
Jefferson University Hospital, Infectious Disease Department. 
University of Minnesota  (May 2002 – May 2004) 
Microbiology Teaching and Lab Assistant 
§ Prepared and set up experiments 
§ Taught laboratory sessions (class size 25) 
§ Supervised and assisted students around the lab and with lecture materials 
 
Awards 
§ Selected for T32 NIH Immunology Training Program Fellowship Grant (Boston 
University 2011–2013). 
§ Awarded four times the Graduate Medical Science Travel Award (2012–2015).  
§ Awarded the American Association of Immunologist 2014 Travel Award. 
§ Awarded the American Association of Immunologist 2014 Abstract Award. 
§ Awarded the Boston University Microbiology Travel Award 2015. 
§ Awarded the Boston University Department of Medicine EVANS Day 2015 
Poster Award. 
§ Awarded the Loretta Rocco Memorial Award 2006 at Thomas Jefferson 
University. 
§ Awarded two times the Undergraduate Research Opportunity Program Awards 
(UROP 2004 and 2005).		
